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ABSTRACT OF THESIS 
Despite the advances that have occurred in the prevention and management of coronary 
heart disease, there remains a substantial residual risk in the general population. Inflammation 
has received considerable attention as a target for therapies, given the inflammatory nature of 
atherosclerosis. Omega-3 fatty acids have anti-inflammatory properties, and recent clinical trial 
evidence has demonstrated a reduction in major adverse cardiovascular events with fish oil. 
The studies presented in this thesis investigated the effects of omega-3 fatty acids on vascular 
inflammation as a possible mechanism of atheroprotection. 
 A review of the literature was performed, focusing on the inflammatory mechanisms of 
atherosclerosis, the effects of omega-3 fatty acids on inflammation, particularly vascular 
inflammation, and the results of cardiovascular outcome trials of fish and fish oil. This provided 
a theoretical basis for the studies presented. 
A systematic review of high-quality randomised controlled trials catalogued in the 
Cochrane Library was performed to evaluate the impact of omega-3 fatty acids on the 
circulating mediators of atherosclerosis. These are among the earliest inducers of endothelial 
injury and vascular inflammation. Omega-3 fatty acids reduced levels of atherogenic mediators 
in all four categories. 
 A combined randomised controlled trial and cell culture study was performed to 
evaluate the effects of omega-3 fatty acids on the gene expression of markers of acute vascular 
inflammation (AVI). Healthy volunteers were supplemented with 4 grams daily of either EPA, 
DHA, fish oil with a 2:1 EPA:DHA ratio, or placebo for 30 days. Serum before and after 
supplementation was added to TNF-stimulated HUVECs in culture. The serum from those 
supplemented with high-dose EPA reduced the gene expression of MCP-1. The gene 
xii 
 
expression of VCAM-1 and MCP-1 correlated positively with HDL-C levels, suggesting a pro-
inflammatory effect at high HDL-C levels. 
 To study the impact of omega-3 fatty acids on the protein expression of markers of 
AVI, C57Bl/6 mice had non-occlusive collars applied surgically to their right carotid arteries 
after receiving 30 days of pre-treatment with either EPA, DHA, an oil control, or no treatment, 
by oral gavage. The intense inflammatory response was reduced by EPA, manifested by 
reduced expression of VCAM-1 and MCP-1 in the artery wall. 
 ApoE-deficient mice were fed an atherogenic diet for 16 weeks to induce advanced 
atherosclerotic lesions and chronic vascular inflammation. In the last 8 weeks they were 
randomised to either EPA, DHA, olive oil, or no treatment by oral gavage. EPA reduced gene 
expression of markers of chronic inflammation in the aorta, however no treatment altered the 
burden, characteristics or lipid content of plaque. EPA and DHA stabilised cholesterol levels 
and reduced triglyceride levels. 
In all experimental studies, blood levels of omega-3 fatty acids, especially EPA, 
correlated inversely with markers of vascular inflammation. 
The findings of this body of work demonstrate the suppressive effects of omega-3 fatty 
acids on acute and chronic vascular inflammation, with EPA being superior to DHA. These 
findings provide a rationale for the reduction in major adverse cardiovascular events seen 
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1.1 Atherosclerosis is an inflammatory disease 
Cardiovascular disease is the leading cause of death worldwide and contributed to 44% 
of non-communicable disease deaths in 2016(1). The most common diseases of the 
cardiovascular system are those caused by atherosclerosis. These include coronary artery 
disease, cerebrovascular disease, and peripheral vascular disease. Atherosclerosis can be 
described in simple terms as the accumulation of fatty plaque in the arterial wall that can 
progress to cause luminal narrowing. When sufficient luminal narrowing occurs, the supply of 
blood and therefore oxygen does not meet the metabolic demand of tissues, and ischaemia or 
infarction occurs. Atherosclerosis has traditionally been viewed as the consequence of 
cumulative injury from a number of risk factors, such as hyperlipidemia, hypertension, diabetes 
mellitus and tobacco smoking. Significant advances in the prevention and treatment of 
atherosclerotic diseases have led to major population-wide reductions in morbidity and 
mortality(2). Despite these advances, there remains a substantial residual cardiovascular risk(3). 
Inflammation has received considerable attention as a target of atherosclerosis, given the 
substantial evidence demonstrating its inflammatory nature. The response-to-injury hypothesis 
of atherosclerosis was first proposed by Russell Ross, who recognised the presence of multiple 
diverse inflammatory cell types in atherosclerotic plaques, revealing a complex milieu of 
inflammatory activity(4). Inflammation is integral to all six stages of the continuum of 









Figure 1.1: Diagrammatic representation of atherogenesis divided into six stages. 
Adapted from Wick, G., & Grundtman, C. (2012). Inflammation and atherosclerosis. 
Wien: Springer-Verlag/Wien(5). 
1.1.1 Atherosclerosis stage I – Increased endothelial cell permeability 
 Minute changes in circulating lipoproteins, glucose, and inflammatory markers lead to 
modulation of endothelial cell (EC) function and increased permeability. This process involves 
changes in three components: (1) the “glycocalyx”, which is the surface layer of glycoproteins, 
proteoglycans, and glycosaminoglycans that together create a scaffold on the endothelial 
surface; (2) energy-dependent vesicular trafficking, also called the “transcellular pathway”; 
and (3) and the opening or rearrangement of cell-to-cell junctions, also called the “paracellular 
pathway”(6). Enhanced vesicular trafficking and/or widened intercellular spaces in the presence 
of a disarrayed or overtly disintegrated glycocalyx may all facilitate the transendothelial flux 
of low-density lipoprotein (LDL), which may ultimately become trapped in the 
subendothelium. Trapped LDL is oxidised by macrophages. Oxidised LDL (ox-LDL) 
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generates free radicals (which are toxic to ECs) leading to the generation of monocyte 
chemoattractant protein 1 (MCP-1). There is subsequent attraction and migration of monocytes 
to the subendothelium. In response to this, antioxidant heme oxygenase 1 is released, which 
reduces monocyte transmigration and toxicity to endothelial cells(7). 
1.1.2 Atherosclerosis stage II – Endothelial cell dysfunction 
 Concurrent with increased endothelial cell permeability, ECs switch to a secretory 
phenotype, producing a hyperplastic, multilayered basal lamina, which further traps LDL in 
the subendothelium(8). ECs express von-Willebrand factor, which binds to glycoprotein 1b on 
platelets and recruits them to the endothelial cell surface. Upon adhesion, platelets secrete a 
variety of proinflammatory cytokines and chemoattractants including platelet factor 4, 
RANTES, P-selectin, soluble CD40 ligand and matrix metalloproteinases. Platelet P-selectin 
interacts with monocyte P-selectin glycoprotein ligand-1, forming platelet-monocyte 
complexes. These activated platelets become more adhesive to vascular cell adhesion molecule 
1 (VCAM-1) and inflamed or atherosclerotic endothelium.  
ECs also lose their net negative surface charge that contributes to the characteristic non-
thrombogenic surface of the endothelium(9). Circulating cells have a negatively-charged 
surface, and hence are more easily able to attach and migrate through the endothelium. 
Endothelial dysfunction activates nuclear factor kappa-B (NF-κB), a transcription 
factor which induces both pro-inflammatory and anti-inflammatory genes(10). NF-κB is also 
activated by adverse conditions such as hypertension, low shear stress, and the presence of pro-
inflammatory cytokines, ox-LDL, and reactive oxygen species (ROS). There are five subunits 
of the nuclear factor kappa B (NF-κB) family, and the main subunit is p65 which mediates 
transcriptional activation of target genes. When NF-κB is activated in endothelial cells (eg. 
during endothelial dysfunction), the response is pro-inflammatory. There is expression of genes 
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that recruit inflammatory cells (eg. VCAM-1, intercellular adhesion molecule 1 [ICAM-1], E-
selectin and P-selectin), cytokines (eg. tumour-necrosis factor-alpha [TNF-α], interleukin-1 
[IL-1β], interleukin-6 [IL-6], and interleukin-8 [IL-8]), chemokines (eg. MCP-1), and matrix 
metalloproteinases [MMPs])(11). This set of molecular and cellular changes is a defence 
reaction assisting the vascular endothelium to recruit blood inflammatory cells. 
1.1.3 Atherosclerosis stage III – Leucocyte transmigration and fatty streak 
formation 
Through the EC expression of MCP-1, adhesion molecules, and through their 
interactions with monocyte integrins, monocytes are captured, roll and adhere to the 
endothelium, then transmigrate to the subendothelium. They subsequently differentiate into 
macrophages and phagocytose ox-LDL and become foam cells, the hallmark of the fatty streak. 
The differentiation process of monocytes to macrophages is normally a coordinated process 
that involves upregulation of scavenger receptors, e.g. SR-A and CD-36. When the 
macrophages encounter modified lipoproteins such as ox-LDL, advanced glycation 
endproducts, anionic phospholipids and apoptotic cells, the receptors are activated. The 
phagocytosis of ox-LDL is normally followed by esterification of cholesterol by Acyl 
coenzyme A:cholesterol acyltransferase-1 (ACAT1) and neutral cholesteryl ester hydrolase 
(nCEH), and then the efflux of cholesterol out of the cell by Adenosine 5' Triphosphate (ATP)-
binding cassette transporters A1 (ABCA1) and G1 (ABCG1), and scavenger receptor BI (SR-
BI). In atherogenic conditions, there is increased ox-LDL influx, increased cholesterol 
esterification, and decreased cholesterol efflux, hence the macrophages are ultimately 
transformed into lipid-laden foam cells(12). Fatty streaks are macroscopically-visible aggregates 
of foam cells. 
Concurrent with the transmigration of monocytes, circulating CD4+ T cells migrate 
into atherosclerotic lesions, where they bind to antigens such as modified lipoproteins, and 
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proliferate. Dendritic cells are specialised antigen presenting cells, required for activation of 
CD4 cells, and their transmigration from the circulation is augmented by EC dysfunction and 
inhibition of nitric oxide synthase(13). Activated CD4 cells release cytokines such as TNF-α, 
which are pro-inflammatory and contributed to macrophage activation(14). 
Other inflammatory cells that migrate into the subendothelium include 
polymorphonuclear cells (PMNs) and mast cells. The extravasation of PMNs is a normal part 
of immune surveillance, induced by selectin-mediated rolling and integrin-mediated 
adhesion(15). The transmigration is augmented by the upregulation of ICAM-1 in acute vascular 
inflammation(16). Mast cells are thought to be recruited to atherosclerotic plaque via the 
chemokine eotaxin-1 (CCL-11) expressed in plaque via the mast cell receptor CCR3(17). Mast 
cells accumulate in the medial and adventitial tissues and cluster around neovessels. When 
activated, they release the contents of their granules such as histamine and proteases, which 
induce vascular leakage and promote intraplaque haemorrhage(18).  
1.1.4 Atherosclerosis stage IV – Development of fibrous plaque 
Foam cells secrete cytokines, growth factors, tissue factor, interferon-gamma, MMPs, 
and reactive oxygen species. With digestion of the internal elastic lamina, there is migration of 
smooth muscle cells (SMCs) from the media to the intima, forming intimal thickenings. The 
migrated SMCs switch to a secretory phenotype, resulting in a hyperplastic, multilayered basal 
lamina and enlarged extracellular matrix (ECM), enriched with collagen bundles and fibrils(19). 
These cellular changes form a fibrous cap. 
1.1.5 Atherosclerosis stage V – Development of calcified atherosclerotic fibro-lipid 
plaque 
The switch of SMCs from a contractile to a secretory phenotype is associated with a 
significant reduction in their ability to metabolise LDL(20). SMCs become lipid-laden, and 
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along with lipid-laden macrophages and extracellular lipid deposits in fibrous plaques, form 
fibro-lipid plaques. Free cholesterol also accumulates within plaque, and the oxidised forms 
are potent inducers of apoptosis of foam cells and SMCs(21). The release of the cytotoxic 
contents of these cells results in formation of the necrotic core encapsulated by fibrous 
tissue(22). Excess extracellular unesterified cholesterol nucleates into cytotoxic crystals. Plaque 
that is surrounded by a robust fibrous cap is considered “stable”. Plaque with a thin fibrous 
cap, accumulation of cholesterol crystals, and with a large necrotic core are considered 
“unstable”. 
1.1.6 Atherosclerosis stage VI – Plaque rupture 
Progressive deterioration and thinning of the EC layer overlying the fibrous cap results 
in exposure of the ECM to circulating blood cells. Circulating macrophages infiltrate the ECM 
and secrete proteases, which digest and destabilise the ECM and contribute to fibrous cap 
thinning. Local foam cells also secrete proteolytic enzymes. SMCs also contribute to fibrous 
cap thinning due to a decrease in collagen synthesis. Local mast cells, among other cells, release 
proteases that destabilise the plaque. The plaque ruptures at its weakest point, either 
spontaneously or in the setting of haemodynamic stress, and platelets aggregate and become 
activated, leading to thrombosis. Ninety-five percent of ruptured fibrous caps are less than 65 
μm in thickness(23), which is the threshold for defining thin-cap fibroatheroma (TCFA)(24).  

















Figure 1.2: A schematic representation of the fundamental processes of atherogenesis, 
including endothelial dysfunction: (A), fatty streak formation (B), formation of advanced 
lesions (C), and plaque rupture (D). Reproduced with permission from (Ross, R. (January 
01, 1999). Atherosclerosis--an inflammatory disease. The New England Journal of 
Medicine, 340, 2, 115-26(4)), Copyright Massachusetts Medical Society. 
 
1.1.7 An alternative fate of atherosclerotic plaques – Erosion 
 An alternative fate of atherosclerotic plaques is superficial erosion leading to 
thrombosis. The lesions associated with superficial erosion are abundant with smooth muscle 
cells and extracellular matrix, and have a paucity of lipid and foam cell accumulation(25). They 





The pathology of plaque erosion is not completely understood. Emerging data, 
including histopathological as well as from intracoronary imaging modalities such as optical 
coherence tomography (OCT) have provided valuable mechanistic insights(27). The 
characteristic feature is a breach in endothelial cell integrity at the site of proteoglycan and 
smooth muscle cell-rich plaque with a thick fibrous cap(28). Collagen and the necrotic core are 
then exposed, which allows platelet aggregation and thrombosis to occur. Plaque erosion tends 
to occur at sites of low shear stress, especially at arterial bifurcations(29). Endothelial apoptosis 
is more prevalent at sites of low shear stress(30), and this apoptosis may be triggered by 
myeloperoxidase release from neutrophils(31) and from the expression of toll-like receptor 2 
(TLR-2)(32). A proposed sequence of events involves a two-hit hypothesis. Firstly, increased 
TLR-2 expression by endothelial cells overlying plaque increases the susceptibility of 
endothelial cells to injury. Secondly, when injury occurs, neutrophils aggregate, and the 
increased TLR-2 expression impairs healing. Endothelial injury continues, and the secreted 
tissue factor by dying endothelial cells promotes thrombosis. The dying endothelial cells have 
contact with the underlying subendothelial matrix, and granulocytes such as neutrophils 
become trapped in fibrin strands and form neutrophil extracellular traps (NETs)(32). The 
prominent role of neutrophils and presence in plaque erosion differentiates it from plaque 
rupture, where macrophages are predominant. Similarly, endothelial cell apoptosis in plaque 
erosion contrasts with destruction of the ECM in plaque rupture. 
 Plaque erosion as a cause of thrombosis is becoming more prevalent, contributing to 
more than one quarter of acute coronary deaths(33). This is likely due to the increasing success 
of LDL-C-lowering therapies(25), thereby lowering the prevalence of lipid-rich plaques. 
Studying plaque erosion has been hampered by the lack of reliable animal models(34), and 
research is ongoing in this field. 
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1.2 Adhesion molecules, cytokines and inflammatory cells in atherosclerosis 
 A vast number of inflammatory mediators contribute to atherogenesis. The 
predominant mediators in acute vascular inflammation are adhesion molecules, endothelium-
derived cytokines, monocytes and neutrophils. In the setting of chronic vascular inflammation, 
prominent mediators include IL-1, IL-6 and TNF-α, which modulate the immune response and 
propagate inflammation. Macrophages are the dominant inflammatory cells, and are directly 
atherogenic. 
1.2.1 Acute vascular inflammation 
1.2.1.1  Vascular Cell Adhesion Molecule 1 
 VCAM-1, also known as CD106, is an immunoglobulin-like adhesion molecule that is 
expressed on the luminal surface of endothelial cells, and binds to the integrin α4β1, which is 
constitutively expressed on lymphocytes, monocytes and eosinophils(35). VCAM-1 is not 
present in basal conditions, and its expression is stimulated in pro-inflammatory conditions. 
These include the presence of TNF-α, IL-1β, lipopolysaccharide (LPS), reactive oxygen 
species, oxLDL, hyperglycaemia, toll-like receptor agonists, and in the context of shear 
stress(36). The gene expression of VCAM-1 is regulated by two specific subunits of the NFκB 
transcription pathway, namely p65 and p50 with low stimulation, and p65 alone with high 
stimulation(37). Upon encountering the integrin α4β1, VCAM-1 mediates rolling of, or firm 
adhesion to, circulating leucocytes, and facilitates their transmigration to the 
subendothelium(38, 39).  
1.2.1.2  Intercellular Adhesion Molecule 1 
 ICAM-1, also known as CD54, is an immunoglobulin-like adhesion molecule that is 
expressed constitutively on the luminal surface of endothelial cells. It binds to two integrins of 
the β2 family on the surface of leucocytes, including CD11a/CD18 (LFA-1) and CD11b/CD18 
(Mac-1). Its expression is regulated by the following transcription factors: NFκB (specifically 
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the p65 subunit), AP-1, CCAAT/enhancer binding protein family, ETS, signal transducer and 
activator of transcription-1 (STAT-1), and Sp1(40). Amongst these transcription factors, NFκB 
activation is always required for ICAM-1 upregulation. ICAM-1 is induced by broad range of pro-
inflammatory molecules in endothelial cells, including cytokines TNF-α, IL-1β, IL-6, and 
interferon-γ, LPS, thrombin, substance P, endothelin 1-3, oxLDL, hydrogen peroxide, and 
cyanate(41, 42). In addition, shear stress induces ICAM-1 expression(41). ICAM-1 functions similarly 
to VCAM-1; upon encountering integrins, it mediates rolling and transmigration of leucocytes into 
the subendothelium. 
1.2.1.3  P-selectin 
  P-selectin is a cell adhesion molecule present in the Weibel-Palade bodies of 
endothelial cells. Upon stimulation of ECs, it is translocated to the external plasma membrane 
where it functions as a receptor for monocytes and neutrophils(43). It is also present in platelets, 
where it is found in α-granules. Stimulants for P-selectin include TNF-α, IL-1β, oxygen free 
radicals, and histamine. The direct translocation to the cell surface after EC stimulation occurs 
within minutes as there is no requirement for transcription and translation(44). P-selectin binds 
to P-selectin glycoprotein ligand 1 (PSGL-1), expressed on almost all leucocytes, as well as 
the sialyl-Lewis X ligand, and there is subsequent leucocyte rolling and transmigration to the 
subendothelium. The expression of P-selectin on the EC surface is initially transient, lasting 
approximately 10 minutes, with the protein then being internalised inside the cell, where it is 
degraded or recycled(45). A more sustained expression occurs after continued EC stimulation, 
with de novo synthesis of P-selectin occurring within 2 hours(45). 
1.2.1.4  E-selectin 
E-selectin is an adhesion molecule present in endothelial cells, and rapidly expressed 
after EC stimulation. The pro-inflammatory mediators TNF-α, interferon-γ, IL-1β and LPS all 
stimulate E-selectin(46). In addition, disturbed and oscillatory shear stress, rather than laminar 
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shear stress, stimulate E-selectin(47, 48). It is transcriptionally regulated by both NFκB and 
Activating Transcription Factor (ATF)(49), and once on the EC surface recognises the sialyl-
Lewis X ligand on leucocytes(50). E-selectin mediates rolling and firm adhesion of leucocytes 
onto the EC surface and subendothelial transmigration. E-selectin is functionally similar to P-
selectin, however its expression occurs a minimum of 3 hrs after stimulation and subsequently 
wanes, despite continued cytokine stimulation(51). 
1.2.1.5  Monocyte Chemoattractant Protein 1 
 Also known as CCL2, MCP-1 is a chemokine (chemoattractant cytokine) secreted by 
numerous cell types including endothelial, fibroblasts, epithelial, smooth muscle, mesangial, 
astrocytic, monocytic, and microglial cells. Monocytes and macrophages are the dominant 
source of circulating MCP-1(52). Stimulants for MCP-1 expression by endothelial cells include 
TNF-α, IL-1β, IL-6, and/or brain-derived neurotrophic factor. MCP-1 is transcriptionally 
regulated by NFκB and mitogen activated protein kinase (MAPK). MCP-1 binds to the CCR2 
receptor on monocytes leading to the activation of intracellular signalling cascades that prompt 
migration toward the chemokine source (endothelial cell). Migration of monocytes from the 
blood stream across the vascular endothelium is required for routine immunological 
surveillance of tissues, as well as in response to inflammation. MCP-1 is also chemotactic for 
memory T lymphocytes and natural killer cells(53, 54).  
1.2.1.6  Monocytes 
 Non-classical monocytes slowly patrol the endothelium of blood vessels, and upon 
endothelial cell activation and subsequent monocyte chemotaxis, are able to rapidly respond to 
local perturbations. In homeostatic conditions, arterioles, capillaries, and postcapillary venules 
are populated by patrollers, perhaps one third of the marginal pool of non-classical 
monocytes(55). Once in the subendothelium, they are able to phagocytose debris and recruit 
neutrophils to mediate focal necrosis of endothelial cells(56). These monocytes (with surface 
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markers CD14hiCD16−) produce high levels of pro-inflammatory cytokines such as TNF-α, 
attracting further monocytes to sites of injury by setting up a chemoattractant gradient(57). They 
also produce proteases including matrix metalloproteinases (MMPs) that cleave collagen and 
other matrix components(58). Hence, they amplify both the inflammatory response and local 
injury. Over hours to days, monocytes differentiate into macrophages with their ultimate 
phenotype depending on different levels of trophic factors, mainly M-CSF and GM-CSF(59).  
 Macrophages that differentiate in an environment dominated by pathogen associated 
molecular patterns (PAMPs), interferon-γ, IL-1, and TNF-α from damaged tissues become 
classically activated. Such macrophages have amplified phagocytic and cytotoxic activity, 
secretion of pro-inflammatory mediators and expression of scavenger receptors. As sites of 
injury heal, with reductions in pro-inflammatory mediators, there is a reduction in macrophage 
activity. Newly-recruited macrophages may differentiate into alternatively-activated 
macrophages, which facilitate tissue repair and promote granuloma formation(60). 
1.2.1.7  Neutrophils 
 Neutrophils play a significant role in early acute vascular inflammation (AVI), and their 
accumulation in the vessel wall is a hallmark feature of AVI. Circulating neutrophils may be 
directed to a site of endothelial inflammation either by nearby monocytes using paracrine 
signalling with IL-1β, keratinocyte chemoattractant (KC), TNF-α, CCL3, or IL-6(56), or via 
chemotactic gradients from more distant sites of injury. At the sites of endothelial injury, 
adhesion molecules are upregulated.  The interactions between these molecules, especially 
selectins, with P-selectin glycoprotein ligand-1 (PSGL-1) on neutrophils, results in neutrophil 
tethering and rolling(61). This is followed by firm adhesion to the endothelium, typically 
mediated by the integrin CD11a/CD18 (LFA-1)(62). Neutrophils then crawl along the 
endothelium, in a slow, CD11b (Mac-1)-dependent meandering motion(62). Following adhesion 
and crawling, neutrophils emigrate from the vasculature, and at the site of injury phagocytose 
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debris and recruit more inflammatory cells (63). The presence of inflammation inhibits the 
apoptosis of neutrophils, and with the continued recruitment of neutrophils, the magnitude of 
the inflammatory response is increased(64, 65).  
Neutrophils can also regulate the function of dendritic cells, lymphocytes and natural 
killer cells(63). After entry into the inflammatory tissue site, in response to pro-inflammatory 
stimuli in the tissue, neutrophils become fully activated, a state characterised by release of 
granule proteins, acquisition of phagocytic capabilities, and production of NETs. Neutrophils 
are relatively nonresponsive to a single stimulus, but exposure to one stimulus enhances the 
ability of the cell to mount an enhanced activation response to a second individual stimulus(66). 
The activation mechanisms that are beneficial for pathogen killing can also be detrimental in 
the context of sterile injury such as in AVI. For example, despite a targeted inflammatory 
response by neutrophils, there is typically local collateral tissue damage from leakage of 
cytosolic contents and oxidative products outside of the neutrophil from phagocytic activity(67).  
The transmigration process of neutrophils across the endothelial cell barrier can induce 
signalling changes in endothelial cells, causing them to contract and thereby generating 
intercellular gaps. This allows serum proteins (such as cytokines, antibodies, and complement) 
to pass through the endothelial barrier, further aggravating the inflammatory state(68). Such 
changes promote a continued inflammatory state that can ultimately progress to chronic 
vascular inflammation. 
1.2.2 Chronic vascular inflammation and atherosclerosis 
1.2.2.1  Interleukin 1-α and β 
 Interleukin 1-α (IL-1α) and interleukin 1-β (IL-1β) are members of the IL-1 cytokine 
superfamily and are produced by macrophages, monocytes, fibroblasts, and dendritic cells. 
They are both produced as precursor proteins that are subsequently cleaved, although IL-1β in 
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its precursor form is not biologically active. The precursor of IL-1α acts as a damage-associated 
molecular pattern (DAMP) molecule, which is recognised by innate immunity cells by pattern 
recognition receptors (PRRs) and functions as a danger signal for the immune system. IL-1α 
and β are produced in response to inflammatory stimuli and bind to interleukin-1 receptors. IL-
1α generally remains associated with the cell surface or is released by dying cells and usually 
acts at short distances by juxtacrine or paracrine signalling. IL-1β on the other hand, can either 
act in a paracrine manner or systemically(69).  
The main function of IL-1-type cytokines is to control proinflammatory reactions in 
response to tissue injury by pathogen-associated molecular patterns (PAMPs, such as bacterial 
or viral products) or (DAMPs)(70). IL-1α and IL-1β rapidly induce the mRNA expression of 
hundreds of genes in multiple different cell types, such as monocytes, macrophages, endothelial 
and epithelial cells. In parallel, IL-1α and IL-1β also induce expression of their own genes, 
which serves as a positive-feedback loop that amplifies the IL-1 response in an autocrine or 
paracrine manner(71). IL-1α and IL-1β can also increase the expression of the IL-1 receptor 
antagonist (IL-RA), enabling negative feedback inhibition, a mechanism that resists 
unrestricted IL-1 signalling(72). 
Another method by which IL-1 signalling is regulated is through the requirement for 
activation of another molecule, caspase-I, for cleavage of pro-IL-1β to IL-1β. Caspase-I is 
present in an inactive form in the cytosol of many phagocytic cells, and is activated after 
stimulation by a myriad of microbial and endogenous signals. These signals stimulate the 
assembly of an inflammasome, specifically Nucleotide-Binding Domain Leucine-Rich-
Containing Family Pyrin Domain-Containing-3 (NLRP3), a macromolecular complex that 
forms a scaffold for pro-caspase-I activation(73). Notable effects of IL-1α and β on cells include 
induction of prostaglandin production through the induction of cyclooxygenase-2; the 
elaboration of nitric oxide by elevation of levels of the inducible isoform of nitric oxide 
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synthase; induction of the expression of many cytokines, including augmenting its own gene 
transcription; increased expression of leucocyte adhesion molecules and thrombogenic 
mediators; and activation of cells involved in innate immunity, prominently including the 
mononuclear phagocytes(70). 
 There are numerous stimulators of the inflammasome in atherosclerotic plaques, 
including cholesterol crystals and inflammatory cytokines. Indeed, there are significant 
amounts of NLRP3, caspase-I and IL-1β in plaques(74). Hence, the requirement of a two-step 
activation process for the inflammasome and subsequent IL-1β generation is not a hindrance 
for continued inflammatory activity in atherosclerotic plaques. Other stimuli for the 
inflammasome in atherosclerotic plaques include altered shear stress, hypoxia and acidosis(75-
77). IL-1β is present in much larger concentrations and is a much greater contributor to 
persistent, chronic inflammation in plaques than IL-1α. Indeed, IL-1β stimulates ICAM-1 and 
VCAM-1 which recruit other leucocytes, stimulates production of MCP-1 and other 
chemokines, and also strongly induces smooth muscle cells to secrete IL-6(78). Il-1β contributes 
to intimal thickening, increases inflammation in the vessel wall, and promotes aneurysm 
formation(79-81). 
1.2.2.2  Interleukin 6 
 IL-6 is a cytokine with both pro- and anti-inflammatory properties, and is produced by 
a variety of cells, most notably monocytes and macrophages at inflammatory sites. Stimulants 
for IL-6 production include IL-1β, TNF-α, platelet-derived growth factor, LPS, and a variety 
of pathogens. In the acute inflammatory response, such as in AVI, large amounts of IL-6 can 
be produced. IL-6 binds to the IL-6 receptor (IL-6R), which is present on macrophages, 
neutrophils, some T cells, and hepatocytes. Following this, the IL-6/IL-6R complex binds to 
two molecules of GP130 (ubiquitously expressed on all cells), leading to signal transduction, 
which includes activation of the JAK/STAT, ERK, and PI3K signal transduction pathways. In 
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addition to binding to IL-6 receptors on cells, IL-6 may also bind to soluble IL-6 receptors 
(sIL-6R). Although this would be expected to dampen the immune response by scavenging 
circulating IL-6, it conversely amplifies the immune response, as IL-6/sIL-6R complexes may 
then bind to cells that express GP130, and then activate IL-6 signal transduction(82). This form 
of “trans-signalling” as opposed to classical cell to cell signalling is crucial for rapid 
lymphocyte trafficking to sites of inflammation, and produces a much more robust 
inflammatory response. One mechanism by which sIL-6R is formed is by the cleavage of 
membrane-bound IL-6R, which can occur during the apoptosis of neutrophils(82).  
The propagation of the effects of IL-6 can be controlled by the production of 
neutralising antibodies, or the release of soluble GP130, which can bind circulating IL-6/sIL-
6R complexes. If these complexes do bind endothelial cells, they induce the secretion of 
adhesion molecules and MCP-1(83). This results in a relative decrease in the secretion of 
cytokines that attract neutrophils, such as IL-8, in favour of monocytes, hence the inflammatory 
response becomes monocyte dominant(84). This switch heralds the IL-6-driven transition from 
an acute to a chronic inflammatory response(85). Furthermore, IL-6 plays a vital role in the 
initiation of specific rather than innate immune responses, such as end-stage B cell 
differentiation, immunoglobulin secretion and T cell activation.  
The activity of IL-6 can be persistent and uncontrolled. This is particularly the case in 
the setting of vascular inflammation, where there is a continuous influx of monocytes that 
differentiate into macrophages in the inflammatory environment and propagate pro-
inflammatory signalling. In addition, IL-6 acts upon naive T-lymphocytes resulting in their 
differentiation into helper or cytotoxic T cells, which are subsequently able to continue 
propagation of the inflammatory cascade(86). IL-6 stimulates the proliferation of SMCs, and is 
produced by foam cells(87). IL-6 has significant procoagulant activity, primarily through 
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inducing monocyte expression of tissue factor, which promotes thrombosis(88). In addition, IL-
6 promotes platelet aggregation(89). 
 Some of this pro-inflammatory activity is balanced by the anti-inflammatory properties 
of IL-6. IL-6 can suppress IL-1 and TNF-α production, induce the IL-1 receptor antagonist, 
and can induce tissue inhibitor of matrix metalloproteinase 1 (TIMP1), which impedes the 
activity of collagenase and therefore has anti-proteolytic activity(90). However, the pro-
inflammatory activity is dominant in the setting of vascular inflammation, and contributes to a 
chronic and atherogenic state. 
1.2.2.3  Tumour necrosis factor-alpha 
 TNF-α is a cytokine that activates multiple transduction pathways, inducing or 
suppressing a wide variety of genes, including those encoding the production of cytokines, 
adhesion molecules, and inducible nitric oxide synthase (iNOS)(91). TNF-α has many pro-
inflammatory actions: orchestrating the inflammatory response through activation of pro-
inflammatory cytokine genes, such as IL-1 and IL-6, as well as its own production(92). The 
activated macrophage is the main source of TNF-α, containing both cell-associated and 
membrane-bound TNF-α, both of which are biologically active(93). Other cells that release 
TNF-α include lymphocytes, fibroblasts, neutrophils, smooth muscle and mast cells.  
TNF-α can bind to either TNF-receptor 1 (TNFR1), which is present on most cells, or 
TNF-receptor-2 (TNFR2), which is present on immune cells. The binding of TNF-α to its 
receptors results in either activation of the NFκB or MAPK transcription pathways, or 
induction of apoptosis(94). The activation of NFκB and its translocation to the nucleus leads to 
the production of a multitude of pro-inflammatory proteins, many of which are relevant to 
vascular inflammation. These include but are not limited to: pro-inflammatory interleukins(95), 
adhesion molecules(96), interferon-γ(97), MCP-1(98), tumour necrosis factor-related apoptosis-
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inducing ligand (TRAIL)(99), toll-like receptors 2 and 9(100, 101), tissue factor-1(102) and vascular 
endothelial growth factor (VEGF)(103). The MAPK pathways control a large number of 
fundamental cellular processes including growth, proliferation, differentiation, motility, stress 
response, survival and apoptosis(104). The MAPK signalling pathways include ERK5, p38, 
JNK, and ERK1/2 pathways. The p38 and JNK pathways may be the most relevant to 
atherosclerosis. They are both necessary for foam cell formation(105, 106). They are both 
activated during vascular endothelial injury, inducing neointima formation(107), and p38 
stimulates the proliferation of SMCs(108). Although TNF-α is an inducer of apoptosis, in 
atherosclerotic plaque apoptosis is reduced in favour of cell necrosis, contributing to the 
necrotic core(109). This effect may be partly due to the stimulation of macrophages and SMCs 
to synthesise matrix proteases(110). Furthermore, the presence of TNF-α promotes more 
advanced, unstable lesions(109). 
1.2.2.4  Macrophages 
 Monocytes that have transmigrated into the subendothelial space may either 
differentiate into classical, “M1”, pro-inflammatory macrophages, or alternative, “M2”, anti-
inflammatory macrophages, depending on the local environment. Macrophages may also be 
derived from the adventitia, either from the vasa vasorum or as resident, locally-derived, 
macrophage progenitors(111). Although the M1/M2 concept is an oversimplification of the role 
of the macrophage, it is practical and for the most part accurate. Macrophages are polarised 
towards an M2 phenotype when in a pro-resolving environment, such as during resolution of 
inflammation, where the emphasis is on tissue repair. Conversely, they are polarised to an M1 
phenotype when in pro-inflammatory environment. Early atherosclerotic lesions have a 
predominance of M2 macrophages, and more advanced lesions, with high levels of 
inflammatory activity, have a predominance of M1(112). The typical activating stimuli for M1 
macrophages are interferon-γ and LPS(60). The activating stimuli for the subclasses of M2 
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macrophages are: IL-4 and IL-13 for M2a, immune complexes plus either IL-1β or LPS for 
M2b, and IL-10, transforming growth factor-β or glucocorticoids for M2c(113).  
 The atherogenic roles of M1 macrophages in the vessel wall include: (1) secretion of 
pro-inflammatory cytokines (eg. IL-6, IL-12, and IL-23), (2) secretion of growth factors that 
induce neovascularisation and vessel permeability (eg. VEGF), (3) production of matrix 
metalloproteinases that digest the matrix and solubilise the fibrous cap, (4) production of 
reactive oxygen species which promote macrophage recruitment, impair efferocytosis of 
apoptotic cells and oxidise LDL, and (5) acting as antigen presenting cells, where the activation 
of antigen-specific T cells results in the amplification of the macrophage response (114). This 
last role contributes to the chronicity of the inflammatory response. 
As stated previously, macrophages are critical to the production of lipidic plaques. The 
ability of macrophages to remove oxidised LDL can be overwhelmed when the ability to 
remove ingested oxLDL is exceeded by the rate of ox-LDL influx and cholesterol 
esterification. This forms the basis for inflammatory, cholesterol-rich plaques. 
1.3 Inflammation as a therapeutic target in atherosclerosis 
Inflammation in the vessel wall has received considerable attention as a target for new 
therapies for atherosclerosis. A conundrum has existed for many years, since numerous anti-
inflammatory agents increase the risk of cardiovascular events, such as non-steroidal anti-
inflammatory drugs(115) and corticosteroids(116). Furthermore, the recent CIRT study, which 
compared the anti-inflammatory agent methotrexate to placebo in patients with coronary artery 
disease, did not reduce cardiovascular events(117). The LoDoCo study, however, demonstrated 
a 67% reduction in the composite incidence of acute coronary syndrome, out-of-hospital 
cardiac arrest, or noncardioembolic ischemic stroke in patients with stable coronary artery 
disease taking the anti-inflammatory agent colchicine compared to placebo (p<0.001)(118). 
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Colchicine’s anti-inflammatory properties include an antitubulin effect that inhibits neutrophil 
function(119). In addition, the potential for cardiovascular benefit by targeting the inflammatory 
nature of atherosclerosis was highlighted by the CANTOS study(120). CANTOS compared 
canakinumab, a monoclonal antibody targeting interleukin-1β, to placebo in patients with a 
previous myocardial infarction and an elevated C-reactive protein (CRP) level. Canakunimab 
at a dose of 150 mg every three months reduced cardiovascular events by 15% compared to 
placebo at 48 months (p=0.021)(120). 
The reductions in cardiovascular events seen in LoDoCo and CANTOS occurred in 
addition to the effects of statins, as more than 90% of patients in both studies were taking 
statins. Statins themselves have been clearly shown to have anti-inflammatory effects amongst 
their numerous pleiotropic effects. The PRINCE trial (2001) was an early study that 
demonstrated the CRP-lowering properties of pravastatin, which occurred independently of 
changes in LDL cholesterol(121). Since then, statins have been shown to increase endothelial 
nitric oxide synthase (eNOS) gene expression and activation(122, 123); reduce NFκB activation 
by pro-inflammatory stimuli(124); upregulate antioxidant enzymes such as heme oxygenase-
1(125); inhibit pro-inflammatory cytokine release such as IL-6(126); and upregulate anti-
inflammatory cytokines such as IL-10(127). The pleiotropic effects of statins have been shown 
to be clinically significant, as several clinical trials have demonstrated reductions in 
cardiovascular events beyond the effects of lipid lowering. For example, in the LIPID trial 
pravastatin reduced cardiovascular events by 24% in patients with a past history of an acute 
coronary syndrome, throughout the continuum of LDL-C levels (p<0.001)(128). In the Heart 
Protection Study, patients with coronary, other occlusive arterial disease, or diabetes, were 
randomised to receive simvastatin or placebo; simvastatin reduced major vascular events by 
24% irrespective of initial cholesterol concentrations (p<0.0001)(129).  
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Statins have been successfully used to reduce cardiovascular events by targeting 
systemic inflammation in addition to their established lipid-lowering effects. In the JUPITER 
study, apparently healthy men and women with low LDL-C levels (<3.4mmol/L) but elevated 
hs-CRP levels (>2.0 mg/L) were randomised to rosuvastatin or placebo; the trial was stopped 
early after a median of 1.9 years due to a 44% reduction in the occurrence of major adverse 
cardiovascular events in the rosuvastatin group (p<0.00001)(130). Similarly, the anti-
inflammatory properties of omega-3 fatty acids have led to considerable research into their 
therapeutic potential for a range of conditions.  
1.4 The effects of omega-3 fatty acids on inflammation 
1.4.1 Fatty acids in health and disease  
1.4.1.1  Overview of fatty acids 
 Fatty acids are organic acids with a hydrocarbon chain and a terminal carboxyl group 
(see Figure 1.3). They are the major components of fats, oils, and waxes. Although there are 
over 1000 naturally-occurring fatty acids, only 20-30 are widely distributed in nature. These 
typically have between 10 and 22 carbon atoms. Fatty acids can be classified by the number of 
carbon atoms present, i.e.: “short-chain” if ≤ 5 carbon atoms, “medium-chain” if 6 to 12 carbon 
atoms, “long-chain” if 13 to 21 carbon atoms, and finally “very long chain” if ≥ 22 carbon 
atoms. A common form of nomenclature for fatty acids is “lipid number” in the form of 
(C:DωN), where C corresponds to the number of carbon atoms, D is the number of double 
bonds, and ωN is the position of the last double bond, if present, in the hydrocarbon chain. The 
position is defined as the number of carbon atoms away from the methyl (CH3) end of the 
structure. For example, (20:5ω3) refers to eicosapentaenoic acid (EPA), which has 20 carbon 
atoms, 5 double bonds, and the position of the last double bond is 3 carbon atoms away from 
the methyl end. The hydrocarbon chain of a fatty acid can have either single carbon-carbon 
bonds with two flanking hydrogen atoms, or double bonds, of which there can be 0 to 6 in any 
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single structure. The double carbon-carbon bonds typically have cis geometry, i.e. the 
continuing carbon chains after the double bond face in the same direction. This creates a kink 
in the structure. In the case of trans geometry, the continuing carbon chains face the opposite 
direction, and the absence of a kink allows them to be pack closer together (see Figure 1.4). It 
is important to distinguish trans-fatty acids from cis-fatty acids, and therefore “trans N” or “cis 
N” may be used in nomenclature for this purpose. “Cis” is implied if this distinction is not 
made. “Trans-fatty acids” have the trans geometry, and are much less commonly found in 
nature than in the commercial food industry. They have a much higher melting point than their 
cis counterparts, and hence can be cooked as liquids at much higher temperatures while 
maintaining chemical stability(131).  
“Saturated fatty acids” are defined by the absence of double bonds in the hydrocarbon 
chain (see Figure 1.5). This makes them very chemically stable, as oxidation and free radial 
damage to fatty acids occur at the sites of double bonds. Saturated fatty acids tend to be solids 
at room temperature due to their very high melting points. They can be found in both plant and 
animal sources, although animal products have the highest saturated fatty acid content. They 
have the maximum number of hydrogen atoms in the hydrocarbon chain, and a higher calorie 
content than unsaturated fatty acids.  
“Monounsaturated fatty acids” (MUFAs) have a single double bond in the hydrocarbon 
chain, and are predominantly comprised of the omega-7 and omega-9 fatty acids. MUFAs are 
abundant in plant and vegetable oils, nuts, milk products, red meat, high fat fruits, and 
avocados. “Polyunsaturated fatty acids” (PUFAs) have at least two double bonds in the 
hydrocarbon chain. PUFAs are predominantly comprised of omega-6 and omega-3 fatty acids. 
Both omega-6 and omega-3 fatty acids are found in plant oils, however the omega-3 fatty acids 
EPA (20:5ω3) and DHA (22:6ω3) are abundant in fish and algal oils. Fatty acids that are 
obtained from plant, animal or fish sources are in the form of mixtures rather than as individual 
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fatty acids. Furthermore, they are not found naturally as free fatty acids, but as either 
triglycerides, phospholipids or less commonly, as cholesterol esters. This is necessary because 
fatty acids, being a form of lipid, are non-polar and hence do not dissolve in aqueous solutions. 
Fatty acids are essential for basic cellular structure and function, and are important 
sources of fuel. The term “essential fatty acid” defines fatty acids that are required for normal 
biological processes in humans and animals, but cannot be synthesisedt(132). These are linoleic 
acid (18:2ω6) and alpha-linolenic acid (18:3ω3), which cannot be synthesised due to the lack 
of the Δ12 and Δ15 desaturase enzymes responsible for converting oleic acid (18:1ω9) into 
linoleic acid (18:2ω6) and alpha-linolenic acid (18:3ω3)(133). 
Table 1.1 summarises the lipid number, name, and composition of the most abundant 






Figure 1.3: The basic structure of a fatty acid, using the saturated fatty acid lauric acid 
(12:0) as an example. Downloaded from the Dallas County Community College website: 













Figure 1.4: The structure of cis- compared to trans-fatty acids, demonstrating the 
direction of the continuing carbon chain after a double bond. Downloaded from the 














Figure 1.5: The structure of a saturated fatty acid compared to an unsaturated fatty acid. 
The absence of double bonds in the hydrocarbon chain defines a fatty acid as saturated. 
Downloaded from the Dallas County Community College website: 










Table 1.1: Summary of the type, lipid number, and common name of the most abundant 
fatty acids 
Type of fatty acid Lipid number Common name 
Saturated  
C12:0 lauric acid 
C14:0 myristic acid 
C15:0 pentadecylic acid 
C16:0 palmitic acid 
C17:0 margaric acid 
C18:0 stearic acid 
C20:0 arachidic acid 
C22:0 behenic acid 
C24:0 lignoceric acid 
Trans-fatty 
t16:1ω-7  trans-palmitoleic acid 
t18:1ω-7  trans-vaccenic acid 
t18:1ω-9 trans-oleic acid 
t18:2ω-6 trans-linoleic acid 
Monounsaturated 
16:1ω-7 palmitoleic acid 
18:1ω-7 vaccenic acid 
18:1ω-9 oleic acid 
20:1ω-9 eicosenoic acid 
22:1ω-9 erucic acid 
24:1ω-9 nervonic acid 
Polyunsaturated 
18:3ω-3 alpha-linolenic acid 
20:5ω-3 eicosapentaenoic acid 
22:5ω-3 docosapentaenoic acid 
22:6ω-3 docosahexaenoic acid 
18:2ω-6 linoleic acid 
18:3ω-6 gamma-linolenic acid 
20:2ω-6 eicosadienoic acid 
20:3ω-6 dihomo-gamma-linolenic acid 
20:4ω-6 arachidonic acid 
 
1.4.1.2  Saturated fatty acids 
Saturated fatty acids (SFAs) are obtained from both plant and animal sources, but can 
also be created from hydrogenation of a corresponding (same carbon chain length) unsaturated 
fatty acid. Of the SFAs, palmitic acid (C16:0) is the most widely occurring in both animal fats 
and vegetable oils, whilst stearic acid (C18:0) is found in lesser quantities in vegetable oils. 
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There has for decades been concerns about the effects of SFAs on serum cholesterol(134). The 
effects have been shown to be fatty acid-dependent, with myristic acid (C14:0), lauric acid 
(C12:0) and palmitic acid raising both LDL and HDL, with no effect on LDL seen with stearic 
acid(135, 136).However, despite these effects, a meta-analysis of 21 prospective cohort studies 
concluded that there is no association between saturated fat consumption and cardiovascular 
disease risk(137). There is still a consensus that SFAs should be substituted for healthier nutrients 
where possible(138). This is based a pooled analysis of 11 cohort studies which concluded that 
substitution of SFAs with PUFAs reduces the risk of coronary events by 13%(139).  
The discrepancy between effects of SFAs on lipids and cardiovascular risk could be 
explained by effects on other atherogenic mediators. However, the effects on other atherogenic 
mediators are still overall detrimental, and hence this area requires continued investigation. For 
example, SFAs have been shown to promote insulin resistance(140), induce low-grade systemic 
inflammation(141), and directly stimulate inflammatory gene expression by way of TLR4 
signalling(142). 
1.4.1.3  Trans-fatty acids 
Trans-fatty acids in the human diet are mostly encountered following partial 
hydrogenation of vegetable oils in the food industry (in particular, trans-oleic acid [t18:1ω-9]). 
This gives food desirable physical and chemical characteristics, as well as distinctive flavour, 
crispness, creaminess, plasticity and oxidative stability(143). Trans-fatty acids are used 
extensively in the preparation of fast foods and in baked goods. A small percentage of trans-
fatty acids is obtained from dairy products and ruminant meats (in particular, trans-vaccenic 
acid [t18:1ω-7]). The contribution of trans-fatty acids to the Australian diet is estimated to be 
0.6% of total energy(144). This compares to 2 to 3% in the United States(145).  
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The widespread production of trans-fatty acids has raised significant health concerns 
given their association with cardiovascular disease. Consumption of trans-fatty acids has been 
shown in a meta-analysis of 60 randomised controlled trials to raise LDL-C, lower HDL-C, 
raise triglycerides, and raise lipoprotein(a) levels(146). In addition, trans-fatty acids also reduce 
LDL particle size, increasing its atherogenicity(147). Trans-fatty acids are pro-inflammatory, 
and their consumption is associated with higher circulating levels of IL-6, TNF-α, CRP and 
MCP-1(148, 149). They also induce endothelial dysfunction, as evidenced by raised soluble 
adhesion molecules and impaired flow-mediated dilatation(148, 150).  
A number of observational studies have demonstrated a significantly higher 
cardiovascular risk associated with an increase in trans-fatty acid consumption. On a per-
calorie basis, coronary heart disease (CHD) risk is raised more by trans-fatty acids than any 
other macronutrient(151). In a meta-analysis of four prospective cohort studies involving nearly 
140,000 subjects, a 2 percent increase in energy intake from trans-fatty acids was associated 
with a 23 percent increase in the incidence of CHD(151-155). One study also demonstrated a 
positive correlation between trans-fatty acid levels in erythrocyte membranes and the risk of 
sudden cardiac death, with an adjusted odds ratio of 1.47 (95% CI: 1.01 to 2.13)(156). The 
mechanisms of the hazardous effects of trans-fatty acids have not been fully established, 
however their detrimental effects on lipids may be due to an increase in the activity of 
cholesteryl ester transfer protein (CETP), the main enzyme that transfers cholesterol esters 
from HDL to LDL and VLDL(157).  
The public health implications of high trans-fatty acid consumption are enormous. 
Since the estimated consumption of trans-fatty acids in the Australian diet is well within the 
World Health Organisation’s target of <1%, there has not been a strong impetus to reduce the 
consumption further. There is no requirement for declaration of trans-fatty acid content on food 
labels in Australia, however the 2009 Australia and New Zealand QSR Industry Survey 
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suggested that a number of strategies were being employed by industries to reduce trans-fatty 
acid levels in foods(158). 
1.4.1.4  Monounsaturated fatty acids 
MUFAs are found in high quantities in most commodity oils, and the vast majority are 
omega-7s or omega-9s. The most prevalent naturally occurring MUFA is oleic acid (18:1ω9), 
found in high concentrations in olive, peanut, palm, canola (rapeseed), and sunflower oils.  
The consumption of MUFAs has been shown to have health benefits, but an important 
consideration is their source and quality. There is convincing observational evidence that the 
cardiovascular benefits of MUFAs of plant origin are greater than those of animal origin(159). 
One large meta-analysis divided studies into tiers of dietary MUFA quality, and found that the 
MUFA diets of the highest quality, considering percentage of olive oil, oleic acid and 
MUFA:SFA ratio, had the lowest rates of all-cause mortality and major adverse cardiovascular 
events(160).  
MUFAs have also been shown to reduce inflammation. A diet rich in MUFAs 
contributes to a more anti-inflammatory gene expression profile in human adipose tissue 
compared with a diet high in SFAs(161). Furthermore, adherence to a Mediterranean diet in 
healthy adults reduces levels of plasma IL-6, CRP, and homocysteine(162). However, since the 
Mediterranean diet is highly abundant in other health-promoting constituents in addition to 
MUFAs, the results obtained from human dietary studies cannot be fully attributable to 
MUFAs. This was exemplified in the landmark PREDIMED study, which randomised 
individuals at high cardiovascular risk to a Mediterranean diet supplemented with extra-virgin 
olive oil (EVOO), a Mediterranean diet supplemented with mixed nuts, or a control diet (advice 
to reduce dietary fat). During a median of 4.8 years of follow-up, the intervention diets 
significantly reduced the primary endpoint of a composite of myocardial infarction, stroke, or 
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death from cardiovascular causes by approximately 30% compared to the control diet (hazard 
ratio of 0.70 [95% CI, 0.53 – 0.91, p=0.009] for the EVOO group and 0.70 [95% CI, 0.53 – 
0.94, p=0.02] for the mixed nuts group)(163). The fatty acid composition of the plasma of 
PREDIMED participants before and after treatment was analysed, and demonstrated that in 
addition to a significant increase in oleic acid in the EVOO group, the mixed nut group had a 
reduction in the omega-6 PUFA gamma-linolenic acid (18:3ω6), and both interventions had a 
reduction in the saturated fatty acid margaric acid (C17:0)(164). The original PREDIMED was 
subsequently retracted due to protocol deviations, particularly related to instances of lack of 
randomisation, and the study was republished in 2018, accepted as being a non-randomised 
trial(165). In the republished manuscript, the hazard ratios for the primary endpoint were 0.69 
(95% CI, 0.53–0.91) for the EVOO group and 0.72 (95% CI, 0.54–0.95) for the mixed nuts 
group, however levels of significance were not reported.(166) 
There is ongoing debate about what defines a Mediterranean diet, and the compositions 
of these diets in human studies have differed. MUFA-enriched high fat diets in animal studies 
have resulted in reduced IL-1β secretion from adipose tissue and improved insulin sensitivity 
compared to SFA-enriched high fat diets(167). The reduction in IL-1β is likely due to the 
inhibitory effects that MUFAs have on the NLRP3 inflammasome (168). 
In addition to plant and animal-derived MUFAs, there has recently been interest in 
marine-derived MUFAs. These long chain fatty acids, eg. gadoleic acid (20:1ω11) and cetoleic 
acid (22:1ω11), are found in fish such as soury, pollock, and herring. Analysis of the diets of 
the Greenland Inuits from the original studies from Bang and Dyerberg demonstrated levels of 
long-chain MUFAs 13 times higher than that of the Danish controls(169). There is evidence in 
animal studies for beneficial effects on glucose and lipid metabolism(170), reduced triglyceride 
and VLDL levels(171), upregulation of the anti-inflammatory transcription pathway PPAR-
γ(172), and reduced atherogenesis(173) with marine-derived MUFAs. With the continued interest 
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in the cardiovascular benefits of marine-derived PUFAs, clinical trials focusing on marine-
derived MUFAs are expected. 
1.4.1.5  Polyunsaturated fatty acids 
The polyunsaturated fatty acids (PUFAs) consist of omega-6 and omega-3 fatty acids. 
These are long-chain molecules with typically 2 to 6 non-contiguous double bonds. In plants, 
the number of double bonds rarely exceeds three, although in algae and fish the fatty acids can 
contain up to six double bonds. The omega-6 and omega-3 fatty acids are present in most plant, 
animal, and commodity oils and fats. As outlined previously, the PUFAs include the essential 
fatty acids, linoleic acid (18:2ω6) and alpha-linolenic acid (18:3ω3). The most common 
omega-6 fatty acids encountered in the human diet are linoleic acid and arachidonic acid 
(20:4ω6). Since mammalian cells lack the omega-3 desaturase enzyme, omega-6 fatty acids 
cannot be converted in vivo to omega-3 fatty acids. Closely-related omega-6 and omega-3 fatty 
acids act as competing substrates for the same enzymes(174), outlining the importance of the 
proportion of omega-6 to omega-3 fatty acids in diet (discussed in Section 1.4.4). 
Omega-6 fatty acids 
Linoleic acid (18:2ω6), the shortest and most common omega-6 PUFA, is metabolised 
to the longer and more unsaturated arachidonic acid (20:4ω6) via the intermediates gamma-
linolenic acid (18:3ω6) and dihomo-gamma-linolenic acid (20:3ω6). Arachidonic acid is 
metabolised by the cyclooxygenase (COX) enzymes to the 2-series of prostaglandins (i.e. 
PGE2, PGI2, PGD2, PGF2α) and thromboxanes (A2 and B2). Arachidonic acid is also 
metabolised via the lipoxygenase (LOX) enzymes to the 4-series of leukotrienes (i.e. LTA4, 
LTB4, LTC4, LTD4, and LTE4). Collectively, the prostaglandins, thromboxanes and leukotrienes 
are referred to as eicosanoids. Although the eicosanoids have important homeostatic functions 
in regulating both the promotion and resolution of inflammation in the immune response, they 
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predominantly have properties that are atherogenic. For example, PGD2 and LTB4 are pro-
inflammatory, TXA2 and TXB2 are pro-aggregatory and vasoconstrictive, LTB4 is chemotactic 
for neutrophils, and PGE2 induces IL-6(175). These properties predict a hazardous effect of 
excessive omega-6 consumption. Indeed, PGE2 and PGI2 are also proarrhythmic(175). However 
cardiovascular outcome studies have not demonstrated an elevated cardiovascular risk 
associated with high omega-6 consumption. Conversely, the aggregate of randomised trials, 
case-control, and cohort studies indicate reduced cardiovascular risk(176). This may be partly 
due to the increasingly recognised anti-inflammatory and atheroprotective effects of omega-6 
PUFAs. For example, omega-6 PUFAs are a substrate for the anti-aggregatory and vasodilatory 
prostacyclin(177), the anti-chemotactic and pro-resolving lipoxin A4(178), and the vasodilatory 
and anti-adhesive epoxyeicosatrienoic acids(179). One human study showed a negative 
correlation between serum omega-6 PUFA levels and IL-6, and a negative correlation with the 
anti-inflammatory transforming growth factor β(180).  
Individual studies of the effects of omega-6 PUFAs on serum lipids have produced 
mixed results, however a meta-analysis of 60 controlled fatty acid intervention trials indicated 
a beneficial effect on blood lipid levels with lower LDL and higher HDL levels(146). 
Increasingly, when considering the physiological effects of omega-6 consumption, there has 
been a shift in focus to omega-6 as a proportion of, or relative to, other fatty acid species, and 
this continues to be studied extensively. 
Omega-3 fatty acids 
 The omega-3 fatty acids are alpha-linolenic acid (ALA, 18:3ω3), eicosapentaenoic acid 
(EPA, 20:5ω3), docosahexaenoic acid (DHA, 22:6ω3), and docosapentaenoic acid (DPA, 
22:5ω3). The latter is the intermediate species between EPA and DHA. ALA is found 
predominantly in plant oils, whereas EPA and DHA are best sourced from marine sources, i.e. 
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oily fish, fish oils and algal oil. In humans, there is a small amount of conversion from the 
essential fatty acid ALA to EPA (6%) via the enzymes Δ6 desaturase, elongase, and Δ5 
desaturase, with an even smaller amount ultimately converted to DHA (3.8%)(181). With a high 
omega-6 intake, these conversion rates are further decreased, leading some to consider EPA 
and DHA to be “conditionally essential”(182).  
The consumption of omega-3 PUFAs leads to their incorporation into cell membranes, 
where they form an essential part of the phospholipid bilayer and alter cell physiology. Cellular 
membranes from some tissues, for example the brain, retina, and myocardium are particularly 
enriched in omega-3 PUFAs. DHA is the predominant fatty acid of membrane phospholipids 
in the brain grey matter and in the retina, and the accretion of DHA in their membranes is 
required for the optimum development of retinal and cerebral functions(183). Despite this, 
supplementation of pregnant women, or fortification of infant formula, with DHA has not 
clearly resulted in improvements in neuropsychological performance in children(184). 
Furthermore, although omega-3 PUFAs are purported to have positive effects on mood(185), 
systematic reviews of the literature have demonstrated mixed results for the prevention and 
treatment of depression(186-188). The enrichment of the myocardium with omega-3 PUFAs 
suggests that they may be important for normal cardiac myocardial function and recovery as 
well as electrical stability. Recent evidence indicates that there is a reduction in adverse left 
ventricular remodelling and myocardial fibrosis following myocardial infarction in those 
supplemented with high-dose omega-3 PUFAs(189). However, despite an increase in electrical 
stability with omega-3 supplementation(190), it has not been shown to reduce atrial or ventricular 
arrhythmias in those at high risk(191-193). 
 There has been considerable interest in the lipid-lowering effects of omega-3 PUFAs, 
and the overall effects could be best summarised as follows. Triglycerides are moderately 
decreased (25 to 30%), HDL-C is increased minimally (1 to 3%), and LDL-C is increased 
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mildly (5 to 10%)(194). Given the modest effects of omega-3 PUFAs on atherogenic 
lipoproteins, there has been substantial interest in their anti-inflammatory effects as a 
mechanism for their cardioprotective effects. 
1.4.3 The anti-inflammatory effects of omega-3 fatty acids 
Omega-3 fatty acids have been shown to reduce inflammation in the in vitro and in vivo 
settings. Omega-3s are able to partly inhibit a number of aspects of inflammation including 
leucocyte chemotaxis, adhesion molecule expression and leucocyte–endothelial adhesive 
interactions, production of eicosanoids like prostaglandins and leukotrienes from the omega-6 
fatty acid arachidonic acid, production of inflammatory cytokines, and T-helper 1 lymphocyte 
reactivity(195). In addition, EPA and DHA give rise to inflammation-resolving resolvins, 
protectins and maresins(196). Furthermore, omega-3s have been showed to attenuate oxidative 
stress-induced DNA damage(197). These anti-inflammatory effects have translated into clinical 
benefit for a range of inflammatory conditions. One of the earliest conditions studied 
extensively was rheumatoid arthritis, given the understanding of the role of arachidonic acid 
metabolites in the disease process, which are clearly reduced by omega-3 fatty acids. One meta-
analysis included data from 10 trials and concluded that dietary fish oil supplementation for 
3 months significantly reduced morning stiffness and tender joint count in patients with 
rheumatoid arthitis(198). There is some evidence for a beneficial effect of omega-3 fatty acids 
in asthma, which is characterised by high levels of pro-inflammatory cytokines, arachidonic 
acid-derived eicosanoids, and prostaglandins. Some studies have demonstrated improved lung 
function and a decline in disease scores after omega-3 supplementation(199, 200), however these 
findings have not been consistently reported(201).  
Oxidative stress has been implicated as a pathogenic mechanism for the chronic, 
inflammatory neurodegenerative disease multiple sclerosis. In a randomised controlled trial, 
omega-3 fatty acids supplemented at a dose of 2 grams per day significantly reduced Expanded 
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Disability Status Scores (EDSS) in patients with multiple sclerosis, associated with reductions 
in serum CRP and the oxidative stress marker malondialdehyde(202). Omega-3 fatty acids have 
been trialled in the setting of inflammatory bowel diseases (IBD), which are associated with 
increases in inflammatory eicosanoids, pro-inflammatory cytokines, and both CD4 and CD8 T 
cell activity(203, 204). Despite omega-3s reducing all of these factors, a systematic review of 
clinical trials of IBD did not show clinical improvement with omega-3 supplementation(205). 
The lack of a predictable clinical benefit based on known biochemical effects is a frequent 
scenario that necessitates further investigation. This is indeed the case for studies of the effects 
of omega-3 fatty acids on cardiovascular disease. In addition to the potential to modulate 
cardiovascular risk by targeting inflammation, omega-3 fatty acids have beneficial effects on 
established cardiovascular risk factors, including high levels of triglycerides(206-208) and blood 
pressure(209-211). However, the results of cardiovascular outcome trials of omega-3 fatty acids 
have been overall neutral. 
1.4.4 The omega 6:3 ratio 
Conventional cardiovascular risk factors such as lipid parameters, blood pressure and 
inflammatory markers, have established and standardised tools for their measurement, as well 
as reference ranges that may define normal or associate with higher or lower risk. This is not 
the case for PUFAs. A common method for quantifying omega-3 “status” is to measure the 
proportion of total blood fatty acids comprised of omega-3s. This value, when measured in 
whole blood, has an inverse association with sudden death(212), and is the basis for the Omega-
3 Index. The Omega-3 Index is the percentage of EPA and DHA in red blood cell fatty acids, 
and based on an analysis of 10 cohort studies, a value of < 4% predicts higher CHD mortality, 
and > 8% predicts lower CHD mortality(213). However, indices such as this do not provide 
insights into the total blood fatty acid composition and the relative amounts of harmful versus 
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beneficial components. Furthermore, factors such as age and gender alter the absorption of 
fatty acids, and consequently the cut-offs for the Omega-3 index(214).  
An alternative, arguably more informative measure is the ratio of pro-inflammatory and 
atherogenic omega-6 fatty acids to anti-inflammatory and atheroprotective omega-3 fatty acids, 
i.e. the Omega 6:3 ratio. The ratio of omega-6 PUFAs to omega-3 PUFAs in the human diet 
has increased markedly from hunter-gatherer times, when it was as low as 1:1, to now, when a 
typical Western diet can provide a ratio of 20:1(215). An important concept exemplified by the 
Omega 6:3 ratio is that of fatty acid substitution. Since omega-6 and omega-3 PUFAs compete 
with each other for incorporation into cell membranes(216, 217), a higher omega-6 intake relative 
to omega-3 would be expected to shift healthy physiology to pathophysiology(218). 
A high omega 6:3 ratio is a predictor of poorer outcomes for a number of chronic 
diseases. There is a positive association with obesity, as omega-6 and omega-3 PUFAs have 
divergent effects on adipogenesis, the brain-gut-adipose tissue axis, and systemic 
inflammation(215). There is also a positive association with disease activity for several 
malignancies including colorectal and breast(219). From a cardiovascular perspective, a lower 
omega 6:3 ratio is associated with reduced platelet aggregation and circulating inflammatory 
markers(219). The Lyon Heart Study compared a Mediterranean-style diet to no dietary advice 
in patients after their first myocardial infarction, and achieved an omega 6:3 ratio in the 
intervention group as low as 4:1. Those receiving the Mediterranean diet had a 70% lower 
mortality rate at 2 years(220). 
1.5 Clinical trials of omega-3 fatty acids 
1.5.1 Dietary studies of omega-3 fatty acids 
 Bang and Dyerberg first proposed a cardioprotective effect of fish consumption after 
observing low lipid levels and rates of ischaemic heart disease in Greenland Inuit who 
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consumed a diet high in fish(221). Since that time, numerous cohort studies have been published 
comparing the effects of fish consumption on outcomes. A meta-analysis of 17 such studies 
including 315 812 participants in the primary prevention setting and an average follow-up of 
15.9 years, demonstrated a dose-response effect of fish intake on survival. Compared to low 
fish intakes (< 1 fish meal per week), the consumption of 1 fish meal per week resulted in a 
16% reduction in mortality due to CHD(222). The dose-response analysis indicated that every 
15 g per day increment of fish intake decreased the risk of CHD mortality by 6%. Musa-Veloso 
et al performed a systematic review of 8 prospective studies comparing an estimated total 
omega-3 intake of < 250 mg versus ≥ 250 mg per day by fish consumption on fatal and non-
fatal CHD in those with no prior history of CHD(223). The higher intake was associated with a 
significant 35.1% reduction in the risk of sudden cardiac death and a near-significant 16.6% 
reduction in the risk of total fatal coronary events, while the risk of non-fatal myocardial 
infarction was not significantly reduced. The risk of CHD death was again found to be dose-
dependently reduced by omega-3 intake.  
One of the first randomised controlled trials of dietary omega-3 consumption on 
cardiovascular outcomes in the secondary prevention setting was the DART study (1989)(224). 
Men admitted to hospital with an acute myocardial infarction were randomised to receive 
dietary advice to either reduce fat consumption, increase fatty fish or fish oil consumption, or 
increase fibre consumption. Those in the fish/fish oil group had a 29% reduction in all-cause 
mortality after 2 years(224). 
 Dietary studies of omega-3 intake in the primary and secondary prevention setting have 
demonstrated a lower mortality rate with fish intake that appears to be dose-responsive. 
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1.5.2 Cardiovascular outcome trials of fish oil 
Supplementation with omega-3 fatty acids in the form of fish oil provides a convenient 
and efficient method of raising blood omega-3 levels. Fish oil is generally well-tolerated with 
minimal side effects, the predominant being gastrointestinal and an anecdotal increase in 
bleeding tendency. Studies have evaluated the risk of bleeding with fish oil supplementation, 
and have demonstrated no clinically significant increase, in a variety of settings(225). Fish oils 
are available either as over the counter supplements or as prescription formulations, the latter 
being typically in the form of carboxylic acids or ethyl esters. Prescription formulations are 
purported to be superior based on having higher omega-3 concentrations, higher manufacturing 
standards, and their need for rigorous evaluation of efficacy and safety. 
The GISSI-Prevenzione trial (1999) studied the impact of fish oil supplementation on 
outcomes in patients with a recent myocardial infarction. In this multi-centre trial, patients were 
randomly assigned to either fish oil alone (900mg of omega-3 per day), vitamin E alone, fish 
oil plus vitamin E, or no supplement (control) for 6 months. There was a 10% reduction in 
death, non-fatal myocardial infarction, and stroke seen in the fish oil group compared to the 
control group(226). A summary of the major CVOTs of omega-3 fatty acid supplementation is 
presented in Table 1.2. In the JELIS study (2007), hypercholesterolaemic patients (total 
cholesterol ≥ 6.5 mmol/L) in Japan were recruited and randomised to either a statin or statin 
plus EPA (1.8g per day) for a mean duration of 4.6 years. There was a significant, 19% 
reduction in major coronary events in the EPA + statin group compared to statin therapy 
alone(227). The reduction was only significant in patients who had a prior history of coronary 
artery disease, and was independent of effects on LDL levels. The Alpha Omega Trial (2010) 
used a much smaller dose of omega-3 fatty acids, as participants were randomised to one of 
four margarines(228). Patients with a prior history of myocardial infarction and on state of the 
art medical therapy, were randomised to consumption of margarines fortified with either EPA 
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+ DHA, EPA + DHA + ALA, ALA alone, or placebo. The average dose of EPA + DHA was 
376mg. There were no significant differences between the groups in the primary endpoint of 
major cardiovascular events. Although the comparative lack of benefit compared to earlier 
studies could be attributed to a low omega-3 dose used, this study raised questions about the 
magnitude of additional benefit that fish oil could provide in the setting of contemporary anti-
atherosclerotic therapies. In the OMEGA trial (2010), published in the same year and with a 
similar population group, i.e. patients with a history of acute myocardial infarction, omega-3 
ethyl esters (1g per day) were initiated and compared with placebo (1g of olive oil per day) for 
1 year(229). On top of standard medical therapy, there was no difference between the treatment 
groups in either sudden cardiac death, total mortality, major adverse cerebrovascular and 
cardiovascular events, or revascularisation. This trend continued in the ORIGIN trial (2012), 
where 1g of fish oil (≥ 900mg of omega-3 fatty acids) daily was compared with placebo (1g of 
olive oil daily), in patients with, or at risk of, diabetes mellitus, and with a previous MI or heart 
failure(230). Over a median follow-up period of 6.2 years, there was no significant difference in 
death from cardiovascular causes between the treatment groups. 
These large CVOTs had significant variability in omega-3 doses and preparations used, 
despite growing interest in the role of the omega-3 dose-effect relationship(231). Two primary 
prevention studies in 2018, the ASCEND study and the VITAL study similarly used an 
intervention dose of 1g of fish oil daily. In the ASCEND study, diabetics without a history of 
atherosclerotic cardiovascular disease were randomised to either 1g of fish oil per day (840mg 
of EPA + DHA) or placebo (1g of olive oil per day), and were followed for a median duration 
of 2.5 years.(232) No significant difference was seen in the primary endpoint of vascular events 
or vascular death between the treatment groups. In the VITAL study, men of at least 50 years 
of age, and women of at least 55 years of age, without a history of cardiovascular disease, were 
randomised to either 1g of fish oil (840mg of EPA + DHA) per day or a matching placebo for 
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a median period of 5.3 years(233). Fish oil did not reduce either of the primary outcomes of 
major adverse cardiovascular events or invasive cancer. 
A major shift in fish oil trial outcomes occurred with the REDUCE-IT trial (2018). This 
study used a much higher dose of omega-3, with 4 grams daily of the prescription EPA form 
“icosapent ethyl”(234). The high dose is required for an optimum triglyceride-lowering effect. 
The higher fish oil dose of 4 grams per day has similarly been used in the ongoing STRENGTH 
trial(235), in the form of EPANOVA®, which contains mixed omega-3 carboxylic acids. 
REDUCE-IT compared icosapent ethyl with placebo in patients with established 
cardiovascular disease or diabetics with other cardiovascular risk factors. Despite statin 
treatment, the patients were required have a triglyceride level between 1.52 and 5.63 mmol/L 
and an LDL level between 1.06 and 2.59mmol/L. Icosapent ethyl reduced the primary endpoint 
of the first episode of a composite of cardiovascular death, nonfatal MI, nonfatal stroke, 
coronary revascularisation and unstable angina by 25% compared to placebo(234). It reduced 
total events at 4.9 years by 30%. Although the success of the higher doses of omega-3 fatty 
acids used in REDUCE-IT could be considered attributable to beneficial effects on lipid 
parameters, the difference in rates of the primary endpoint compared to placebo was 
independent of effects on triglycerides and LDL levels. This suggests an alternative anti-
atherosclerotic mechanism of omega-3 fatty acids.  
Given the inflammatory nature of atherosclerosis, it is logical to consider that a 
potential anti-atherosclerotic mechanism of omega-3 fatty acids is the amelioration of vascular 
inflammation. Indeed, canakinumab, which reduced MACE in the CANTOS study, targets 
interleukin 1-β, which plays an important role in the pathogenic mechanisms leading to 
vascular inflammation(236). Phospholipase A2 (PLA2), a superfamily of enzymes that liberate 
free fatty acids such as arachidonic acid from phospholipid membranes, has also been targeted 
to reduce vascular inflammation. The by-products of arachidonic acid oxidation, eicosanoids, 
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can induce microvascular dysfunction, oxidative stress and vascular inflammation(237).  Several 
families of PLA2 exist, and two of them have been the subject of cardiovascular outcome trials. 
An inhibitor of secretory PLA2, varespladib, was compared with placebo in the VISTA-16 trial 
(2014), which examined its cardioprotective effects in patients with a recent acute coronary 
syndrome(238). The trial was stopped early due to futility and possible harm, with a hazard ratio 
for the primary endpoint of MACE of 1.25 (95% CI, 0.97 – 1.61, p=0.08). In addition, 
darapladib, an inhibitor of lipoprotein-associated PLA2, was studied in the STABILITY trial 
(2014), which compared it to placebo in patients with stable coronary artery disease(239). 
Darapladib did not significantly reduce the primary endpoint of MACE (HR 0.94 [95% CI, 
0.85 – 1.03]), however did significantly reduce the rate of major and total coronary events by 
10% and 9% respectively. 
The cardioprotective effects of agents that target vascular inflammation deserve further 
















dose per day Comparator Effect of intervention 
GISSI-Prevenzione (1999)(226) Recent MI 11324 Fish oil (ethyl esters) 900mg No supplement HR = 0.90 (95% CI, 0.82-0.99) for MACE  
JELIS (2007)(227) Total cholesterol ≥ 6.5* 18645 
EPA (ethyl esters) + 
statin 1800mg Statin alone HR = 0.81 (95% CI, 0.69-0.95) for MACE  
Alpha Omega (2010)(228) Previous MI 4837 
Margarine fortified 
with EPA + DHA 400mg 
Margarine 
without 
fortification HR = 1.01 (95% CI, 0.87-1.17) for MACE 
OMEGA (2010)(229) Previous MI 3851 Fish oil (ethyl esters) 1000mg olive oil HR = 0.95 (95% CI, 0.56-1.60) for SCD 
ORIGIN (2012)(230) Dysglycemia 12536 Fish oil (ethyl esters) 900mg olive oil HR = 0.98 (95% CI, 0.87-1.10) for CV death 
ASCEND (2018)(232) Diabetes mellitus 15480 Fish oil (unspecified) 840mg olive oil HR = 0.97 (95% CI, 0.87-1.08) for vascular events  
VITAL (2018)(240) Men ≥ 50, Women ≥ 55 25871 Fish oil (ethyl esters) 840mg olive oil HR = 0.92 (95% CI, 0.80-1.06) for MACE 
REDUCE-IT (2018)(234) 
CVD or diabetes mellitus 
with trigs 1.52 to 5.63* 8179 Fish oil (ethyl esters) 4000mg mineral oil HR = 0.74 (95% CI, 0.65-0.83) for MACE 
           
MI = Myocardial infarction        
HR = Hazard ratio          
MACE = Major adverse cardiovascular events 
CV = Cardiovascular 
CVD = Cardiovascular disease       
SCD = Sudden cardiac death 
* = mmol/L 
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1.6 Effects of omega-3 fatty acids on acute vascular inflammation 
 The role of vascular cells during the inflammatory response is critical. Multiple 
cytokines, leucocytes, and growth factors are present at sites of inflammation, and each of these 
can potentially influence the nature of the inflammatory response(241). Endothelial cells and 
smooth muscle cells must integrate the signals generated by these multiple factors to effectively 
regulate the immunoinflammatory response through the expression of adhesion molecules, 
cytokines, chemokines, MMPs, and growth factors. This requires changes in signal 
transduction, which are mediated through NFκB, JAK/STAT and AP-1 signalling pathways.  
Several studies have investigated the impact of omega-3 fatty acids on early (acute) 
vascular inflammation, with strong evidence for a reduction in adhesion molecule expression 
based on cell culture studies. For example, the DHA derivative maresin-1 has been shown to 
downregulate E-selectin expression in cultured endothelial cells stimulated with TNF-α(242). 
Conversely, the EPA-derived Resolvin E1 did not alter circulating E-selectin, VCAM-1 or 
MCP-1 in ApoE*3Leiden mice, although this was in the setting of prolonged high fat feeding 
which can confound studies of acute inflammation(243). De Caterina et al added DHA to human 
saphenous vein endothelial cells in culture stimulated with either TNF-α or IL-1, and 
demonstrated a reduction in protein expression of VCAM-1 and E-selectin(244). DHA was not 
directly compared to EPA for these experiments. Yates et al. made direct comparisons of EPA 
with DHA and demonstrated a reduction in neutrophil adhesion to TNF-stimulated human 
umbilical vein endothelial cells (HUVECs) with DHA, but not with EPA(245). This was 
achieved through the modulation of E-selectin expression, independent of effects on 
transcriptional regulation. This was one of the first studies to identify a differential effect of 
these two fatty acids on acute vascular inflammation. Both DHA and EPA have been shown to 
suppress protein expression of VCAM-1 and ICAM-1 in LPS-stimulated human aortic 
endothelial cells (HAECs) in a study by Huang et al, with a greater reduction seen with 
DHA(246). The mechanisms were concluded to be (1) inhibition of the translocation of TLR4 
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into lipid raft domains, (2) suppression of TAK1 phosphorylation, (3) attenuation of NFκB 
activity by suppressing p38 and IκBα activation, and (4) induction of the expression of the anti-
inflammatory and NFκB-suppressor gene A20 for EPA but not DHA(246). Similar results were 
published by Wang et al, who reported a reduction in protein expression of VCAM-1 in TNF-
stimulated HAECs co-incubated with DHA, and to a much lesser extent, EPA(247). ICAM-1 
was suppressed by DHA only at very high doses, and not at all by EPA. The superior effect of 
DHA in this study may be related to the modification of the structure and composition of 
membrane rafts and the membrane bilayer that occurs when PUFAs are incorporated into cell 
membrane phospholipids(248). Specifically, DHA incorporates into (sphingomyelin and 
cholesterol-rich) membrane rafts with more than twice the affinity of EPA, making them more 
disordered and dysfunctional(249).  
Based on the above results of studies of acute vascular inflammation, further 
investigation into the differential effects of EPA versus DHA is required. Furthermore, despite 
the results and mechanistic insights that cell culture studies of PUFAs have provided, there 
remains a significant limitation in the translatability of the results. Specifically, the addition of 
pure fatty acids to cell culture does not model the conditions that occur in vivo. Since PUFAs 
undergo metabolism and oxidation after oral consumption, the genetic, humoral and cellular 
responses in vivo are likely to be different to what is measured in the cell culture setting. Indeed, 
oxidised omega-3 fatty acids have different actions to pure unoxidised fatty acids, and are still 
beneficial, if not superior(250). Sethi et al demonstrated that oxidised, but not native unoxidised 
EPA significantly inhibited human neutrophil and monocyte adhesion to endothelial cells in 
vitro by inhibiting endothelial adhesion receptor expression. In transcriptional coactivation 
assays, oxidised EPA potently activated the peroxisome proliferator-activated receptor α 
(PPAR-α)(251). Similarly, Mishra et al demonstrated that oxidised but not unoxidised EPA and 
DHA inhibit cytokine-induced endothelial expression of MCP-1 and IL-8(252). In this study, 
oxidised EPA potently inhibited cytokine-induced activation of NFκB expression (although 
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this was not caused by prevention of phosphorylation of IκBα as concluded by Huang et al). It 
is evident that the favourable effects of pure, unoxidised omega-3 fatty acids on acute vascular 
inflammation identified in a cell culture need to be replicated in a more physiological setting.  
1.7 Effects of omega-3 fatty acids on chronic vascular inflammation and 
atherosclerosis 
 The continuum of atherogenesis, as outlined in Section 1.1.1, presents a challenge in 
studying the late stages of atherosclerosis in isolation, i.e. independent of inflammatory 
processes that have occurred earlier. Nonetheless, it is highly relevant to the translational 
potential of omega-3 fatty acids, as most of their demonstrated clinical efficacy and ultimately 
practical utility is in secondary prevention. The vast majority of studies of omega-3 fatty acids 
in chronic vascular inflammation and atherosclerosis have been in animal models. However, 
studies of human atherosclerosis have been performed, such as that by Thies et al, who studied 
the inflammatory composition of plaque after fish oil consumption(253). Patients awaiting 
carotid endarterectomy were randomised to receive fish oil or a placebo oil leading up to 
surgery. The macrophage content of plaques was significant lower in the fish oil group, and 
higher concentrations of EPA and DHA were found within these plaques(253). Xu et al measured 
the burden of atherosclerotic plaque and lipids in the aortas of ApoE-deficient mice fed an 
atherogenic diet and randomised to the addition of fish oil (1% w/w of diet) or unaltered 
diet(254). No difference was seen in either parameter between treatment groups despite high 
measured circulating omega-3 levels. In this study, the dose of fish oil was low, triglyceride 
levels were significantly and unexpectedly increased in the fish oil group, and there was no oil 
control, which were limitations. EPA alone was studied by Matsumoto et al, who measured 
lipid and plaque burden in the aortas of ApoE-deficient and LDLR-knockout mice who were 
randomised to EPA (5% of diet by weight) or a standard atherogenic diet(255). EPA reduced 
aortic lipid and plaque burden, reduced macrophage accumulation in plaque, increased smooth 
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muscle cell content, and increased plaque collagen content. These changes were seen in the 
absence of effects on circulating lipids. No comparison was made with DHA.  
Li et al studied the functional aspects of plaque inflammation, including the ability of 
plaque macrophages to clear apoptotic cells (efferocytosis)(256). Macrophage efferocytosis was 
defective in ob/ob;LDL-receptor deficient mice fed an atherogenic diet for 6 weeks, and this 
was reversed by dietary fish oil supplementation for a further 6 weeks, compared to an olive 
oil control. Another functional aspect of plaque inflammation, studied by Altenburg et al, is 
the uptake of oxidised LDL (oxLDL), which is mediated by IFN-γ-induced CXCL16 
expression. DHA reduced CXCL16 expression by human aortic smooth muscle cells, measured 
by flow cytometry(257). Furthermore, oxLDL uptake was reduced as measured by fluorescent 
labelling. Foam cell formation, the internalisation of modified lipoproteins such as oxLDL, is 
also reduced by omega-3 fatty acids. Song et al cultured THP-1 monocytes in oxLDL and 
phorbol myristate acetate to induce foam cell formation, and added various ratios of EPA to 
(the omega-6) arachidonic acid(257). The conditions with the highest omega-3 content had the 
lowest cholesterol levels detected in foam cells, and a lower concentration of IL6 and TNF-α 
in the supernatant. DHA was not used in this study. The LPS-induced expression of toll-like 
receptor 4 (TLR4) on the lipid rafts of murine macrophages (RAW264.7 cells), is a marker of 
macrophage activation. In in vitro studies, both DHA alone and a combination of EPA and 
DHA reduced TLR4 expression, but EPA alone did not(258).  
Further to studies of the functional aspects of plaque inflammation, the regression of 
atherosclerosis has been studied in LDL-receptor deficient mice by Nakajima et al(259). After 8 
weeks on an atherogenic diet, mice were fed with either a standard chow diet or one with the 
addition of EPA (5% w/w) for 4 weeks. The mice in the EPA group had a 22% reduction in 
atherosclerosis burden compared to the chow-fed mice, as well as a reduction in the content of 
macrophages, CD4+ T cells and dendritic cells in atherosclerotic lesions(259). No comparison 
was made with DHA. Although much attention has been focused on EPA, the anti-
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atherosclerotic effects of DHA were studied by Tan et al, by esterifying phytosterols with 
DHA(260). In ApoE-deficient mice fed an atherogenic diet with or without phytosteryl DHA 
added (2% w/w) for 7 weeks, those in the DHA group had lower plasma cholesterol levels and 
three times smaller atherosclerotic lesions. No comparison was made with EPA.  
A study comparing the effects of EPA and DHA in different ratios on atherosclerosis 
in ApoE-deficient mice did not demonstrate a clear difference in plaque or lipid burden in 
atherosclerotic aortas(261). Nor was there a difference in markers of oxidative stress, markers of 
acute and chronic inflammation, or oxLDL uptake. Markers of chronic inflammation included 
IL1-β, IL6 and TNF-α. Takashima et al compared EPA with 1:1 combinations of EPA and 
DHA at different doses(258). ApoE-deficient mice fed an atherogenic diet had the burden and 
characteristics in the aortic arch quantified after randomisation to either a control atherogenic 
diet, a diet supplemented with 5% EPA (w/w), one supplemented with 2.5% EPA + DHA 
(w/w), or one supplemented with 5% EPA + DHA (w/w). The latter group had the lowest 
burden of plaque and the highest plaque stability, which was significantly different to all other 
groups. The results of these studies of chronic inflammation and atherosclerosis demonstrate 
differential and beneficial effects of EPA and DHA. Despite much attention being focused on 
the anti-atherosclerotic effects of EPA, these studies highlight the potential benefits of 
combination therapy, which may be synergistic and/or take advantage of their unique 
mechanisms of action. 
1.8 Areas for further investigation  
1.8.1 Methodological considerations 
The unique anti-inflammatory and anti-atherosclerotic mechanisms of action of EPA 
and DHA are yet to be fully elucidated, and there is evidence that different EPA/DHA 
combinations produce divergent effects. To further evaluate the effects of omega-3 fatty acids 
on acute vascular inflammation, it is prudent to first establish the effects of individual fatty 
acids. Modelling AVI in vitro requires a physiologically-appropriate inflammatory stimulus 
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applied to vascular endothelial cells. Omega-3 fatty acids, being non-polar molecules, do not 
dissolve readily in aqueous solutions such as cell culture media, and hence are commonly 
bound to albumin (with polar and non-polar sites), and subsequently ethanol (polar) before use 
in cell culture experiments. This process is not only highly challenging, but is temperature-
sensitive, is not physiological, and produces variable results. Studies of AVI performed in vitro 
should ideally use systems whereby fatty acids are presented to cells in a form that replicates 
the in vivo setting.  
Studies of AVI performed in vivo such as animal studies, must use models of pure acute 
vascular inflammation that do not induce atherosclerosis. For animal studies, omega-3 fatty 
acids are typically added to diet. This strategy results in animal-to-animal variations in both 
total omega-3 fatty acid consumption as well as total fatty acid oxidation. Furthermore, there 
is no adjustment for weight. A more accurate method that mimics human fish oil consumption, 
is to provide precise quantities of unoxidised fish oil directly to animals by oral gavage. An 
important consideration for human studies is ensuring adequate dosing. The studies quoted 
above have demonstrated the dose-dependent nature of the effects of omega-3 fatty acids, with 
oral doses directly correlating with blood and tissue concentrations(262-264). At present, there is 
no upper limit for omega-3 dosing in humans, and dosing up to 5 grams per day is considered 
safe by the European Food Safety Authority(265). 
1.8.2 Knowledge gap analysis 
 The in vitro, animal, and human studies of fish oil have used highly heterogeneous 
omega-3 preparations and dosing, leading to inconsistencies in results. With emerging evidence 
of differential mechanistic effects of EPA and DHA, it has become imperative to identify 
optimal preparations, either in combination or isolation, for specific indications. Currently, 
there is no clearly superior omega-3 fatty acid for the amelioration of acute vascular 
inflammation. The beneficial effects of EPA demonstrated in the JELIS study led to a focus on 
EPA for studies of atherogenesis, without sufficient comparisons with DHA or combinations. 
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There is a paucity of data on the effects of individual fatty acids on the nature as well as total 
burden of atherosclerotic plaque. Their impact on the inflammatory characteristics, stability, 
and lipid content of plaque need further evaluation. Since almost 10% of whole body omega-3 
fatty acids are circulating in the bloodstream, it is likely that an important component of their 
anti-atherosclerotic effects is on circulating factors. It is important, therefore, to establish their 
effects on circulating atherosclerotic mediators. 
1.9 Aims of research study 
The aims of this body of work are: 
1. To systematically review the literature on the impact of omega-3 fatty acids on the 
circulating mediators of atherosclerosis. These include atherogenic lipoproteins, 
inflammatory cytokines and adipokines, atherogenic amino acids and derivatives, and 
advanced glycation end products. 
2. To determine the effects of omega-3 fatty acids on acute vascular inflammation in an 
in vitro model using serum from healthy volunteers supplemented with fish oil. 
Comparisons will be made between fish oils with different EPA:DHA ratios. 
3. To determine the impact of individual omega-3 fatty acids on acute vascular 
inflammation in an in vivo animal model. 
4. To determine the impact of individual omega-3 fatty acids on chronic vascular 
inflammation and atherosclerosis in an in vivo animal model. 
1.10 Hypotheses 
The overarching hypotheses for this examination of the impact of omega-3 fatty acids on the 
inflammatory mediators of atherosclerosis are: 
1. Fish oils in various preparations and doses reduce levels of the established circulating 
mediators of atherosclerosis. 
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2. Omega-3 fatty acids that are delivered to cultured endothelial cells in a physiological 
manner will reduce markers of acute vascular inflammation measured at the gene level 
after cellular stimulation. 
3. Omega-3 fatty acid pre-treatment reduces the protein expression of markers of acute 
vascular inflammation in an animal model. 
4. In an animal model of atherosclerosis, omega-3 fatty acid supplementation reduces 
plaque lipid burden, the vulnerability and inflammatory cell content of plaque measured 
histologically and at the protein level, and reduces chronic vascular inflammation at the 
gene level, independent of changes in blood lipid levels. 
5. EPA has a superior effect compared to DHA on ameliorating acute and chronic vascular 
inflammation and atherogenesis. 
1.11 Outline of thesis 
Chapter 1: Introduction and literature review 
Chapter 2: General methods 
Chapter 3: The impact of omega-3 fatty acids on circulating mediators of atherosclerosis – A 
systematic review 
Chapter 4: Fish Oil Cell Uptake Study of INflammation (FOCUS IN). A randomised controlled 
trial of fish oil supplementation in healthy volunteers 
Chapter 5: The impact of omega-3 fatty acids on acute vascular inflammation in a mouse model 
Chapter 6: The impact of omega-3 fatty acids on atherosclerosis and chronic vascular 
inflammation 

























2.1 Isolation of serum and plasma from whole blood 
Whole blood was collected in either clot-activating collection tubes (for serum) or 
ethylenediaminetetraacetic acid (EDTA) tubes (for plasma). For serum isolation, blood was 
allowed to sit undisturbed for 30 mins at room temperature for clotting to occur, following by 
either immediate centrifugation or storage at 4oC until centrifugation could be performed, 
which was no more than 4 hours in all cases. Blood collected for plasma isolation was stored 
at 4oC for no more than 4 hours and then centrifuged. In both cases, centrifugation was 
performed at 1900 x g for 15 mins at 4oC. Supernatant was aspirated using a pipette and 
immediately stored at -80oC. 
2.2 Fatty acid analysis by dry blood spot 
Whole blood was spotted onto pre-made dry blood spot (DBS) cards for fatty acid 
analysis. DBS cards were hand-made using cardboard and PUFACoat paper (developed by Dr. 
Ge Liu and Professor Robert Gibson at the FoodPlus Research Centre, University of 
Adelaide)(266). PUFACoat paper stabilises fatty acids in biological samples for at least 9 weeks 
when stored at room temperature, and for at least 18 months when stored at -20oC. Immediately 
after blood collection, 30 µl of whole blood was pipetted directly onto the PUFACoat paper, 
and the DBS cards were then stored in sealed foil bags with desiccant at -20oC prior to 
processing. 
2.2.1. Preparation of DBS cards 
 PUFACoat paper was created as follows. Using a sonicator, 70 ml of pure ethanol was 
mixed with 200 mg of butylated hydroxytoluene (BHT) in a beaker. Then 3 ml of 0.5 M EDTA 
was added to 27 ml of distilled water, and brought to a pH of 8.0. This solution was then added 
to the ethanol/BHT solution, and sonicated for 5 mins. Filter paper cut to size was dipped into 
this final solution and allowed to air-dry. This paper was stapled to thin cardboard with holes 
punched out that allow blood to be spotted on to the paper underneath.  
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2.2.2. Fatty acid extraction from DBS specimens by transmethylation 
 Forceps and scissors were first sonicated in isopropanol and then dried. The blood-
stained area of the PUFACoat paper was cut out and placed in 5 ml capped scintillation vials 
filled with 2 ml of 1% H2SO4. The vials were then heated to 70oC for 2.5 hours. After the first 
30 mins, the caps were released briefly to expel gas and the vials were vortexed. After each 
subsequent 30-min period the vials were vortexed only.  The vials were allowed to cool to room 
temperature, and then 250 µl of distilled water and 700 µl of heptane were added to the vials, 
which were then vortexed. Using a Pasteur pipette, the top layer was transferred to a gas 
chromatography (GC) vial. The GC vial was sealed and then stored at -20oC until GC analysis 
was performed. 
2.2.3 Gas chromatography analysis 
Gas chromatographic analysis was performed semi-quantitatively for the following 
fatty acids: 
Saturated fatty acids 
C14:0 (myristic acid) 
C15:0 (pentadecylic acid) 
C16:0 (palmitic acid) 
C17:0 (margaric acid) 
C18:0 (stearic acid) 
C20:0 (arachidic acid) 
C22:0 (behenic acid) 
C24:0 (lignoceric acid) 
 
Trans-fatty acids 
t16:1ω-7 (trans-palmitoleic acid) 
t18:1ω-7 (trans-vaccenic acid) 
t18:1ω-9 (trans-oleic acid) 





Monounsaturated fatty acids 
16:1ω-7 (palmitoleic acid) 
18:1ω-7 (vaccenic acid) 
18:1ω-9 (oleic acid) 
20:1ω-9 (eicosenoic acid) 
22:1ω-9 (erucic acid) 
24:1ω-9 (nervonic acid) 
 
Polyunsaturated fatty acids 
18:3ω-3 (alpha-linolenic acid) 
20:5ω-3 (eicosapentaenoic acid) 
22:5ω-3 (docosapentaenoic acid) 
22:6ω-3 (docosahexaenoic acid) 
18:2ω-6 (linoleic acid) 
18:3ω-6 (gamma-linolenic acid) 
20:2ω-6 (eicosadienoic acid) 
20:3ω-6 (dihomo-gamma-linolenic acid) 
 
20:4ω-6 (arachidonic acid) 
 
           Results were expressed as a percentage of total specimen fatty acid content. GC analysis 
was performed using a Hewlett-Packard 6890 system (Palo Alto, CA, USA) equipped with a 
BPX70 capillary column 50 m × 0.32 mm, film thickness 0.25 µm (SGC Pty Ltd., Victoria, 
Australia), programmed temperature vaporisation injector and a flame ionisation detector 
(FID). The injector temperature was set at 250 °C and the FID temperature at 300 °C, a 
programmed temperature ramp (140–240 °C) was used. Helium gas was utilised as a carrier at 
a flow rate of 35 cm per second in the column and the inlet split ratio was set at 20:1. 
Quantification was achieved by comparing the retention times and peak area values of 
unknown samples to those of commercial lipid standards (Nu-Chek Prep Inc., Elysian, MN, 
USA) using the Hewlett-Packard Chemstation data system. 
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2.3        Preparation and maintenance of human umbilical vein endothelial cells (HUVECs) 
HUVECs were obtained from fresh umbilical cords donated by the Women’s and 
Children’s Hospital, North Adelaide. They were cultured and used up to passage 5. For culture, 
HUVECs were plated in gelatin-coated flasks at a density of 10000 cells per cm2. For general 
culture and experiments requiring serum, HUVECs were grown in MesoEndo Cell Growth 
Medium (Cell Applications, San Diego, CA, USA) supplemented with an extra 5% foetal 
bovine serum (FBS) to make a total of 10% FBS. For experiments requiring serum-free media, 
EBM-2 basal media plus SingleQuot kit supplements and growth factors (Lonza, Basel, 
Switzerland), with serum omitted, were used. Cells were cultured in incubators at 37oC with 
5% CO2. Cells were passaged when they reached 90% confluency, and experimental conditions 
were added when cells were 80% confluent. Cells were passaged using Accutase® (BD 
Biosciences, Franklin Lakes, NJ, USA) by first washing the cells with room-temperature 
phosphate-buffered saline (PBS), then adding room-temperature Accutase®. Once cells were 
fully detached, Accutase® was neutralised with warm media. Centrifugation was performed at 
220 x g for 5 mins, and after supernatant was removed, cells were resuspended in growth media. 
Cells were counted using Trypan blue exclusion. For experiments, HUVECs were cultured in 
6-well plates.  
2.4 Polymerase Chain Reaction 
Reverse transcription polymerase chain reaction (RT-PCR) was performed after 
extraction of ribonucleic acid (RNA) from either cultured cells or tissues, making 
complementary deoxyribonucleic acid (cDNA), and then amplification and semi-quantification 
of DNA. RNA extraction from cells was performed using either a Bio-Rad (Hercules, CA, 
USA) Aurum™ Total RNA Mini Kit or using the TRI Reagent® method. RNA extraction of 




2.4.1 RNA Extraction from cultured cells using the Bio-Rad Aurum™ Total RNA 
Mini kit 
Cell culture media was aspirated, and then cells were washed with PBS at room 
temperature. Cells were detached from culture plates using room-temperature Accutase® (BD 
Biosciences, Franklin Lakes, NJ, USA). After neutralisation of Accutase® with warm media, 
cell solutions were centrifuged at 220 x g for 5 mins at 4oC. Supernatant was aspirated, and 
then cells were immediately processed for RNA extraction using the Bio-Rad (Hercules, CA, 
USA) Aurum™ Total RNA Mini Kit. The Spin Protocol was followed as per the Instruction 
Manual (Catalogue # 732-6820). In summary, cell pellets were treated with the lysis solution 
and then 70% (w/v) ethanol. Subsequently, cell solutions were added to an RNA binding 
column, and high-speed centrifugation was performed. The RNA binding column was washed 
with low stringency and high stringency wash solutions, and then 40 µl of elution solution was 
added to the RNA binding column for 1 min, followed by high-speed centrifugation. The eluted 
RNA solution was quantified using the NanoDrop™ 8000 Spectrophotometer (Thermo Fisher 
Scientific, Waltham, MA, USA). RNA was either used immediately for cDNA synthesis or 
stored at -80oC for later use.  
2.4.2 RNA extraction from cultured cells using the TRI-Reagent method 
The media from cultured cells was aspirated, and then the cells were washed with 1 ml 
of cold (4oC) PBS. After the PBS was aspirated, 500 µl of TRI Reagent® (Sigma-Aldrich, St. 
Louis, MO, USA) was added to each well of a 6-well plate and immediately frozen at -80oC. 
After thawing at room temperature, cells were scraped off of 6-well plates using a cell scraper, 
and the cell/TRI reagent solution was transferred to sterile 1.5 ml microcentrifuge tubes. One 
tenth of the TRI reagent volume (50 µl) of 1-Bromo-3-chloropropane (Sigma-Aldrich, St. 
Louis, MO, USA) was added, and the mixture was vortexed for 15 seconds, ensuring complete 
mixing of both phases. The solution was centrifuged for 15 mins at 19000 x g at 4oC. The 
aqueous phase was transferred to another sterile 1.5 ml microcentrifuge tube, and 250 µl of 
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isopropanol was added. This solution was transferred to a -20oC freezer for RNA precipitation. 
At least 24 hours later, the solution was vortexed, and centrifuged at 19000 x g at 4oC for 15 
mins. The supernatant was removed using a pipette, and the RNA pellet was then washed by 
adding 250 µl of ice-cold 75% ethanol. The solution was vortexed and centrifuged at 19000 x 
g for 10 mins at 4oC. The ethanol was removed, and the RNA pellet was air-dried for 10 mins. 
Pre-warmed (60oC) nuclease-free water (20 µl) was added to the RNA pellet, followed by 
vortexing and brief centrifugation. The RNA solution was kept on ice until RNA quantification 
was performed, using the NanoDrop 8000 spectrophotometer. RNA was stored at -80oC until 
use. 
2.4.3 RNA, DNA, and protein extraction from tissues using the Qiagen AllPrep 
DNA/RNA/Protein Mini Kit 
RNA was extracted from tissues (mouse aortas) using the Qiagen AllPrep 
DNA/RNA/Protein Mini kit, and DNA and protein were extracted simultaneously. The 
protocol followed was from the kit’s handbook. In summary, snap-frozen mouse aortas were 
thawed on ice and then transferred to a 1.5 ml microcentrifuge tube. “Buffer RLT” (600 µl) 
was added to tube, and then the aortas were homogenised using a Precellys24 Homogenizer 
(Bertin Instruments, Montigny-le-Bretonneux, France). The lysate was centrifuged for 3 mins 
at full speed, and the supernatant was then transferred to an AllPrep DNA spin column placed 
in a 2 ml microcentrifuge tube. The tube was centrifuged for 30 seconds at >8000 x g, and the 
spin column was placed in a new 2ml collection tube and stored at 4oC for later DNA 
purification. The flow-through was used for RNA purification.  
Pure ethanol (430 µl) was added to the flow-through, and mixed well by pipetting. Up 
to 700 µl of sample was transferred to an RNeasy spin column placed in a 2 ml collection tube, 
which was then centrifuged for 15 seconds at >8000 x g. The flow through was transferred to 
a 2 ml collection tube for later protein purification. The RNeasy spin column was washed by 
adding 700 µl of “Buffer RW1” and centrifuging at >8000 x g for 15 seconds. After discarding 
59 
 
the flow-through, 500 µl of “Buffer RPE” was added to the spin column, centrifugation was 
performed for 15 seconds at >8000 x g, and then this was repeated with a 2-minute spin. The 
RNeasy spin column was transferred to a new 1.5 ml microcentrifuge tube, and 30 µl of pre-
warmed (70oC) nuclease-free water was added to the spin column membrane. After 5 mins, 
centrifugation was performed for 1 min and > 8000 x g to elute the RNA. The RNA was then 
quantified using the NanoDrop 8000 Spectrophotometer, and stored at -80oC until future use. 
 Protein purification was performed by adding 1000 µl of “Buffer APP” to the flow-
through collected earlier. The solution was mixed vigorously and thoroughly by vortexing, and 
incubated for 10 mins at room temperature to precipitate protein. The solution in the 2 ml 
collection tube was centrifuged at full-speed for 10 mins, and the supernatant was discarded. 
Following this, 500 µl of 70% (w/v) ethanol was added to the protein pellet, centrifugation at 
full speed for 1 minute was performed, and the supernatant was again discarded. The protein 
pellet was dried for 10 mins at room temperature, then 250 µl of “Buffer ALO” and 10 µl of 8 
M urea were added. The protein pellet solution was dissolved by prolonged vortexing and 
heating to 95 degrees for 5 minutes using an Eppendorf Thermomixer (Hamburg, Germany). 
The solution was cooled to room temperature and centrifuged for 1 min at full speed, and the 
protein solution and residual pellet were stored immediately at -80oC. 
 For genomic DNA purification, 500 µl of “Buffer AW1” was added to the AllPrep 
DNA spin column, which was then centrifuged for 15 seconds at >8000 x g. This step was 
repeated with 500 µl of “Buffer AW2”, with 2 mins of centrifugation. The AllPrep DNA spin 
column was placed in a sterile 1.5 ml microcentrifuge tube, and then 100 µl of prewarmed 
(70oC) nuclease-free water was added to the spin column membrane. After 5 mins, 
centrifugation was performed for 1 min at > 8000 x g. The eluted DNA was stored at 4oC. 
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2.4.4. Conversion of RNA to complementary DNA (cDNA) 
Prior to conversion to cDNA, all RNA samples to be used for the same experiment were 
normalised to the same concentration. RNA was converted to cDNA using iScript™ Reverse 
Transcription Supermix for RT-PCR (Bio-Rad, Hercules, CA, USA). A desired quantity of 
RNA for the cDNA synthesis reaction was determined. RNA was thawed on ice, and the 
required volume was added to iScript RT Supermix, which comprised 20% of the total reaction 
mix (i.e. 4 µl iScript for a 20 µl cDNA reaction). The remaining volume was nuclease-free 
water. The mix was vortexed and centrifuged, and then incubated in a thermal cycler (T100™ 
Thermal Cycler, Bio-Rad) using the following protocol: priming – 5 mins at 25oC, reverse 
transcription – 30 mins at 42oC, and reverse transcription inactivation – 5 mins at 85oC. cDNA 
was stored at 4oC until further use. 
2.4.5 Reverse Transcription Polymerase Chain Reaction 
RT-PCR was performed using a Bio-Rad CFX Connect™ Real-Time PCR Detection 
System. Reactions were 20 µl in volume and were performed in 96-well plates. Reaction mixes 
consisted of 10 µl of Bio-Rad SsoAdvanced™ Universal SYBR® Green Supermix, 6 µl of 
nuclease-free water, 1 µl of forward primer, 1 µl of reverse primer, and 2 µl of cDNA. The 
reaction protocol was set at: 50oC for 2 mins, 95oC for 15 mins, then 40 cycles of: 94oC for 15 
seconds, 60-64oC (primer-specific based on optimisation) for 30 seconds, 72oC for 30 seconds, 
then 65oC to 95oC at 0.5oC increments for 5 seconds each. Primer stocks were diluted to a 
concentration of 100 µM, and the working solution was 10 µM. All RT-PCR reactions were 
performed with reference genes (B2M for human, and 36B4 for mouse). 
2.5 Primers for Polymerase Chain Reaction 
 For RT-PCR experiments, the primers used are listed in Table 2.1 below. All primers 




Table 2.1: List of human primers used in RT-PCR experiments 
Human primers 5’ to 3’ sequence 
Vascular Cell Adhesion Molecule 1 (VCAM-1) 
Forward 
AAGGCAGGCTGTAAAAGAATTGC 
Vascular Cell Adhesion Molecule 1 (VCAM-1) 
Reverse 
AGGTCATGGTCACAGAGCCACC 
Intercellular Adhesion Molecule 1 (ICAM-1) 
Forward 
CAGAGTTGCAACCTCAGCCT 
Intercellular Adhesion Molecule 1 (ICAM-1) 
Reverse 
GGACACAGATGTCTGGGCATT 




Monocyte Chemoattractant protein 1 (MCP-1) 
Reverse 
TGCTTG TCCAGGTGGTCCAT 
Nuclear Factor Kappa-Light-Chain-Enhancer of 
Activated B cells p65 Subunit (NFkBp65) 
Forward 
ACTGCCGGGATGGCTTCTAT 
Nuclear Factor Kappa-Light-Chain-Enhancer of 
Activated B cells p65 Subunit (NFkBp65) 
Reverse 
AGGTCCCGCTTCTTCACACA 
Beta-2 microglobulin (B2M) Forward GAGTATGCCTGCCGTGTGAAC 
Beta-2 microglobulin (B2M) Reverse CCAATCCAAATGCGGCATCTTC 
Peroxisome Proliferator-Activated Receptor 
Gamma (PPAR-γ) Forward 
CACAATGCCATCAGGTTTGG 
Peroxisome Proliferator-Activated Receptor 














Table 2.2: List of mouse primers used in RT-PCR experiments 
Mouse primers 5’ to 3’ sequence 
Interleukin 1-beta (Il-1beta) Forward 
 
TGGATGCTCTCATCAGGACAG 
Interleukin 1-beta (Il-1beta) Reverse GAAATGCCACCTTTTGACAGTG 
Tumour necrosis factor alpha (TNF-α) Forward CAGGCGGTGCCTATGTCTC 
Tumour necrosis factor alpha (TNF-α) Reverse CGATCACCCCGAAGTTCAGTAG 
Monocyte chemoattractant protein 1 (MCP-1) 
Forward 
GCTGGAGCATCCACGTGTT 
Monocyte chemoattractant protein 1 (MCP-1) 
Reverse 
ATCTTGCTGGTGAATGAGTAGCA 
Nuclear Factor Kappa-Light-Chain-Enhancer of 
Activated B cells p65 Subunit (NFkBp65) 
Forward 
ATTGCTGTGCCTACCCGAAA 
Nuclear Factor Kappa-Light-Chain-Enhancer of 
Activated B cells p65 Subunit (NFkBp65) Reverse 
GATGCTGGGAAGGTGTAGGG 
Peroxisome Proliferator-Activated Receptor 
Gamma (PPAR-γ) Forward 
CACAATGCCATCAGGTTTGG 
Peroxisome Proliferator-Activated Receptor 
Gamma (PPAR-γ) Reverse 
GCTGGTCGATATCACTGGAGATC 

















2.6 Mouse husbandry 
 Mice were housed and managed at the South Australian Health and Medical Research 
Institute (SAHMRI), in accordance with the Australian code for the care and use of animals for 
scientific purposes (National Health and Medical Research Council (2013) Australian code for 
the care and use of animals for scientific purposes, 8th edition. Canberra: National Health and 
Medical Research Council)(267). Mice were housed in cages with siblings of the same gender. 
There were up to 5 mice per cage. Mice were monitored daily. C57Bl/6 mice and ApoE(-/-) mice 
on a C57Bl/6 genetic background were obtained from The Jackson Laboratory (ME, USA). 
Homozygous ApoE deficiency was confirmed on-site using the Genetic Engineering and 
63 
 
Archiving Services (GENEAS) genotyping service. Mice were given food and water ad-
libitum. C57Bl/6 mice were fed a standard rodent chow diet (Teklad Global 18% Protein 
Rodent Diet [Harlan Laboratories, Madison, WI, USA]). This diet contains 18.6% protein, 
6.2% fat, 44.2% carbohydrates, and no cholesterol. ApoE(-/-) mice were fed the Teklad Global 
18% Protein Rodent Diet until 8 weeks of age, and were then fed a high cholesterol, high fat 
diet (SF00-219) from Specialty Feeds (Glen Forrest, Western Australia). This diet consists of 
22% fat and 0.15% cholesterol. This diet has previously been demonstrated by our group to 
significantly increase plasma cholesterol levels and lead to accelerated atherosclerosis 
development(268). Ethics approval for all animal work was obtained from both the SAHMRI 
Animal Ethics Committee and the University of Adelaide Animal Ethics Committee. 
2.7 Oral gavaging of mice 
 The equipment used to gavage mice orally with either EPA, DHA, or olive oil included 
three 50 µl SGE GT LL syringes (SGE Analytical Science Pty Ltd, Ringwood, Victoria, 
Australia), three stainless steel 20-gauge ball-tipped animal feeding needles (Sigma-Aldrich 
catalogue number CAD7902 (Sigma-Aldrich, St. Louis, MO, USA), sterile gauze, water, 70% 
w/v ethanol, and disposable gloves. The EPA and DHA used for the study of acute vascular 
inflammation were >99% pure free fatty acids, purchased from Nu-Chek Prep, Inc (Elysian, 
MN, USA). The EPA and DHA used for the study of atherosclerosis and chronic inflammation 
were >97% pure ethyl esters donated by Bizen Chemical Co. (Okayama, Japan). The Olive Oil 
used for all experiments was Bertolli Olive Oil (Florence, Italy). Each needle and syringe pair 
was used to deliver a single liquid, either EPA, DHA, or olive oil, and there was no cross-
contamination. 
 Mice were gavaged in accordance with the SAHMRI Standard Operating Procedure 
(SOP) (SOP9/098). The animal feeding needle was attached to the syringe, and the required 
volume was slowly drawn up. The mouse was scruffed with the thumb and index finger, and 
the middle finger was used to pull the head back to the neutral position. When the oropharynx 
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and body were aligned and the mouse was still, the feeding needle was advanced into the 
oropharynx, and into the oesophagus. The liquid was delivered, and the mouse was returned to 
its cage and monitored for any signs of distress that may represent aspiration. The animal 
feeding needle was flushed and rinsed with 70% ethanol, and then flushed and rinsed with tap 
water. After drying, the needle was used for the next mouse. 
2.8 Superficial facial vein bleeding (submandibular cheek bleeding) in mice 
 Superficial facial vein bleeding was performed using sterile 5 mm Goldenrod (Beacon 
Falls, CT, USA) animal lancets, following the SAHMRI Standard Operating Procedure (SOP) 
(4/087).  In brief, the volume of blood to be taken without rehydration was determined 
beforehand based on weight, in accordance with the SAHMRI SOP (4/086), with one drop of 
blood being estimated to be 50 µl. No more than 150 µl was taken from any mouse at any time. 
Mice were restrained by scruffing at the neck, using the thumb and index finger. The location 
of the inferior branch of the superficial facial vein was determined as lying underneath the 
visible sebaceous gland near the jaw. The intended puncture site was the common superficial 
facial vein. This was estimated to be 2 mm superior and 2 mm posterior to the sebaceous gland. 
A single pass was made with a lancet to elicit venous blood, which was collected for plasma 
into Sarstedt (Nümbrecht, Germany) Microvette® 500 K3E 500 µl EDTA collection tubes. 
After the predetermined blood volume was taken, pressure was applied with gauze until 
haemostasis was achieved. Mice were observed for ill-health for 10 mins after this procedure, 
and then returned to their cages if well. Blood was stored at 4oC until centrifugation, plasma 
isolation, and plasma storage at -80oC. 
2.9 Mouse general anaesthesia 
 Prior to general anaesthesia, mice were pre-oxygenated with 100% oxygen for 5 mins 
in a closed chamber. Induction of general anaesthesia was performed using 3% isoflurane plus 
supplemental oxygen delivered in the same closed chamber. Anaesthesia was confirmed using 
the toe-pinch test. Maintenance anaesthesia was achieved with 1.5% isoflurane plus 
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supplemental oxygen, delivered via a nose cone. To minimise dry eye from the nose cone, eye 
drops were administered to both eyes immediately after induction. After surgery, isoflurane 
was ceased, and 100% oxygen was delivered for 5 mins. Mice were allowed to recover alone 
in pre-warmed (37oC) recovery boxes, and when behaviour and activity levels returned to 
normal they were returned to their cages. 
2.10 Mice humane killing and terminal cardiac puncture 
 Mice were humanely killed under general anaesthesia by both terminal cardiac puncture 
and vital organ harvesting (heart, lungs and major blood vessels). After anaesthesia was 
confirmed, betadine was applied to the chest and abdomen, and terminal cardiac puncture was 
performed using a 25-gauge needle attached to a 1 ml syringe. The puncture was made 1 mm 
left of the midline, below the ribcage. The needle was advanced until flashback was seen, and 
after slight further advancement, complete exsanguination was performed. The heart, lungs, 
and major blood vessels were removed routinely, and isoflurane was continued for the entire 
procedure. 
2.11 Cholesterol and triglyceride assays in mice 
 Plasma total cholesterol and triglyceride levels in mice were measured by colorimetric 
assays, using LabAssay™ Cholesterol and LabAssay™ Triglyceride kits (Wako Pure 
Chemical Industries, Osaka, Japan). The assays were performed in 96-well plates. Plasma 
samples of 2 µl were added to 300 µl of chromogen reagent, and concentrations were calculated 
after generating a standard curve from standards of known concentrations. Plates were mixed 
and incubated for 5 mins at 37oC. They were then read using a GloMax® Discover microplate 
reader (Promega Corporation, Madison, Wisconsin, USA) using a main wavelength of 600 nm 
and a subtracted wavelength of 700 nm. 
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2.12 Assessment and quantification of plaque burden, collagen content and medial 
expansion 
 Mouse specimens of brachiocephalic artery and heart were stored in 10% neutral-
buffered formalin after harvesting, followed by dehydration, clearing and embedded in paraffin 
blocks. Specimens were cut at the level of the proximal brachiocephalic artery and the aortic 
sinus into 5 µm sections using a microtome, and then mounted onto silane-coated slides. The 
slides were then deparaffinised and rehydrated and subsequently stained with either 
haematoxylin and eosin (H&E) for plaque quantification and assessment of medial thickness, 
or the Masson’s trichrome stain for assessment of collagen content. Slides were mounted, 
coverslipped and photographed using the Nanozoomer C9600-12 slide scanner (Hamamatsu 
Photonics, Shizuoka, Japan). Image resolution was 228 nm per pixel. Images were saved 
uncompressed and then converted to .tiff files using ImagePro Premier 9.1 (Rockville, MD, 
USA) for analysis using ImageJ 1.51 (Rasband, W.S., ImageJ, U. S. National Institutes of 
Health, Bethesda, MD, USA). To quantify plaque area, the total artery area or aortic sinus area 
was measured using the Freehand selection tool. The area of plaque was then measured and 
expressed as a percentage of total artery or aortic sinus area. The thicknesses of the intimal and 
medial layers were measured using the Freehand selection tool, and expressed as a percentage 
of total artery area (“intimal and medial thickness”). The collagen content of plaque in the 
brachiocephalic artery or aortic sinus was quantified using a macro in ImageJ 1.51 published 
by Kennedy DJ et al(269). The macro is detailed below: 
 
run("Brightness/Contrast...");           set brightness and contrast to automatic 
run("RGB Stack");                            convert RGB image to a stack 
run("Convert Stack to Images");       split stack to three images, Red, Blue and Green 
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run("Image Calculator...", "image1=Blue operation=Divide image2=Red create 32-bit");                                             
divide blue by red 
run("Brightness/Contrast...");            set brightness and contrast to automatic 
run("Subtract...", "value=1.2");          discard all image where blue intensity is not 120% of red 
intensity    
run("Multiply...", "value=10000000"); convert all decimal values to integers 
run("Brightness/Contrast...");             set brightness and contrast to automatic 
run("Max...", "value=1");                    set max value to be 1 
run("Min...", "value=0");                     set min value to be 0 
run("Measure");                                  add up 1s and express as fraction of total area 
The collagen content was hence expressed as a percentage of total plaque area. 
2.13 Immunohistochemical staining 
 Immunohistochemical staining of mouse specimens was performed using the Avidin-
Biotin peroxidase technique. Harvested organs were initially stored in 10% neutral-buffered 
formalin for fixation, followed by dehydration, clearing and embedding in paraffin blocks. 
Glass slides were coated with silane. Thermo Scientific Menzel X72 SuperFrost® Plus 
(Thermo Fisher Scientific, Waltham, MA, USA) slides were loaded onto racks and rinsed in 
100% ethanol. They were dipped in a silane solution comprised of a 1 in 50 dilution of 3-
aminopropyl-triethoxy-silane in 100% ethanol, and subsequently rinsed in 100% ethanol and 
then deionised water before being dried. Specimens were cut into 5 µm sections using a 
microtome, and placed in a waterbath filled with deionised water, and then mounted onto 
silane-coated slides. The slides were dried in a 56oC oven for 1 hour.  
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To deparaffinise and rehydrate the slides, they were heated to 70oC for 10 mins and 
then sequentially incubated twice in 100% xylene for 3 mins each time, and then sequentially 
incubated twice in 100% ethanol for 3 mins each time. Endogenous peroxidase was then 
blocked by incubating slides in 0.5% hydrogen peroxide in methanol for 30 mins at room 
temperature.  The slides were then rinsed twice in PBS for 5 mins each time, and then placed 
in the antigen retrieval buffer (10 mM sodium citrate buffer, pH 6). This was heated in a 
microwave on the highest setting until the solution boiled.  The solution was then transferred 
to a second, calibrated microwave, which heated the solution to 98oC for 10 mins. The solution 
was allowed to cool at room temperature. This was followed by two sequential PBS washes 
for 5 mins each. Using a Pasteur pipette, the specimens were coated with 3% normal horse 
serum (NHS) for 30 mins. The NHS was drained from the slides, and specimens were then 
coated with the primary antibody at a concentration determined by prior optimisation. 
Incubation occurred overnight. The following day the slides were rinsed twice with PBS for 5 
mins each time, and then the specimens were coated with the secondary antibody for 30 mins 
at a concentration determined by prior optimisation. The slides were washed twice in PBS for 
5 mins each time. The tertiary antibody, a 1:1000 streptavidin peroxidase:NHS solution, was 
added to the specimens for 60 mins. The specimens were washed twice in PBS for 5 mins each 
time. A 75 mg/ml of 3,3’-diamino benzidine (DAB)/PBS solution was added to the specimens 
for exactly 7 mins, and then the slides were thoroughly rinsed in running water for 10 mins. 
The DAB was subsequently neutralised by adding an equal volume of 0.2 M potassium 
permanganate and the same volume of 2.0 M sulphuric acid. The mixture was allowed to stand 
overnight, and then 5% (w/v) of ascorbic acid was added until the colour disappeared. The 
solution was then discarded. The slides were counterstained in haemotoxylin and coverslipped 
using distyrene, plasticiser and xylene (DPX) Mounting Media (Labworks, Victoria, Australia) 
and Deckgläser 24 x 50mm cover slips (Menzel-Gläser GmbH, Braunscheig, Germany).  
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2.14 Antibodies used for immunohistochemical staining 
Table 2.3: Antibodies used for mouse acute vascular inflammation study 
Company and 
catalogue no. Name Host Reactivity Conjugation Clonality Isotype 
Primary 






human Unconjugated Monoclonal IgG 
Abcam - 
ab119871 Anti-ICAM1 antibody rat Mouse Unconjugated Monoclonal IgG2b 
Abcam - ab8101 Anti-MCP1 antibody rat Mouse Unconjugated Monoclonal IgG1 
Abcam - 
ab119830 Anti-CD18 antibody rat mouse Unconjugated Monoclonal IgG2A 
Isotype controls       
Abcam - 
ab18450 
Rat IgG2A kappa 
isotype control  rat   Monoclonal IgG2A 
Abcam - 
ab18407 
Rat IgG1 kappa 
isotype control rat   Monoclonal IgG1 k 
Abcam - 
ab18541 
Rat IgG2b kappa 





Rabbit IgG isotype 
control rabbit   Monoclonal IgG 
Secondary 
antibodies       
Abcam - ab7096 
Goat anti-rat IgG H&L 
Biotin preadsorbed goat rat Biotin Polyclonal IgG 
Abcam - ab7082 
Donkey anti-rabbit 
IgG H&L Biotin 

















Table 2.4: Antibodies used for mouse atherosclerosis and chronic inflammation study 
Company and 
catalogue no. Name Host Reactivity Conjugation Clonality Isotype 
Primary 
antibodies       
BD Biosciences 
- 550292 
Purified Rat Anti-Mouse 
CD107b (Mac-3) rat mouse Unconjugated Monoclonal IgG1 k 
Abcam - 
ab32575 
Anti-actin alpha smooth 
muscle antibody rabbit 
mouse, 
rat, human Unconjugated Monoclonal IgG 
Isotype controls       
Abcam - 
ab18412 
Rat IgG kappa isotype 
control rat   Monoclonal IgG1 k 
Abcam - 
ab172730 
Rabbit IgG monoclonal 
isotype control rabbit   Monoclonal IgG 
Secondary 




Rat IgG Antibody 




Rabbit IgG Antibody 
(H+L) goat rabbit Biotin Polyclonal IgG 
 
2.15 Immunohistochemical analysis using ImagePro Premier 9.1 and ImageJ 
 Slides were photographed using a Nanozoomer C9600-12 slide scanner (Hamamatsu 
Photonics, Shizuoka, Japan). Image resolution was 228 nm per pixel. Images were saved 
uncompressed and then analysed in either ImagePro Premier 9.1 (Rockville, MD, USA) or 
converted to .tiff files and analysed using ImageJ 1.51. 
2.15.1 Analysis using ImagePro Premier 9.1 
 After selecting and cropping a region of interest for analysis, the DAB analysis app was 
used to quantify the degree of antibody staining. Staining intensity was expressed as Integrated 
Optical Density (IOD) in units of lumens x pixels2 and corrected for total area. 
2.15.2 Analysis using ImageJ 
 Antibody staining was quantified in ImageJ using the Colour Deconvolution plugin, 
based on the technique described by Helps SC, et al(270). The original .ndip files were first 
opened in ImagePro Premier 9.1 and cropped and saved into .tiff format. Cropped sizes were 
either 7000 x 7000 pixels for quantification in brachiocephalic artery specimens, or 20000 x 
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20000 pixels for quantification in aortic sinus specimens. The .tiff images were then opened in 
Adobe Photoshop CS6 (Adobe Systems, San Jose, CA, USA), and the Magic Wand tool was 
used to select the background (canvas). The background colour changed to white (RGB 
255,255,255) using the paint bucket tool, to maximise contrast. The image was saved and then 
opened in ImageJ. Uneven illuminated background was removed using the “rolling ball” 
method as follows. The background was subtracted using the following commands: Process  
Subtract background  rolling ball radius of 50.0 pixels. DAB staining was quantified using 
the Colour Deconvolution Plugin version 3.0.1 using the following commands: Plugins  
Colour Deconvolution  H DAB. Three separate images are returned, and Image 2 with brown 
DAB staining visible being the image of interest. The region of interest for DAB analysis was 
then traced from Image 2, and then subjected to histogram analysis using commands Analyze 
 Histogram. The histogram list was then imported into a Microsoft Excel worksheet. The 
histogram list provides the number of pixels at each pixel intensity. The darkest pixels, which 
represent positive DAB staining are worth 0, whereas the lightest pixels are worth 255. These 
values were inverted so that maximum DAB staining was worth 255, and absence of staining 
was worth 0. To estimate the amount of DAB in a section, each pixel intensity was multiplied 
by the number of pixels at that intensity (0 to 255) and then summed. Hence, this dimensionless 
weighted DAB value (DABwt) = Σ[(255-histogramvalue) x (histogramvaluecount)]. To 
express this as a percentage, this value was divided by the maximum theoretical DAB, where 
each pixel in the image has a histogram value of 255, and multiplied by 100, obtain 
“DABwt%”. 
Therefore, DABwt% values obtained represent an estimate of the amount of DAB (and 
thus antigen) on the original tissue section. The DABwt% can then be compared with different 
sections (images) and the results subjected to statistical analysis. 
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2.16 Oil Red O staining and analysis using ImageJ 
 Lipid content in mouse aortas was assessed and quantified by Oil Red O staining. 
Harvested aortas were stored in formalin and then adventitial fat was carefully and thoroughly 
removed under stereo microscopy. Aortas were then cut and opened en-face for staining and 
returned to formalin until Oil Red O staining was performed. The Oil Red O solution for 
staining consisted of 1 g of Oil Red O powder (Sigma-Aldrich), 250 ml of propan-2-ol, and 
150 ml of MilliQ water (Millipore Corporation, Billerica, MA, USA). First, the Oil Red O 
powder was added to the propan-2-ol while stirring. After 10 mins of stirring, the MilliQ water 
was added, and stirring continued for another minute. The solution was left to stand for 6 mins, 
and then filtered through a 0.2 μm vacuum hose. The solution was used to stain aortas 
immediately. 
2.16.1 Oil Red O staining method 
 Aortas with adventitial fat removed and cut for en-face staining were first rinsed in 
distilled water and then dipped in 60% propan-2-ol solution, then incubated in the Oil Red-O 
solution for 15 mins. They were then dipped in 60% propan-2-ol again, and then rinsed in 
distilled water, before being transferred to 10% neutral-buffered formalin again, for later 
pinning and photography. 
2.16.2 Photography of stained aortas 
 Aortas were placed in 100 mm petri dishes filled with paraffin wax for pinning. Aortas 
were pinned en-face using 0.15 mm rod diameter Minutien Pins (Fine Science Tools, North 
Vancouver, British Columbia, Canada), to expose as much luminal surface area as possible. 
Aortas were photographed using a Zeiss Axio Scope A1 microscope polarised light microscope 
(Carl Zeiss AG, Oberkochen, Germany). All aortas were photographed with a colour 
temperature of 5500K, and an exposure time of 5 milliseconds, which were found to be the 
optimal settings. Images were saved in .tiff format. Three to four overlapping segments of each 
aorta were photographed separately. 
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2.16.3 Analysis of Oil Red O staining 
 Segments of images were merged in Adobe Photoshop CS6 using the Photomerge tool. 
They were then opened in ImageJ 1.51 and then the background was subtracted using the 
command Process  Subtract background, and selecting a rolling ball radius of 5.0 pixels, 
which was found to be optimal. The region of interest was selected by tracing around the aorta 
using the Freehand selection tool. An RGB stack was created, and the green channel was 
selected. A threshold was set using the commands Image  Adjust  Threshold. The 
minimum and maximum thresholds were set at 0 and 120 respectively as these settings were 
found to be optimal. The total area staining red was then determined by selecting Results  
Area, and was expressed as a percentage of total aortic luminal surface area. 
2.17 Laboratory analytes in humans 
 Venepuncture was performed on fasting human study participants by accessing forearm 
veins using the needle and syringe method. Blood was collected in EDTA tubes for plasma, 
and clot activating tubes for serum. Serum specimens were initially allowed to clot for 30 mins 
at room temperature, and both serum and plasma specimens were stored at 4oC until laboratory 
analysis was performed. Blood was sent to SA Pathology laboratories for commercial analysis 
for lipid profile (total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein 
cholesterol, and triglycerides), lipoprotein (a), and high sensitivity C-reactive protein (hs-
CRP). Human studies were performed at SAHMRI and were approved by the University of 
Adelaide Human Research Ethics Committee, and authorised after a SAHMRI Site Specific 
Assessment. 
2.18 Statistical analysis 
GraphPad Prism 7 (GraphPad Software Inc, La Jolla, CA, USA), SPSS 19 (IBM 
Corporation, Armonk, New York, USA), and Microsoft Excel 2016 (Microsoft, Albuquerque, 
NM, USA) were used to analyse data. Categorical data were analysed using the Chi-Square 
74 
 
Test or Fisher’s Exact Test if n < 5 for any group. The D’Agostino-Pearson normality test was 
performed to determine whether continuous data was normally-distributed. Normally-
distributed data were analysed using either the T-test if comparing means between two groups, 
or the One-way Analysis of Variance (ANOVA) if comparing means between multiple groups. 
If correcting for multiple comparisons, the Dunnett test was used. If comparing means between 
multiple groups adjusted for a covariate, an Analysis of Covariance (ANCOVA) was 
performed. The Two-way ANOVA test was used to compare means between multiple groups 
depending on two independent categorical variables. If continuous data were not normally-
distributed, analysis was performed between two groups using the Mann-Whitney U Test, and 
the Kruskal-Wallis test if more than two groups were being compared. If correcting for multiple 
comparisons, Dunn’s test was used. Statistical correlations were analysed using a linear 














CHAPTER 3: THE IMPACT OF OMEGA-3 FATTY ACIDS ON CIRCULATING 













Background: Atherosclerosis is a systemic disease with multiple established systemic risk 
factors. Recent randomised trial evidence has demonstrated a reduction in major adverse 
cardiovascular events with omega-3 fatty acid supplementation. Their high concentrations in 
blood after ingestion present substantial opportunity to favourably affect the circulating 
mediators of atherosclerosis. The aim of this systematic review was to evaluate the impact of 
omega-3 fatty acids (O3FAs) compared to placebo on measured levels of circulating mediators 
of atherosclerosis in humans. These fall into the following four classes: atherogenic 
lipoproteins (native LDL, oxidised LDL, VLDL, IDL, Lp(a)), which are components of non-
HDL cholesterol; inflammatory cytokines and adipokines (IL-1β, IL-6, IL-8, TNF-α, MCP-1, 
IFN-γ, leptin, resistin); atherogenic amino acids and derivatives (homocysteine, asymmetric 
dimethylarginine); and advanced glycation endproducts (AGEs). 
Methods: To obtain the highest quality evidence from human clinical trials of O3FA 
supplementation, only randomised, placebo-controlled trials from the Cochrane Library with 
an NHMRC Evidence Level of I or II were included. Search dates were from database inception 
until January 2018, with independent record screening by two authors. Atherogenic mediators 
were required to be measured in blood either directly in vivo, or ex vivo in cell culture after 
human omega-3 supplementation. The heterogeneity of omega-3 formulations available, and 
the inclusion of in vivo and ex vivo studies, required qualitative rather than quantitative 
assessments of effect sizes for each mediator. 
Results: 1012 results were obtained, with 109 studies eligible for inclusion, comprised of 1 
Cochrane systematic review, 6 non-Cochrane systematic reviews, and 102 randomised 
controlled trials. It was concluded that O3FAs reduce atherosclerotic mediators from all four 
classes. Specifically, significant reductions were noted for oxLDL, VLDL-C, non-HDL-C, 
leptin, homocysteine, and AGEs. Mild reductions were noted for IL-6, and TNF-α. No 
significant changes were noted for the other mediators evaluated. 
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Conclusions: This systematic review of the literature demonstrates that omega-3 supplementation 
in humans has favourable effects on all four classes of circulating atherogenic mediators.  This 
provides mechanistic insights for the reduction in cardiovascular events seen in a number of clinical 
trials of both fish and fish oil consumption. There is a need to further elucidate the effects of O3FAs 
at the tissue level, especially those of EPA compared to DHA, and to correlate these with clinical 
outcomes. 
 


















3.1.1 Introduction and rationale for systematic review 
Atherosclerosis is a complex inflammatory disease(4), and the factors leading to its 
initiation and progression have been extensively studied but not been fully elucidated. As a 
systemic disease, the mediators of atherosclerosis include systemic factors such as 
hypertension(271-274), hyperlipidemia(273, 275-277), diabetes mellitus(278-280), tobacco smoking(281-
283), and hyperhomocysteinaemia(284-286). There has been considerable interest in circulating 
atherogenic factors, particularly those that are pro-inflammatory, as new pathogenic roles for 
cellular signalling molecules, chemokines, and lipoproteins are elucidated. It is predictable that 
compounds with anti-inflammatory, anti-hypertensive, and lipid-modulating effects would 
have favourable effects on atherosclerosis. Omega-3 fatty acids are such compounds(195, 287-289), 
and there is evidence for anti-atherogenic effects, with reductions in atherosclerotic plaque 
volume seen in animal studies(258, 261). Advances in plaque imaging have allowed changes in 
plaque volume to be measured in vivo, however few such studies have been performed studying 
the effects of omega-3s, and these have produced inconsistent results(290, 291).  
Human cardiovascular outcome trials (CVOTs) of dietary omega-3 intake (i.e. fish 
consumption) have demonstrated a dose-dependent reduction in mortality from coronary heart 
disease(222).  However, CVOTs of fish oil supplementation have produced inconsistent results 
and have frequently suffered from methodological issues such as the use of low omega-3 doses. 
Both the JELIS (2007) and GISSI Prevenzione (1999) studies demonstrated reductions in major 
adverse cardiovascular events (MACE) in the primary and secondary prevention settings 
respectively(226, 227). The later OMEGA (2010) and ORIGIN (2012) secondary prevention 
studies, and the ASCEND (2018) and VITAL (2018) primary prevention studies, reported no 
reduction in MACE, and thus challenged the purported cardioprotective effects of omega-3 
fatty acids(229, 230, 232, 233). In contrast to these studies which mostly treated with no more than 
1g of omega-3 fatty acids per day, the REDUCE-IT study (2018) evaluated the effects of 4 g 
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per day of the prescription EPA formulation icosapent ethyl(234). In this study of 
hypertriglyceridemic patients on statin therapy with a history of cardiovascular disease or 
diabetes mellitus, EPA reduced the primary endpoint of a composite of cardiovascular death, 
nonfatal MI, nonfatal stroke, coronary revascularisation and unstable angina by 25% compared 
to placebo. This occurred irrespective of changes in triglyceride levels, and hence there are 
likely to be alternative mechanisms for the benefits observed. EPA (as ethyl ester) was provided 
at a dose of 1.8 g per day to statin-treated hyperlipidemic patients in the JELIS study, and a 
significant, 19% relative reduction in the primary endpoint of any major coronary event was 
seen, compared to placebo(227). REDUCE-IT and JELIS used higher-than-average omega-3 
doses, and provided EPA only. The cardioprotective effects of omega-3 fatty acids are likely 
to be both dose and formulation dependent, however the mechanisms for this observation are 
at present unclear. 
Omega-3 fatty acids are known to impact on multiple atherogenic conditions, such as 
inflammation, hypertension and hyperlipidemia. Omega-3 fatty acids are known to modulate 
inflammation through several mechanisms. These include incorporation into the phospholipids 
of inflammatory cells(292, 293), reduced eicosanoid production(294),  synthesis of resolvins(295), 
inhibition of the pro-inflammatory NF-κB transcription pathway(296-298), induction of the anti-
inflammatory PPAR-γ transcription pathway(299), disruption of lipid rafts(300, 301), and binding 
to the G-protein coupled receptor GPR120(302) which initiates an anti-inflammatory signalling 
cascade. Omega-3 fatty acids have been shown to reduce systolic and diastolic blood 
pressure(303), as well as triglycerides(304). The effects of omega-3 fatty acids on lipoproteins is 
less pronounced, with increases in HDL-C and LDL-C seen with combinations of EPA and 
DHA(194, 305, 306).  
After oral consumption, omega-3 fatty acids appear in the bloodstream within an hour, 
and are in their free forms for up to 8 hours before they are redistributed(307). Their 
incorporation into tissues, however, including the time taken to do this and maximum 
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concentration achievable, is highly variable(308). Indeed, after prolonged, high dose oral omega-
3 consumption, total concentrations in tissues can be as little as 1 per cent of total fatty 
acids(308). This is in contrast to blood, in which omega-3s can comprise almost 10% of total 
body fatty acids(309). Hence, there is substantial opportunity for omega-3 fatty acids to impact 
the circulating mediators of atherosclerosis. The vascular endothelium has direct, constant 
contact with the bloodstream, and minute changes in the levels of circulating atherogenic 
mediators affect endothelial function. The atherogenicity of all of these factors involves 
induction of inflammation in the vessel wall(310-316). If omega-3 fatty acids do indeed have 
clinically-significant anti-atherogenic properties, it is likely that an important component of 
these is their impact on circulating atherosclerosis mediators. This would be the earliest 
mechanism of altering vascular inflammation. This has not been systematically investigated. 
3.1.2 Objectives 
The aim of this systematic review is to evaluate the current literature on the impact of 
omega-3 fatty acids on circulating mediators of atherosclerosis. These mediators all have clear 
evidence for their atherogenicity and can be categorised into four classes: 
(i) Atherogenic lipoproteins, including (native) LDL(317, 318), oxidised LDL(319), 
VLDL(320, 321), IDL(320), and Lp(a)(322). These lipoproteins are components of non-HDL 
cholesterol. 
(ii) Inflammatory cytokines and adipokines, including IL-1β(323-325), IL-6(326), IL-
8(327), TNF-α(328), MCP-1 (CCL2) (329, 330), IFN-γ(331), leptin(332, 333) and resistin(334, 335). 
(iii) Atherogenic amino acids and derivatives, including homocysteine(336, 337) and 
asymmetric dimethylarginine (ADMA)(315, 338, 339). 




This systematic review aims to incorporate the highest quality of evidence from human 
clinical trials of omega-3 supplementation, through accessing only high-quality clinical trial 
databases. 
3.2 Review Protocol 
This study was performed based on the preferred reporting items for systematic reviews and 
meta-analyses (PRISMA) guidelines(342). 
3.2.1 Sources 
A comprehensive search of the medical literature was performed from database inception until 
January 2018 using the Cochrane Library to obtain only the highest quality clinical trials. 
3.2.2 Search strategy 
The following search string was used for the Cochrane Library search: 
("MeSH descriptor: [Fish Oils] explode all trees" OR "MeSH descriptor: [Fishes] explode all 
trees" OR "MeSH descriptor: [Fatty Acids, Omega-3] explode all trees" OR “MeSH descriptor: 
[Fatty Acids, Unsaturated] explode all trees” OR “MeSH descriptor: [Eicosapentaenoic Acid] 
explode all trees” OR “MeSH descriptor: [Docosahexaenoic Acids] explode all trees” OR 
“MeSH descriptor: [alpha-Linolenic Acid] explode all trees” OR “Docosapentaenoic acid”) 
AND 
(“MeSH descriptor: [Cholesterol, LDL] explode all trees” OR “Oxidized LDL” OR “oxidized 
low density lipoprotein” OR “MeSH descriptor: [Cholesterol, VLDL] explode all trees” OR 
“MeSH descriptor: [Lipoproteins, IDL] explode all trees” OR “MeSH descriptor: 
[Lipoprotein(a)] explode all trees” OR “non-HDL” OR “non-HDL Cholesterol” OR “MeSH 
descriptor: [Interleukin-1beta] explode all trees” OR “MeSH descriptor: [Interleukin-6] 
explode all trees” OR “MeSH descriptor: [Interleukin-8] explode all trees” OR “MeSH 
descriptor: [Tumor Necrosis Factor-alpha] explode all trees” OR “MeSH descriptor: 
[Chemokine CCL2] explode all trees” OR “MeSH descriptor: [Interferon-gamma] explode all 
82 
 
trees” OR “MeSH descriptor: [Leptin] explode all trees” OR “MeSH descriptor: [Resistin] 
explode all trees” OR “MeSH descriptor: [Homocysteine] explode all trees” OR 
“dimethylarginine” OR “MeSH descriptor: [Glycation End Products, Advanced] explode all 
trees”) 
3.2.3 Eligibility criteria 
 Only articles written in English were included. Only studies that measured the pre-
specified mediators in the context of omega-3 exposure were included. Studied had to be high 
quality (NHMRC Evidence level I or II(343)) randomised placebo-controlled studies of omega-
3 supplementation. Atherogenic mediators were required to be measured in blood either 
directly in vivo, or ex vivo in cell culture after human omega-3 supplementation. Studies in 
which omega-3 levels were measured in the absence of omega-3 supplementation were 
excluded. Studies were eligible if omega-3 supplementation included at least one of EPA, DPA 
or DHA. Studies of gene expression of atherogenic mediators were not included.  
3.2.4 Study selection 
 The titles, abstracts and keywords of every record were retrieved and separately 
screened by two authors (AP and JA) to find potentially relevant studies for the full review. 
Any discrepancies were resolved by discussion. Full text articles were retrieved if records 
indicated that eligibility criteria were likely to be met. Duplicate records were excluded.  
3.2.5 Data collection process 
 Data were extracted from the studies independently by AP and JA. Disagreements were 
resolved by discussion. The data extracted were: study type, study design, study quality, sample 
size, method and nature of omega-3 exposure, controls used, treatment duration, analytes 
(mediators) measured, and results including changes in measured levels with 
intervention/exposure. When studies included more than one dose or duration of an omega-3 
supplement, the results from the maximum dose and maximum duration were included. When 
studies included separate EPA and DHA treatment arms, results for both were reported. 
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3.2.6 Quality of studies 
 The quality of each study was appraised, and the level of evidence was graded from I 
to IV based on the NHMRC Evidence Hierarchy(343) for human studies. 
3.2.7 Summary measures 
 Changes in the levels of circulating atherogenic mediators were expressed as either as 
a concentration change or a percentage change. Summaries of studies that measured percentage 
changes were graphed separately to those that measured concentration changes. 
3.2.8 Synthesis of results 
 Studies of omega-3 supplementation are heterogeneous, with different study designs, 
omega-3 formulations, doses, durations, and placebo controls used. In this systematic review, 
circulating atherogenic mediators were measured either in vivo or ex vivo, adding another 
source of heterogeneity. Therefore, an overall effect size of omega-3 supplementation on any 
individual mediator was assessed qualitatively, as it was not possible to accurately do so 
quantitatively.  
3.3 Results 
3.3.1 Study characteristics and selection 
The Cochrane Library search yielded 1012 results, of which 2 were Cochrane 
systematic reviews, 14 were non-Cochrane systematic reviews and meta-analyses, 992 were 
randomised controlled clinical trials, and 4 were economic evaluations. In total there were 1012 
results to review. 
One Cochrane systematic review, 6 non-Cochrane systematic reviews and meta-
analyses, 102 randomised controlled trials, and 0 economic evaluations were eligible for 
inclusion in this systematic review. Hence, 109 of 1012 studies were included in the analysis. 
Reasons for study exclusion are itemised in Table 3.1 below. 
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Table 3.1: Reasons for exclusion of studies from systematic review 
Reason for study exclusion No. of studies 
Not a study of omega-3 supplementation 602 
Results do not include pre-specified circulating mediators 132 
Full text article not available 51 
Multiple omega-3 formulations compared in the same study 25 
Results are not clearly or suitably reported 22 
Lack of a suitable choice or dose of a placebo 21 
Omega-3 supplementation includes ALA only (no EPA, DPA or DHA) 16 
Study of gene expression 7 
Article not written in English 6 
Unsuitable study design 5 
Economic evaluation only 4 
Lack of suitable omega-3 intervention or sufficient supplementation 3 
Duplicate data from another article 3 
Significant confounders present 3 
Multiple subject groups for same intervention 2 
Outcome measures are not relevant 1 
TOTAL 903 
 
3.3.2 Quality of studies 
 All studies, aside from the four economic evaluations, had an NHMRC evidence level 
of I or II. 
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3.3.3 Synthesis of results 
 The studies analysed for each atherogenic mediator were not compared to each other in 
the form of a meta-analysis due to the clinical and methodological heterogeneity observed 
across studies. For example, measurements of atherogenic mediators in human serum versus 
in cell culture media supplemented with human serum are not comparable. Weighting systems 
such as that described by Deeks et al(344) cannot be applied. Effect sizes and the homogeneity 
of studies were also not comparable. Instead, the results of studies have been reported and 
graphically represented. On each graph, a qualitatively-estimated overall effect for each 
mediator is indicated. Systematic reviews and meta-analyses have suffixes of “S/R” and “M/A” 
added to author names on forest plots to highlight the higher level of evidence. Studies with a 
statistically significant overall effect are presented in blue. Studies are graphed together in the 
same units. A 95% confidence interval is presented when reported, or when it can be calculated 
from the original manuscript(345). 
 A summary of the included studies is presented in Appendix A. 
3.3.3.1  Atherogenic lipoproteins 
 Sixty-one studies measured (native) LDL-C, including two systematic reviews and one 
meta-analysis. In 16 studies, the net effect of omega-3s was a statistically significant increase 
in LDL-C. In 7 studies, the net effect was a significant decrease in LDL-C. No significant 
change was seen in 38 studies. Overall, omega-3s were concluded to not significantly alter 
LDL-C, with the average change amongst positive studies of +0.11 mmol/L, and an average 


























Figure 3.1: Summary of studies of omega-3 fatty acids and LDL-C. Studies with 
statistically significant changes are highlighted in blue. n=61 studies. 
-2 -1 0 1 2
Hartweg J et al 2008 S/R, n=1075
Bernstein A et al 2012 M/A, n=485
Eslick G et al 2009 S/R, n=16511
Root M et al 2013, n=57
Tardivo A et al 2015, n=63
Simons L et al 1985, n=25
Gharekhani A et al 2016, n=54
Dunbar R et al 2015, n=647
Bragt M et al 2012, n=20
Mori T et al 1991, n=27
Zheng J et al 2016, n=185
Buckley R et al 2004 EPA, n=42
Buckley R et al 2004 DHA, n=42
Poreba M et al 2017, n=74
Zhang Jet al 2010, n=92
Maki K et al 2011, n=31
Bays H et al 2012, n=229
Mori T et al 2000 EPA, n=56
Mori T et al 2000 DHA, n=56
Bays H et al 2010 A, n=245
Moeinzadeh F et al 2016, n=52
Rizza S et al 2009, n=50
Brinton E et al 2013, n=501
Jacobson T 2012, n=229
Ballantyne C et al 2015, n=427
Contacos C et al 1993, n=40
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Thirteen studies measured oxidised LDL (oxLDL), and in 6 studies omega-3 fatty acids 
significantly reduced oxLDL levels. In no studies did omega-3 fatty acids significantly increase 
oxLDL levels. Overall, omega-3 fatty acids were concluded to decrease oxLDL, with the 
average change amongst positive studies of -7.7%, and an average change amongst all studies 









Figure 3.2: Summary of studies of omega-3 fatty acids and oxidised LDL. Studies with 
statistically significant changes are highlighted in blue. n=13 studies. 
 
Twenty studies measured VLDL-C, and in 14 studies omega-3 fatty acids significantly 
reduced VLDL-C levels. In no studies did omega-3 fatty acids significantly increase VLDL-C 
levels. Overall, omega-3 fatty acids were concluded to decrease VLDL-C levels, with the 
average change amongst positive studies of -0.33 mmol/L, and an average change amongst all 
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Figure 3.3: Summary of studies of omega-3 fatty acids and VLDL-C. Studies with 
statistically significant changes are highlighted in blue. n=20 studies. 
 
 Five studies measured IDL-C, and in one study omega-3 fatty acids significantly 
reduced IDL-C levels, with a change of -0.04 mmol/L. The average change amongst all studies 
was -0.03 mmol/L. There was no significant effect of omega-3 fatty acids on IDL-C 
demonstrated, see Figure 3.4. 
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Figure 3.4: Summary of studies of omega-3 fatty acids and IDL-C. Studies with 
statistically significant changes are highlighted in blue. n=5 studies. 
 Six studies measured Lp(a), and in two studies omega-3 fatty acids significantly 
reduced Lp(a) levels, with an average change of -14.3%. Four studies showed no change in 
Lp(a). The overall change from all studies was -1.8%, see Figure 3.5. Omega-3 fatty acids were 








Figure 3.5: Summary of studies of omega-3 fatty acids and Lp(a). Studies with statistically 
significant changes are highlighted in blue. n=6 studies. 
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 Total non-HDL cholesterol was measured in 17 studies, and in 12 studies there was a 
significant reduction with omega-3 fatty acids. In 2 studies, non-HDL-C was significantly 
increased. The average change was -0.24mmol/L, see Figure 3.6. Omega-3 fatty acids were 
















Figure 3.6: Summary of studies of omega-3 fatty acids and non-HDL-C. Studies with 
statistically significant changes are highlighted in blue. n=17 studies. 
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Atherogenic lipoproteins were overall reduced by omega-3 fatty acid supplementation, 
both as a collective non-HDL-C class, and individually for VLDL-C and Lp(a). Notably, 
oxLDL was reduced, and no change was seen in with LDL-C.  
3.3.3.2  Inflammatory cytokines and adipokines 
 Changes in IL-1β with omega-3 supplementation were reported in either pg/ml units (6 
studies) or as a percentage change (5 studies). In the former, 3 out of 6 studies demonstrated a 
significant reduction in IL-1β with omega-3 supplementation, with an overall average change 
of -0.6 pg/ml. In the latter, omega-3 supplementation did not significantly reduce IL-1β in any 
of the studies, with an average change of +7.0%, see Figures 3.7 and 3.8. It was concluded that 








Figure 3.7: Summary of studies of omega-3 fatty acids and IL-1β reported as pg/ml. 
Studies with statistically significant changes are highlighted in blue. n=6 studies. 
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Figure 3.8: Summary of studies of omega-3 fatty acids and IL-1β reported as %. No 
studies had statistically significant changes. n=5 studies. 
 
Changes in IL6 with omega-3 supplementation were likewise measured in both pg/ml 
and % change. In the former, 9 out of 26 studies demonstrated a significant reduction after 
omega-3 supplementation, with an average change of -0.3 pg/ml. In the latter, omega-3 fatty 
acids reduced IL6 in 5 out of 14 studies, and increased it in 2, with an average change of -
17.6%. Omega-3 fatty acids were concluded to mildly reduce IL6, see Figures 3.9 and 3.10. 
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Figure 3.9: Summary of studies of omega-3 fatty acids and IL6 reported as pg/ml. Studies 
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Figure 3.10: Summary of studies of omega-3 fatty acids and IL6 reported as %. Studies 
with statistically significant changes are highlighted in blue. n=14 studies. 
 
The effect of omega-3 supplementation on IL8 was measured in both pg/ml (1 study) 
and % change in 2 studies. One study in the latter demonstrated a statistically significant 
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Figure 3.11: Summary of studies of omega-3 fatty acids and IL-8. The study with a 
statistically significant change is highlighted in blue. n=2 studies. 
 
 Changes in TNF-α were measured in pg/ml and %, and for the former, 6 out of 17 
studies demonstrated a reduction with omega-3 supplementation, with an average change of -
0.6 pg/ml. For the latter, omega-3s significantly reduced TNF-α in 3 out of 16 studies, and 
increased TNF-α in one study. The average change was -5.0% (see Figures 3.12 and 3.13). 
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Figure 3.12: Summary of studies of omegas-3 fatty acids and TNF-α reported in pg/ml. 
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Figure 3.13: Summary of studies of omegas-3 fatty acids and TNF-α reported in %. 
Studies with statistically significant changes are highlighted in blue. n=16 studies. 
 
MCP-1 was measured in 3 studies, in both pg/ml and % changes. In the former, 1 out 
of 2 studies demonstrated a significant reduction with omega-3 fatty acids, and there was no 
significant change with the latter (see Figures 3.14 and 3.15). No significant effect of omega-
3s on MCP-1 could be demonstrated. 
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Figure 3.14: Summary of studies of omega-3 fatty acids and MCP-1 reported in ng/ml. 
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Figure 3.15: Summary of studies of omega-3 fatty acids and MCP-1 reported in %. The 
single study did not have a statistically significant change. 
 
 The effects of omega-3 fatty acids on IFN-γ were measured in 2 studies as % change. 
In one study there was a statistically-significant reduction, with an overall change of -53% (see 
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Figure 3.16: Summary of studies of omega-3 fatty acids and IFN-γ. The single study with 
a statistically significant change is highlighted in blue. n=2 studies. 
 
 The adipokine leptin was measured in 9 studies, and in 4 there was a significant 
reduction with omega-3 fatty acids. The average change was -0.22 ng/ml (see Figure 3.17). It 
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Figure 3.17: Summary of studies of omega-3 fatty acids and leptin. Studies with 
statistically significant changes are highlighted in blue. n= 9 studies. 
 
 The adipokine resistin was not measured in any of the studies. 
 The atherogenic inflammatory mediators were overall mildly reduced by omega-3 fatty 
acids, with effects on the cytokines IL6 and TNF-α, as well as the adipokine leptin. 
3.3.3.3  Atherogenic amino acids and derivatives 
 Homocysteine was evaluated in 11 studies, and in 8 studies omega-3 fatty acids 
significantly reduced circulating homocysteine levels. In one study homocysteine was 
significantly elevated, and the overall average change was -1.8 μmol/L (see Figure 3.18). 
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Figure 3.18: Summary of studies of omega-3 fatty acids and homocysteine. Studies with 
statistically significant changes are highlighted in blue. n= 11 studies. 
 
 The impact of omega-3 fatty acids on asymmetric dimethylarginine (ADMA) was 
evaluated in two studies. No significant changes were seen, with an average change of +3 
μmol/L (see Figure 3.19) 
Omega-3 fatty acids significantly reduced the atherogenic amino acid homocysteine, 
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Figure 3.19: Summary of studies of omega-3 fatty acids and ADMA. The two studies did 
not have statistically significant changes. n=2 studies. 
 
3.3.3.4  Advanced glycation end products 
 Changes in levels of advanced glycation end products (AGEs) with omega-3 fatty acid 
supplementation were investigated in a single study. AGEs are conventionally measured in 
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Figure 3.20: Single study of omega-3 fatty acids on advanced glycation endproducts 
(AGEs). The result was statistically significant and presented in blue. 
 
3.4 Discussion 
 This systematic review evaluated the impact of omega-3 fatty acids on circulating 
atherogenic mediators, and included only high-quality studies catalogued in the Cochrane 
library. Systematic reviews, meta-analyses, and randomised placebo-controlled trials were 
included exclusively. The recently-published clinical trial REDUCE-IT provided evidence for 
an atheroprotective effect of omega-3 fatty acids(234), however previously published CVOTs of 
omega-3 fatty acids, especially those of fish oil supplementation, produced variable results and 
suffered from limitations of study design(346). To understand the cardioprotective effects of 
omega-3 fatty acids, and the possible reasons for disparity amongst studies, it is essential to 
directly study their effects on atherogenic mediators. Despite the associations of innumerable 
circulating factors with atherosclerosis, only mediators with clear evidence for direct 
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atherogenicity were evaluated. Given the heterogeneity of study design, which included both 
in vivo and in vitro studies, it was not possible to apply a weighting to individual studies as is 
commonly performed in systematic reviews. Nonetheless, general conclusions could be made 
from the results generated. 
Omega-3 fatty acids reduced levels of circulating atherogenic markers in all four 
classes. Among the atherogenic lipoproteins studied, non-HDL cholesterol, oxLDL, VLDL-C 
and Lp(a) were reduced by omega-3 fatty acids. LDL-C levels were not significantly altered 
by omega-3 fatty acids. It is important to note that triglycerides were not included in this review 
as they are not directly atherogenic(347). Rather, high triglyceride levels associate with higher 
cardiovascular risk by virtue of triglyceride-rich lipoproteins and remnant particles(347). The 
mechanisms by which omega-3s reduce levels of atherogenic lipoproteins are not completely 
understood. There is evidence that omega-3 fatty acids reduce VLDL production rate(348), and 
this may be due to their ability to reduce hepatic fat content(349) or reduce fatty acid availability 
for triglyceride and subsequent VLDL production by means of increased fatty acid 
oxidation(350, 351). Omega-3 fatty acids have been shown to increase hepatic production of LDL 
particles(348), which likely explains the increased LDL-C levels seen in some studies.  
Omega-3 fatty acids reduced the cytokines IL6 and TNF-α to a mild degree. This is 
likely due to the inhibitory effects of omega-3s on the pro-inflammatory NF-κB transcription 
pathway(195), as well as being a natural ligand for the anti-inflammatory nuclear receptor PPAR-
γ(352). Despite the known inhibitory effects of omega-3 fatty acids on activation of the NLRP3 
inflammasome(353-355), no overall effect was seen on IL-1β levels. This suggests additional 
effects of omega-3s on IL-1β regulation. This is particularly relevant given the reduction in 
major adverse cardiovascular events seen with IL-1β lowering seen in the CANTOS study(120). 
In this study, canakinumab reduced recurrent cardiovascular events in patients with a history 
of myocardial infarction and elevated C-reactive protein levels, without lowering lipid levels. 
The effects of omega-3 fatty acids on the inflammasome, in particular the regulation of IL-1β, 
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require further study. Insufficient studies of IL8, MCP-1, IFN-γ and resistin were included in 
this systematic review to allow conclusions to be made. 
Omega-3 fatty acids significantly reduced homocysteine levels, likely due to regulatory 
effects on genes associated with homocysteine metabolism(356). The upregulation of 
cystathionine-γ-lyase (CSE) with both EPA and DHA, the upregulation of 5-
methyltetrahydrofolate reductase (MTHFR) with DHA and ALA, and the downregulation of 
methionine adenosyltransferase (MAT) with EPA, DHA and ALA, have all been demonstrated, 
and likely contribute to the significant reductions in homocysteine levels seen in this systematic 
review(356).  Only two studies measured ADMA levels, with no effects observed. 
A single study measured advanced glycation endproducts, demonstrating a significant 
reduction. The mechanisms by which omega-3 fatty acids may reduce AGEs are unclear, 
although NFκB has been implicated in their formation(357). Given the significant role of AGEs 
in atherogenesis, the lack of high-quality studies yielded by this review suggests an important 
area of future investigation. This may identify new roles for omega-3 fatty acids in the 
management of patients with diabetes mellitus. 
This systematic review provides mechanistic insights into the atheroprotective effects 
of omega-3 fatty acids. They reduce levels of all four classes of circulating atherogenic 
mediators and hence this is their earliest mechanism of reducing vascular inflammation after 
ingestion. Given that the atheroprotective effects of omega-3 fatty acids appear to be dose-
responsive based on dietary studies, and have been demonstrated with high omega-3 doses in 
fish oil studies, there may now be further impetus to routinely measure omega-3 levels in blood 
and aim for high levels. Thus far, no correlation has been shown between the concentration of 
blood omega-3 levels and the degree of suppression of circulating atherogenic mediators, 
although this would be predicted. Several methods exist for measuring and expressing blood 
omega-3 levels. Firstly, measuring the proportion of total fatty acids in whole blood comprised 
of omega-3s, which has an inverse association with sudden death(212). Secondly, measuring the 
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total omega-3 content of the red cell component of blood, which forms the basis of the Omega-
3 Index. This value has cut-offs that predict a higher mortality (< 4%) or a lower mortality (> 
8%)(213). Thirdly, measuring the ratio of pro-inflammatory omega-6s to anti-inflammatory 
omega-3s in whole blood, i.e. the omega 6:3 ratio. It is conceivable that since omega-6 and 
omega-3 fatty acids compete with each other for incorporation into cell membranes(216, 217), a 
higher relative omega-6 content could dampen the beneficial effects of omega-3s even if they 
were present in high concentrations. The measurement of blood omega-3 fatty acid content and 
its relationship with circulating atherosclerotic mediators, and ultimately cardiovascular 
outcomes requires further investigation.  
This systematic review has several limitations. The literature search was restricted to 
studies with an NHMRC Class I or II level of evidence, and were extracted from a single 
database (Cochrane). This was to maximise the quality of articles retrieved, and to ensure that 
the conclusions drawn were informed by robust evidence. This limited the number of studies 
that could be included.  In view of the heterogeneity of the study designs, individual studies 
could not be weighted against each other. Hence, studies with a higher level of evidence and 
those with a high number of participants could not be appropriately apportioned greater 
significance. The possible effects of concomitant use of 3-hydroxy-3-methyl-glutaryl-
coenzyme A (HMG Co-A) reductase inhibitors by subjects were not accounted for in this 
review, however this is unlikely to significantly confound the results given the randomised 
nature of the included studies. This review did not investigate the relative effects of the two 
main omega-3 fatty acids, EPA and DHA, as the vast majority of studies used combinations of 
EPA and DHA. 
3.5 Conclusions 
 This systematic review of the literature demonstrates that omega-3 fatty acids have 
favourable effects on all four classes of circulating atherogenic mediators. They modestly 
reduce atherogenic cytokines and adipokines, and this likely reflects the complexities of their 
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regulation. Atherogenic lipoproteins as well as homocysteine are reduced by omega-3s to a 
greater degree, and a single study of advanced glycation endproducts demonstrated a 
significant reduction. The findings of this systematic review provide mechanistic insights for 
the reduction in cardiovascular events seen in a number of CVOTs of fish and fish oil 
consumption. The reduction in circulating atherogenic mediators by omega-3s, suggests that 
there may be value in targeting specific blood omega-3 levels, and further research is required 
in this area. Moreover, there is a need to elucidate the effects of omega-3 fatty acids, especially 
the differential effects of EPA versus DHA on mediators of atherogenesis at the tissue level, 




3.6 Appendix A: Summary of included studies 
AUTHORS COMORBIDITIES STUDY TYPE 
SAMPLE 





Aadland E et al 2015(358)  RCT placebo controlled 20 EPA + DHA control diet 4 weeks LDL 
Abbey M et al 1990(359)  RCT placebo controlled 33 EPA + DHA 
safflower 
oil 6 weeks IDL, VLDL, LDL 
Ando M et al 1999(360) ESKD on haemodialysis RCT placebo controlled 38 EPA 
control 
capsules 7 months oxLDL 
Andrade PM et al 2007(361)  RCT placebo controlled 20 EPA + DHA mineral oil 6 weeks IFN, TNF 
Asztalos I et al 2016(362)  RCT placebo controlled 121 EPA or DHA olive oil 6 weeks TNF, IL6, LDL, Lp(a) 
Ballantyne C et al 
2012(363)  RCT placebo controlled 702 ICOSAPENT ETHYL (EPA) 
control 
capsules 12 weeks 
LDL, non-HDL, VLDL, 
HDL 
Ballantyne C et al 
2015(364)  RCT placebo controlled 427 ICOSAPENT ETHYL (EPA) 
control 
capsules 12 weeks 
VLDL, LDL, IDL, non-
HDL 
Bays H et al 2010 A(365) Hyperlipidemia RCT placebo controlled 245 EPA + DHA corn oil 16 weeks VLDL, LDL, non-HDL 
Bays H et al 2010 B(366) Hypertriglyceridemia RCT placebo controlled 135 EPA + DHA 
control 
capsules 8 weeks LDL, VLDL 
Bays H et al 2012(367) Hypertriglyceridemia RCT placebo controlled 229 ICOSAPENT ETHYL (EPA) 
control 
capsules 12 weeks IDL, VLDL, LDL 
Bays H et al 2013(368)  RCT placebo controlled 931 ICOSAPENT ETHYL (EPA) 
control 
capsules 12 weeks oxLDL, IL6 
Bays H et al 2015(369) Metabolic syndrome RCT placebo controlled 849 EPA 
control 
capsules 12 weeks LDL, non-HDL 
Beavers K et al 2008(370) End stage kidney disease RCT placebo controlled 69 EPA + DHA corn oil 6 months homocysteine 
Bell S et al 1996(371) HIV RCT placebo controlled 19 EPA + DHA 
safflower 
oil 6 weeks IL6, TNF 
Benito P et al 2006(372) Metabolic syndrome RCT placebo controlled 66 EPA + DHA milk 3 months LDL, homocysteine 
Bernstein A et al 2012 
M/A(373)  
Meta-analysis of 11 
RCTs 485 Algal oil (41% DHA) multiple 4-17 weeks LDL 
Bitzur R et al 2010(374)  RCT placebo controlled 67 EPA + DHA corn oil 12 weeks LDL 
Bloedon L et al 2008(375)  RCT placebo controlled 62 EPA + DHA control diet 10 weeks Lp(a), LDL, VLDL, IL6 
Bloomer R et al 2009(376)  RCT placebo controlled 14 EPA + DHA soybean oil 6 weeks TNF, oxLDL 
Bourque C et al 2003(377)  RCT placebo controlled 17 EPA + DHA control diet 27 days homocysteine, LDL 
Bragt M et al 2012(378) Overweight and obese RCT placebo controlled 20 EPA + DHA 
sunflower 
oil 6 weeks LDL, MCP1,  
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Brinton E et al 2013(379) 
Type 2 DM and 
hypertriglyceridemia RCT placebo controlled 501 ICOSAPENT ETHYL (EPA) 
control 
capsules 12 weeks 
oxLDL, LDL, VLDL, 
non-HDL 
Buckley R et al 2004(380)  RCT placebo controlled 42 EPA + DHA olive oil 4 weeks LDL 
Chiang Y et al 2012(381)  RCT placebo controlled 25 EPA + DHA 
low omega-
3 diet 4 weeks IL1b, TNF, IL6 
Ciubotaru I et al 2003(382)  RCT placebo controlled 30 EPA + DHA 
sunflower 
oil 5 weeks LDL, IL6 
Connor W et al 1993(383) Type 2 DM RCT placebo controlled 16 EPA + DHA olive oil 6 months VLDL, LDL 
Contacos C et al 1993(384)  RCT placebo controlled 40 EPA + DHA 
control 
capsules 18 weeks VLDL, LDL, IDL 
Damsgaard C et al 
2008(385)  RCT placebo controlled 64 EPA + DHA olive oil 8 weeks IL6, LDL 
Damsgaard C et al 
2009(386)  RCT placebo controlled 64 EPA + DHA olive oil 8 weeks IL6 
Davidson M et al 1997(387) 
Elevated triglycerides and 




soybean) 6 weeks LDL, non-HDL 




salts 6 months IL6, TNF 
Dunbar R et al 2015(389) Hypertriglyceridemia RCT placebo controlled 647 EPA + DHA olive oil 6 weeks LDL, VLDL, IDL 
Eritsland J et al 1995(390) Coronary artery disease RCT placebo controlled 549 EPA + DHA 
control 
capsules 6 months Lp(a) 
Eslick G et al 2009 S/R(391)  
Systematic review of 47 
RCTs 16511 EPA ± DHA multiple 3-182 weeks LDL 
Flock M et al 2014(392)  RCT placebo controlled 116 EPA + DHA soybean oil 5 months IL6, TNF 
Fontani G et al 2005(393)  RCT placebo controlled 33 EPA + DHA olive oil 70 days homocysteine 
Gammelmark A et al 
2012(394)  RCT placebo controlled 50 EPA + DHA olive oil 6 weeks IL6, TNF, LDL 
García-Alonso F et al 
2012(395)  RCT placebo controlled 18 EPA + DHA 
tomato 
juice 2 weeks homocysteine, LDL 
Gharekhani A et al 
2014(396) ESKD on haemodialysis RCT placebo controlled 54 EPA + DHA paraffin oil 4 months IL6, TNF 
Gharekhani A et al 
2016(397) ESKD on haemodialysis RCT placebo controlled 54 EPA + DHA paraffin oil 4 months LDL, leptin 
Gidding S et al 2014(398) Hypertriglyceridemia RCT placebo controlled 42 EPA + DHA corn oil 8 weeks LDL, IL6 
Grundt H et al 2003(399)  RCT placebo controlled 300 EPA + DHA corn oil 12 months homocysteine 
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Haberka M et al 2011(400)  RCT placebo controlled 40 EPA + DHA 
control 
therapy 1 month ADMA 
Haghiac M et al 2015(401) Obesity and pregnancy RCT placebo controlled 72 EPA + DHA 
wheat germ 
oil until delivery IL6, IL8, TNF, leptin 
Hariri M et al 2015 
S/R(402)  
Systematic review of 14 
RCTs 915 EPA + DHA multiple 4-24 weeks leptin 
Hartweg J et al S/R 
2008(403) Type 2 DM 
Systematic review of 23 
RCTs 1075 EPA + DHA multiple 3-24 weeks LDL, VLDL 
Herrmann W et al 
1995(404)  RCT placebo controlled 53 EPA + DHA rapeseed oil 4 weeks Lp(a) 
Huang T et al 2011 
M/A(405)  
Meta-analysis of 11 
RCTs 702 EPA + DHA multiple 6-48 weeks homocysteine 
Hung A et al 2015(406)  RCT placebo controlled 34 EPA + DHA 
control 
capsules 6 weeks ADMA, IL6, TNF, MCP1 
Itariu B et al 2012(407) Severe obesity RCT placebo controlled 55 EPA + DHA butterfat 8 weeks leptin, IL6 
Jacobson T 2012(408)  RCT placebo controlled 229 EPA 
control 
capsules 12 weeks 
oxLDL, LDL, VLDL, 
non-HDL 
Jellema A et al 2004(409) Obesity and pregnancy RCT placebo controlled 11 EPA + DHA 
sunflower 
oil 6 weeks IL6, TNF 
Kastelein J et al 2014(206) Hypertriglyceridemia RCT placebo controlled 364 EPA + DHA olive oil 12 weeks 
VLDL, HDL, LDL, non-
HDL 
Kooshki A et al 2011(410) ESKD on haemodialysis RCT placebo controlled 34 EPA + DHA 
medium 
chain trigs 10 weeks IL6, TNF 
Lewis N et al 2000(411)  RCT placebo controlled 25 EPA + DHA control diet 6 weeks LDL 
Li K, et al 2014 M/A(412)  
Meta-analysis of 68 
RCTs 4601 EPA + DHA multiple 2-26 weeks IL6, TNF 
Lopez-Alarcon M et al 
2012(413) Septic neonates RCT placebo controlled 63 DHA olive oil 14 days IL6, IL1b, TNF 
Maki K et al 2008(414) Mixed dyslipidemia RCT placebo controlled 39 EPA + DHA 
vegetable 
oil 6 weeks VLDL, LDL, non-HDL 
Maki K et al 2011(415)  RCT placebo controlled 31 EPA + DHA soy oil 6 weeks VLDL LDL 
Maki K et al 2013(416) 
Hypertriglyceridemia on 
statins RCT placebo controlled 647 EPA + DHA olive oil 6 weeks LDL, VLDL 
Maki K et al 2015(417) Hypertriglyceridemia RCT placebo controlled 102 EPA olive oil 8 weeks LDL, oxLDL, non-HDL 
Malekshahi Moghadam A 
et al 2012(418) Type 2 DM RCT placebo controlled 84 EPA + DHA 
sunflower 
oil 8 weeks TNF 
Mesa M et al 2004(419)  RCT placebo controlled 42 EPA + DHA olive oil 4 weeks oxLDL 
Metkus T et al 2013(420) 
HIV with 
hypertriglyceridemia RCT placebo controlled 48 EPA + DHA corn oil 8 weeks TNF, IL6, non-HDL 
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Mirhashemi S et al 
2016(421) 
Type 2 DM with 
nephropathy RCT placebo controlled 60 EPA + DHA 
control 
capsules 12 weeks AGEs 
Mocellin C et al 2013(422) Colorectal Cancer RCT placebo controlled 11 EPA + DHA not stated 9 weeks IL1b, TNF 
Moeinzadeh F et al 
2016(423) ESKD on haemodialysis RCT placebo controlled 52 EPA + DHA 
control 
capsules 6 months LDL 
Mori T et al 1991(424)  RCT placebo controlled 27 EPA olive oil 3 weeks LDL 
Mori T et al 2000(288) Hyperlipidemia RCT placebo controlled 56 EPA or DHA olive oil 6 weeks LDL 
Mori T et al 2004(211) Overweight and HT RCT placebo controlled 63 EPA + DHA control diet 16 weeks leptin 
Mosca L et at 2017(425)  RCT placebo controlled 215 EPA + DHA not stated 12 weeks LDL, VLDL, oxLDL 
Mostad I et al 2008(426) Type 2 DM RCT placebo controlled 26 EPA + DHA corn oil 9 weeks oxLDL 
Mostowik M et al 2013(427)  RCT placebo controlled 48 EPA + DHA soybean oil 30 days leptin 
Muldoon M et al 2016(428)  RCT placebo controlled 261 EPA + DHA soybean oil 18 weeks IL6 
Murphy KJ et al 2006(429)  RCT placebo controlled 30 EPA + DHA olive oil 6 weeks IL1b, TNF 
Nielsen A et al 2007(430) Crohn's disease RCT placebo controlled 31 EPA + DHA 
omega-6 
enriched 
supplement 9 weeks leptin 
Nilsson A et al 2012(431)  RCT placebo controlled 40 EPA + DHA olive oil 5 weeks TNF 
Oliveira J et al 2015(432) HIV RCT placebo controlled 83 EPA + DHA soy oil 24 weeks IL1b, IL6, TNF 
Olszewski A et al 1993(433)  RCT placebo controlled 15 EPA + DHA olive oil 3 weeks homocysteine 
Palomäki A et al 2010(434)  RCT placebo controlled 37 EPA + DHA butter 8 weeks oxLDL 
Paoli A et al 2015(435)  RCT placebo controlled 34 EPA + DHA control diet 4 weeks IL6, IL1b, TNF, LDL 
Pedersen H et al 2010(436)  RCT placebo controlled 78 EPA + DHA 
vegetable 
oil 16 weeks LDL, non-HDL 
Pooya S et al 2010(437) Type 2 DM RCT placebo controlled 81 EPA + DHA 
sunflower 
oil 2 months homocysteine, LDL 
Poreba M et al 2017(438) 
Type 2 DM and 
cardiovascular disease RCT placebo controlled 74 EPA + DHA 
control 
therapy 3 months LDL, IL6, TNF, leptin 
Rizza S et al 2009(439)  RCT placebo controlled 50 EPA + DHA olive oil 12 weeks IL6, TNF, LDL 
Root M et al 2013(440)  RCT placebo controlled 57 EPA + DHA 
safflower 
oil 4 weeks IL6, IL8, TNF 
Rytter D et al 2011(441)  RCT placebo controlled 533 EPA + DHA olive oil 3 months LDL 
Sabour H et al 2015(442) Spinal cord injury RCT placebo controlled 104 EPA + DHA 
control 
capsules 14 months leptin 
Simons L et al 1985(443)  RCT placebo controlled 25 EPA + DHA olive oil 3 months VLDL LDL 
Singer P et al 2004(444)  RCT placebo controlled 65 EPA + DHA olive oil 6 months LDL 
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Skouroliakou M et al 
2016(445)  RCT placebo controlled 60 EPA + DHA soybean oil 30 days IL6, TNF 
Su H et al 2015(446) Metabolic syndrome RCT placebo controlled 143 EPA + DHA control diet 12 weeks LDL, IL6 
Sundrarjun T et al 
2004(447)  RCT placebo controlled 35 EPA + DHA control diet 24 weeks IL6, TNF 
Suzukawa M et al 
1995(448)  RCT placebo controlled 20 EPA + DHA corn oil 12 weeks LDL 
Tardivo A et al 2015(449) Metabolic syndrome RCT placebo controlled 63 EPA + DHA control diet 6 months LDL, IL1b, TNF, IL6 
Tartibian B et al 2011(450)  RCT placebo controlled 45 EPA + DHA 
soybean 
plus corn 
oil 48 hours IL6, TNF 
Tayebi-Khosroshahi H et 
al 2013(451) ESKD on haemodialysis RCT placebo controlled 88 EPA + DHA 
control 
capsules 8 weeks homocysteine, LDL 
Vedin I et al 2008(452) Alzheimers disease RCT placebo controlled 174 EPA + DHA corn oil 6 months IL1b, IL6, IL8, TNF 
Vega-Lopez S et al 
2004(453)  RCT placebo controlled 80 EPA + DHA 
control 
capsules 12 weeks IL1b, IL6, TNF 
Vessby B et al 1990(454) Type 2 DM RCT placebo controlled 14 EPA + DHA olive oil 16 weeks VLDL, LDL 
Vikøren L et al 2013(455)  RCT placebo controlled 34 EPA + DHA 
control 
capsules 8 weeks LDL 
Wallace F et al 2003(456)  RCT placebo controlled 40 EPA + DHA 
linolenic 
acid 12 weeks IFN, TNF, IL1b, IL6 
Westerveld T et al 
1993(457) Type 2 DM RCT placebo controlled 24 EPA olive oil 8 weeks LDL 
Xin W, et al 2012 M/A(458) Congestive heart failure 
Meta-analysis of 7 
RCTs 465 EPA + DHA multiple 3-12 months TNF, IL1b, IL6 




fatty acids 8 weeks IL6 
Zeman M et al 2006(460)  RCT placebo controlled 24 EPA + DHA olive oil 3 months Lp(a), homocysteine 
Zhang J et al 2010(461)  RCT placebo controlled 92 EPA + DHA control diet 8 week IL6, LDL 
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Background: Acute vascular inflammation (AVI) is an early and critical stage of 
atherogenesis. Omega-3 fatty acids have anti-inflammatory properties, and although they have 
been studied in the setting of AVI, the study settings have typically not reflected physiological 
conditions.  With the findings of the recent REDUCE-IT study that omega-3 fatty acids reduce 
cardiovascular events in high-risk patients, there is a need to understand the factors underlying 
this benefit. This study aimed to examine the effects of omega-3 fatty acids on AVI on a cellular 
level, in an in vitro setting that was physiological and translatable. 
Methods: Forty healthy volunteers with a low baseline omega-3 fatty acid consumption were 
randomised to treatment with either (1) fish oil high in EPA (86% of total mass), (2) fish oil 
high in DHA (90% of total mass), (3) fish oil with a standard 2:1 EPA:DHA ratio, or (4) placebo 
oil, for 30 days. Baseline and post-treatment heart rate (HR), blood pressure (BP), lipids 
(including total cholesterol, LDL-C, HDL-C, and triglycerides), fatty acid profile, and 
inflammatory markers (high-sensitivity CRP and lipoprotein[a]) were measured. Serum taken 
pre- and post-treatment was added to tumour necrosis factor-alpha-stimulated human umbilical 
vein endothelial cells (HUVECs) in culture. Gene expression of markers of AVI: VCAM-1, 
ICAM-1, MCP-1 and NFκBp65 were measured by RT-PCR. To identify any associations 
between gene expression and participant characteristics, correlations were made between the 
expression of inflammatory markers and lipid parameters, omega 6:3 ratio, blood EPA content, 
blood DHA content, and saturated fats. 
Results: The baseline parameters of participants included: age 38.5±11.0 years, 70% female, 
LDL-C 2.9±0.8 mmol/L, HDL-C 1.6±0.3 mmol/L, and triglycerides 1.1±0.5 mmol/L. Blood 
EPA and DHA levels increased significantly and predictably in the different fish oil groups 
compared to placebo. DHA reduced triglycerides by 27% (p=0.02 compared to placebo, see 
Abstract Table). None of the fish oil treatments significantly altered cholesterol parameters, 
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heart rate or systolic BP. DHA reduced diastolic BP by 4.1±1.8 mmHg, which was significantly 
more than placebo (p=0.05, corrected for baseline values). The gene expression of MCP-1 by 
TNF-stimulated HUVECs reduced by 59% in the EPA group compared to baseline (p=0.02), 
and was 25% lower than in the placebo group (p=0.03, corrected for baseline values). No 
significant correlation was present between the expression of markers of AVI and blood 
omega-3 levels. A positive, significant association was present between HDL-C levels and both 
VCAM-1 (r=0.36, p=0.02) and MCP-1 (r=0.40, p=0.01) expression. 
Conclusions: The administration of serum from healthy volunteers supplemented with EPA to 
TNF-stimulated endothelial cells reduced gene expression of MCP-1, indicating a favourable 
effect of EPA on AVI. Higher fasting HDL-C levels associated with greater serum-induced 
expression of endothelial inflammatory factors implicated in early atherosclerosis. The positive 
correlation between HDL-C and endothelial inflammatory factors is consistent with HDL 
dysfunctionality at very high HDL-C levels, and this warrants further investigation. 
Abstract Table: Changes in lipid parameters and inflammatory markers 
 High EPA High DHA EPA:DHA 2:1 Placebo P value 
LDL-C 0% -7% -7% -4% 0.49 
HDL-C -1% +7% +1% +6% 0.37 
TG +3% -27% 
P=0.02* 
-18% +8% 0.03 
CRP +22% +22% -17% -25% 0.28 
VCAM-1 +5% -31% -23% +4% 0.41 
ICAM-1 +27% -69% -42% -21% 0.19 
MCP-1 -59% 
p=0.02* 
-22% 0% +9% 0.03 
NFκB-p65 -6% -40% -40% -7% 0.51 
*P value compared with baseline  





 Since the time a cardioprotective effect of polyunsaturated fatty acids was first 
proposed(221), researchers have been considering and investigating potential anti-
atherosclerotic mechanisms. In the randomised controlled trials of fish oil in the primary and 
secondary prevention setting that demonstrated a reduction in major adverse cardiac events, 
such as JELIS(227) and GISSI-Prevenzione(463), the benefits were observed independent of 
cholesterol levels. Given the inflammatory nature of atherosclerosis(4), it may be the anti-
inflammatory effects of fish oil that have contributed to their atheroprotective effects. Although 
the anti-inflammatory effects of fish oil are wide-ranging, it is likely to be the effects on 
vascular inflammation that are most important in the setting of cardiovascular disease. 
 Previous studies have examined the effects of omega-3 fatty acids on markers of 
vascular inflammation, particularly in the in vitro setting. Acute vascular inflammation (AVI) 
can be induced by stimulating vascular endothelial or smooth muscle cells with pro-
inflammatory agents such as TNF-α and lipopolysaccharide. The adhesion molecules and 
cytokines produced can be measured at the gene and protein level. Chronic vascular 
inflammation (CVI) as it pertains to atherosclerosis is more complex, as it occurs in conjunction 
with plaque formation and not in isolation(464). To summarise the effects of omega-3 fatty acids 
on in vitro models of AVI from less than 10 published studies, both EPA and DHA reduce 
adhesion molecule expression, with a greater effect seen with DHA compared to EPA(242, 244-
247). In these studies, EPA and DHA were added in purified forms. Although these studies have 
provided mechanistic insights into the effects of omega-3 fatty acids on AVI, they have limited 
translatability as they do not model in vivo conditions. Since omega-3 fatty acids undergo 
metabolism and oxidation after oral consumption, the genetic, humoral and cellular responses 
in vivo are likely to be different to what is measured in the cell culture setting. Indeed, oxidised 
omega-3 fatty acids have different actions to pure unoxidised fatty acids, and are still 
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beneficial, if not superior(250). Sethi et al demonstrated that oxidised, but not native unoxidised 
EPA significantly inhibited human neutrophil and monocyte adhesion to endothelial cells in 
vitro by inhibiting endothelial adhesion receptor expression(251). Similarly, Mishra et al 
demonstrated that oxidised but not unoxidised EPA and DHA inhibit cytokine-induced 
endothelial expression of MCP-1 and IL-8(252). A translatable, physiological method of 
studying the effects of omega-3 fatty acids is to deliver them to cells after oral consumption. 
The concept of adding serum from humans to endothelial cells in culture and studying its 
effects has been utilised previously and demonstrated to be effective(465).  
Fish oil is available in numerous formulations commercially, including with high 
concentrations of EPA or DHA. The most commonly available preparations have an EPA:DHA 
ratio of between 1.5:1 and 3:1(466). The availability of a wide range of fish oil products allows 
the relative effects of EPA and DHA on AVI to be studied. 
4.1.1 Aims and rationale of study 
The primary objective of the FOCUS IN study was to evaluate and compare the effects 
of different omega-3 fish oil preparations on endothelial cell markers of acute vascular 
inflammation after supplementation in healthy volunteers. FOCUS IN should identify an 
optimal omega-3 fish oil formulation which could be further studied in a primary and secondary 
prevention setting. 
The omega-3 formulations studied in FOCUS IN would be (1) high in EPA, (2) high in 
DHA, and (3) have a standard 2:1 ratio of EPA:DHA. These formulations would be compared 
with a placebo. Although the cardioprotective effects of omega-3 fatty acid supplementation 
have been questioned in a recent meta-analysis(467), the formulations and doses evaluated in 
that meta-analysis were highly heterogeneous. In high-risk patients, daily doses of ≥ 4 grams 
of omega-3 fatty acids have been shown to optimally reduce blood pressure, triglycerides, total 
119 
 
cholesterol, and circulating inflammatory markers(209, 368, 468). Furthermore, this dose has been 
shown to reduce major adverse cardiac events(234). 
4.1.2 Hypotheses 
The hypotheses of this study were that: 
• Omega-3 fatty acids would reduce endothelial cell markers of AVI, with EPA having 
a superior effect over DHA. 
• Changes in endothelial cell markers of acute vascular inflammation with omega-3 
fatty acids would occur independent of any effects on plasma cholesterol and 
triglyceride levels. 
• Blood levels of omega-3 fatty acids would correlate inversely with the gene 
expression of markers of AVI. 
4.2 Methods 
4.2.1  Study outline 
Forty healthy adult volunteers were recruited from the staff and students of the South 
Australian Health and Medical Research Institute for participation in the study. The volunteers 
were required to fulfil the eligibility criteria listed below: 
Eligibility criteria 
Healthy males and females aged ≥ 18 years 
Has not taken omega-3 supplements or eaten more than one fish meal per week in the 
preceding 6 months. 
No bleeding tendency or significant health problems 
Not allergic to fish or fish oil supplements 
Not currently taking medications that are anti-inflammatory or increase bleeding risk. 
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Not currently pregnant or breastfeeding 
No anticipated need to stop taking fish oil in the next 30 days, such as upcoming 
surgery. 
Volunteers who satisfied the eligibility criteria underwent a baseline health assessment at 
a clinic visit, which included measurement of height, weight, blood pressure and heart rate. A 
blood sample (20 mL) was taken by venepuncture; half of the sample was used to extract serum 
(as per Section 2.1) and then stored at -80oC, and half was used for biochemical analysis. For 
this, 30 microlitres of whole blood was spotted onto dry blood spot cards for fatty acid analysis 
(as per Section 2.2), and the remainder was analysed for serum levels of total cholesterol, LDL-
C, HDL-C, high-sensitivity C-reactive protein (hs-CRP) and lipoprotein(a) (Lp(a)). 
The forty participants were randomised in a double-blind fashion to one of four treatment 
groups using random number generation by an unblinded investigator.  
The four treatment groups (10 participants each) were: 
(1) A high EPA-containing fish oil, “PharmEPA® Step 1 Restore” (Igennus HealthCare 
Nutrition, Cambridge, UK). Each 580mg capsule contains 500mg of EPA (86% of total mass) 
and no detectable DHA. Omega-3 is in triglyceride form. Participants were give 8 capsules per 
day to achieve 4 g of omega-3.  
(2) A high DHA-containing fish oil, “Nature’s OwnTM Red Algal Omega-3” (Sanofi Consumer 
Healthcare, Virginia, QLD, Australia). Each 787.5mg capsule contains 707.5mg of DHA (90% 
by mass), and 30mg of EPA (4% by mass). Omega-3 is in triglyceride form. Participants were 
given 6 capsules per day to achieve 4 g of omega-3. 
(3) Fish oil containing a standard EPA:DHA ratio of 2:1, “AlaskOmega® 400200 TG” 
(Bioriginal, Den Bommel, Netherlands). Each 1000mg capsule contains 420mg of EPA (42% 
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by mass) and 209mg of DHA (21% by mass). Omega-3 is in triglyceride form. Participants 
were given 7 capsules per day to achieve 4 g of omega-3. 
(4) Placebo capsule (Bioriginal, Den Bommel, Netherlands). Each 1000mg capsule contains a 
mixture of palm oil, sunflower oil, rapeseed oil, and fish oil to preserve the smell and taste of 
fish oil. Each capsule contained 1% EPA by mass and 0.6% DHA by mass. Participants were 
given 7 capsules per day. 
The participants took the capsules daily for 30 days. During this period, participants kept a 
diary of capsule consumption and fish intake. After study completion a second health 
assessment was performed and a blood sample was taken, as before. 
4.2.2 Cell culture experiments 
A cell culture model of acute vascular inflammation was used to study the impact of 
the different omega-3 treatments on this process. The stored serum from each participant, taken 
before and after treatment, was added to cells in culture with the method described below. 
 Human Umbilical Vein Endothelial Cells (HUVECs) were obtained from fresh 
umbilical cords donated by the Women’s and Children’s Hospital, North Adelaide. They were 
plated in gelatin-coated flasks at a density of 10000 cells per cm2. They were cultured using 
MesoEndo Cell Growth Medium (Cell Applications, San Diego, CA, USA) supplemented with 
an extra 5% of foetal bovine serum (FBS) to make a total of 10% FBS. Passage 3 HUVECs 
were plated onto 6-well plates until they reached 75% confluence, with 2 ml of media used per 
well. They were then washed twice with warm sterile PBS and then cultured for 24 hours in 
EBM-2 basal media plus SingleQuot kit supplements and growth factors without the serum 
aliquot (Lonza, Basel, Switzerland). The serum was taken from participants at baseline and 
again at end of study, and was added for 24 hours at a concentration of 10%. Control conditions 
used 10% foetal bovine serum. All wells were then washed twice with warm sterile PBS, and 
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then fresh EBM-2 basal media plus SingleQuot kit supplements and growth factors except for 
serum was added again. For each condition, there was either TNF or no TNF added for 4 hours 
in serum-free media. For TNF conditions, human TNF-α (Sigma-Aldrich, St. Louis, MO, USA) 
was added at a concentration of 10 ng/ml. This dose and duration have been demonstrated to 
significantly increase cell adhesion molecule expression(469, 470). 
The cell culture media was then aspirated from each well, immediately placed on dry 
ice and stored at -80oC. The cells were washed with PBS at 4oC, and the Tri-reagent method 
was then used to extract RNA from the cells (as per Section 2.4.2). The RNA was quantified 
using a NanoDrop™ 8000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA). The concentration of RNA was normalised between all samples and then RNA was 
reverse transcribed to cDNA (as per Section 2.4.4). Reverse transcription PCR was performed 
(as per Section 2.4.5) to measure the relative expression of the following human genes: VCAM-
1, ICAM-1, MCP-1 and NFkBp65, with B2M being used as a reference gene (see Section 2.5 
for primers). All PCR reactions used 100ng of cDNA. Due to the large number of 96-well PCR 
plates used for this experiment, control conditions were used on each PCR plate. These 
conditions were the culture conditions of (1) HUVECs cultured in 10% FBS, and (2) HUVECs 
cultured in 10% FBS plus TNF-α. Inter-PCR-plate calibration was performed using Bio-Rad 
CFX ManagerTM software version 3.0.1224.1015 (Hercules, CA, USA). Data analysis was 
performed using GraphPad Prism 7 (La Jolla, CA, USA). To identify any associations between 
gene expression and participant characteristics, correlations were made between the expression 
of inflammatory markers and lipid parameters (total cholesterol, LDL, HDL, triglycerides), 
omega 6:3 ratio, blood EPA content, blood DHA content, and saturated fats. 
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4.2.3 Statistical and data analysis 
4.2.3.1  Sample size calculation 
The sample size of 10 participants per group was based on a study by Jiang et al(471). 
The most important factor for calculating sample size was the gene expression of VCAM-1. In 
Jiang et al’s study, the active treatment, irbesartan, reduced TNF-α-induced VCAM gene 
expression by 45% and this was statistically significant. Using a one-way ANOVA power 
calculation for 4 groups with a significance level of 0.05, with 80% power, for an effect size 
of 0.45, a sample size of 10 subjects per group was required. 
4.2.3.2  Statistical methods 
Participant data were de-identified, and statistical analysis was performed using 
GraphPad Prism 7 software. This analysis was performed blinded to treatment allocation, and 
according to the intention-to-treat principle. The D’Agostino-Pearson normality test was 
performed to determine whether continuous data were normally-distributed. Normally-
distributed data were analysed using the One-way Analysis of Variance (ANOVA) to compare 
means between multiple groups. If correcting for multiple comparisons, the Dunnett test was 
used. Results were expressed as mean ± standard error of the mean (SEM). If continuous data 
were not normally-distributed, analysis was performed using the Kruskal-Wallis test, with 
Dunn’s test used to correct for multiple comparisons. Results were expressed as median + 
interquartile range (IQR). Statistical correlations were analysed using a linear regression 
model. Statistical significance was set at the 0.05 level. 
4.2.4  Ethical and site approval  
 Ethics approval was obtained from the University of Adelaide Human Research Ethics 
Committee. The trial was registered with the Australian New Zealand Clinical Trials Registry 
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(Trial ID: ACTRN12616000928415). Site specific authorisation was obtained from the South 
Australian Health and Medical Research Institute. 
 
4.3 Results 
4.3.1 Baseline participant characteristics 
 The demographics of the participants are summarised in Table 4.1. Seventy percent of 
participants were female, and the mean age of participants was 38.5 years (see Table 4.1). 
Participants in the EPA group were older, but otherwise participants in all four groups were 
evenly matched. The baseline body mass index (BMI), resting heart rate, systolic and diastolic 
BP, lipid parameters, high-sensitivity CRP, Lp(a), and percentage of EPA and DHA in blood 
are presented in Table 4.1. These parameters were not significantly different between allocated 
treatment groups at baseline. Participants on average were mildly overweight with a normal 
blood pressure and mildly elevated resting heart rate. Total cholesterol and LDL-C levels were 
at the upper end of normal, and the inflammatory markers were low. EPA and DHA levels 










Table 4.1 – Summary of baseline participant characteristics by treatment group 
 Placebo Std Fish Oil* EPA DHA p value 
Number of participants 10 10 10 10 NA 
Male (%) 40 30 30 20 0.36 
Age (SD) 34.6 (7.1) 32.7 (7.8) 47.5 (10.2) 39.3 (12.6) 0.02 
BMI (SD) 25.4 (2.8) 24.6 (2.2) 25.4 (4.8) 26.1 (3.9) 0.81 
Resting HR bpm (SD) 77.8 (8.5) 69.2 (11.4) 70.2 (7.4) 67.4 (11.4) 0.11 
Systolic BP mmHg (SD) 126.7 (19.5) 124.3 (12.3) 116.5 (14.2) 119.9 (12.3) 0.43 
Diastolic BP mmHg (SD) 80.6 (9.3) 78.8 (6.2) 76.6 (9.5) 76.2 (10.4) 0.67 
Tchol mmol/L (SD) 5.0 (0.8) 4.5 (0.8) 5.3 (0.7) 5.3 (1.2) 0.23 
LDL-C mmol/L (SD) 3.0 (1.1) 2.4 (0.6) 3.1 (0.6) 3.2 (0.8) 0.11 
HDL-C mmol/L (SD) 1.5 (0.2) 1.7 (0.4) 1.7 (0.3) 1.6 (0.4) 0.24 
Trigs mmol/L (IQR) 1.3 (1.1-1.5) 0.9 (0.7-1.3) 0.9 (0.7-1.1) 1.0 (0.7-1.2) 0.4 
hs-CRP mg/L (IQR) 1.1 (0.9-1.9) 0.7 (0.5-1.4) 0.4 (0.3-2.1) 1.0 (0.8-2.9) 0.5 
Lp(a) g/L (IQR) 0.1 (0-0.3) 0.1 (0-0.2) 0.1 (0-1.4) 0.4 (0.1-0.6) 0.72 
EPA % (IQR) 0.5 (0.4-0.8) 0.7 (0.6-0.8) 0.8 (0.5-0.9) 0.5 (0.4-0.7) 0.35 
DHA % (IQR) 1.7 (1.5-1.8) 1.9 (1.6-2.3) 1.9 (1.6-2.3) 1.7 (1.4-1.8) 0.12 
*Std Fish Oil = standard fish oil 
Capsule compliance was assessed by an unblinded investigator based on the return of a 
capsule diary. Capsule compliance in the study was high (94±5%). There was no significant 
difference in capsule compliance between treatment groups (p=0.63). The average number of 
treatment days was 30.5±4, and did not differ significantly between treatment groups (p=0.38). 
One participant discontinued the capsules after 6 days due to gastrointestinal side effects, 
however completed the follow up assessment and investigations. 
4.3.2 Effect of fish oil treatment on physical and biochemical measures 
Effects on physical measures  
None of the fish oil treatments had a significant effect on resting heart rate (p=0.33, corrected 












Figure 4.1: Effect of fish oil supplementation on resting heart rate. n = 10 per group. 
Results expressed as mean ± SEM. 
No fish oil treatment had a significant effect on systolic blood pressure (p=0.54). DHA reduced 
diastolic blood pressure by 4.1±1.8 mmHg, which was significantly more than placebo (p=0.05, 







Figure 4.2: Effect of fish oil supplementation on systolic and diastolic blood pressure. n = 
10 per group. *p=0.05. Results expressed as mean ± SEM. 










































 None of the fish oil treatments resulted in a significant change in body weight (p=0.80 









Figure 4.3: Effect of fish oil supplementation on body weight. n = 10 per group. Results 
expressed as mean ± SEM. 
 
Effects on blood fatty acid levels  
The distribution of fatty acids in blood was significantly altered by the fish oil 
treatments. Both EPA and standard fish oil (which has a predominance of EPA) significantly 
increased EPA levels in the blood by an average of 253% each (p<0.001 for each, corrected 
for baseline values, see Figure 4.4). There was a slight but non-significant increase in the DHA 
treatment group. 




















Figure 4.4: Effect of fish oil supplementation on EPA levels in blood, expressed as a 
percentage of total fatty acids. ***p<0.001. n = 10 per group. Results expressed as mean 
± SEM. 
 
 Both DHA and standard fish oil supplementation significantly increased DHA levels in 
blood by 145% (p<0.001) and 28% (p=0.02) respectively, corrected for baseline values (see 
Figure 4.5). The changes seen in EPA and DHA levels after fish oil supplementation confirm 
the efficacy of, and compliance with, the respective capsules. 


























Figure 4.5: Effect of fish oil supplementation on DHA levels in blood, expressed as a 
percentage of total fatty acids. ****p<0.0001, *p<0.05. n = 10 per group. Results 
expressed as mean ± SEM. 
 
 The omega 6:3 ratio, which has a U-shaped association with mortality(472), was not 
significantly different between treatment groups at baseline (p=0.79), with a mean ratio of 
7.3±1.1. After supplementation, the omega 6:3 ratio was significantly lower in all fish oil 
treatment groups compared to placebo (43 – 49% reductions, p<0.0001 for all comparisons, 































Figure 4.6: Ratio of omega-6 to omega-3 at the end of the study. ****p<0.0001. n = 10 per 
group. Results expressed as mean ± SEM. 
 
Effects on serum lipids and inflammatory markers 
There were no significant differences between treatment groups in levels of either total 
cholesterol (p=0.29), LDL (p=0.49), or HDL (p=0.37) when correcting for baseline values (see 
Figure 4.7). DHA significantly reduced triglyceride levels, by an average of 0.31 mmol/L (27% 
reduction, p=0.018 corrected for baseline values). There was a numerical but non-significant 
reduction in triglycerides in the standard fish oil group of 0.18 mmol/L (p=0.08, corrected for 
baseline values, see Figure 4.7). 
 





























Figure 4.7: Effect of fish oil supplementation on total cholesterol, LDL-C, HDL-C and 
triglycerides. *p<0.05. n = 10 per group. Results expressed as mean ± SEM, except for 
triglycerides, which is median + interquartile range. 
 
Levels of lipoprotein(a), which is a particle associated with increased cardiovascular 
risk(473) and is pro-inflammatory(474), were measured before and after treatment. Complete 
results were only obtained for 4 to 7 participants per group, because on multiple occasions the 
request for this uncommonly-performed test was incorrectly interpreted as another lipoprotein 
or as lipase. Lp(a) levels were low in this cohort, with a median level at baseline of 0.15 (IQR 
















































0.00 – 0.47) g/L (reference range 0 - 0.3 g/L). Fish oil supplementation did not significantly 









Figure 4.8: Effect of fish oil supplementation on lipoprotein(a) levels. n = 4-7 per group. 
Results expressed as median + interquartile range. 
 
High-sensitivity C-reactive protein (hs-CRP) levels were generally low, with a median 
of 0.9 (IQR 0.42 – 2.1) mg/L (reference range 0 - 2mg/L). Fish oil supplementation did not 
significantly alter hs-CRP levels (p=0.28, corrected for baseline values, see Figure 4.9). There 
was a trend towards an increase in hs-CRP levels in the EPA group (p=0.10). 
 



















Figure 4.9: Effect of fish oil supplementation on hs-CRP levels. n = 10 per group. Results 
expressed as median + interquartile range. 
 
4.3.3 In vitro studies of vascular inflammation 
 Gene expression of VCAM-1, ICAM-1, MCP-1 and NFκB-p65 was measured by RT-
PCR in HUVECs co-incubated with serum from participants before and after treatment, and 
with or without TNF stimulation. As expected, only conditions with TNF stimulation resulted 
in significantly increased gene expression. This gene expression was compared between the 
different treatment group allocations at baseline, and was not significantly different (p=0.68 
for VCAM-1, p=0.65 for ICAM-1, p=0.16 for MCP-1, and p=0.83 for NFκBp65). This was 
predictable as the participants were healthy and had comparable characteristics as evident in 
Table 4.1. Relative gene expression was set at 100% for the TNF-stimulated expression with 
serum taken at baseline. 














The VCAM-1 expression of TNF-stimulated HUVECs co-incubated with serum 
obtained at study completion was not significantly different between treatment groups. There 
was a trend towards a reduction in the standard fish oil group compared to placebo (35% 











Figure 4.10: Relative gene expression of VCAM-1 by TNF-stimulated HUVECs co-
incubated with serum obtained at study completion, relative to baseline. n = 40 for 





























ICAM-1 expression was also not significantly different between treatment groups 











Figure 4.11: Relative gene expression of ICAM-1 by TNF-stimulated HUVECs co-
incubated with serum obtained at study completion, relative to baseline. n = 40 for 
combined baseline and n = 10 for treatment groups. Results expressed as mean ± SEM. 
 
MCP-1 expression was 25% lower in the EPA group compared to placebo (p=0.03 
corrected for baseline values, see Figure 4.12). There was a trend towards a reduction in the 
standard fish oil group compared to placebo (19% reduction, p=0.10 corrected for baseline 
values). 
 




































Figure 4.12: Relative gene expression of MCP-1 by TNF-stimulated HUVECs co-
incubated with serum obtained at study completion, relative to baseline. *p<0.05. n = 40 
for combined baseline and n = 10 for treatment groups. Results expressed as mean ± SEM. 
  
Gene expression of the pro-inflammatory transcription factor NFκBp65 was not significantly 








































Figure 4.13: Relative gene expression of NFκBp65 by TNF-stimulated HUVECs co-
incubated with serum obtained at study completion, relative to baseline. n = 40 for 
combined baseline and n = 10 for treatment groups. Results expressed as mean ± SEM. 
 
4.3.4 Correlations between inflammatory markers and circulating factors 
 The expression of VCAM-1, ICAM-1, MCP-1 and NFκBp65 by stimulated HUVECs 
was correlated with the following patient characteristics to determine whether any significant 
associations exist: total cholesterol, LDL-C, HDL-C, triglycerides, omega 6:3 ratio, blood EPA 
levels, blood DHA levels, and saturated fats. 
 
 


























 No significant correlations were present between total cholesterol and VCAM-1, 













Figure 4.14: Correlations of gene expression of VCAM-1, ICAM-1, MCP-1, NFκBp65 






























r = -0.03, p = 0.87























n r = -0.23, p = 0.14























n r = 0.21, p = 0.19


























 No significant correlations were present between LDL-C and VCAM-1, ICAM-1, 
MCP-1 or NFκBp65 (see Figure 4.15). 













Figure 4.15: Correlations of gene expression of VCAM-1, ICAM-1, MCP-1, NFκBp65 
and LDL-C. n = 40 for each graph. 
 


























r = -0.06, p = 0.72
























r = -0.19,  p = 0.23























n r = 0.13,  p = 0.40


























 A positive, significant association was present between HDL-C levels and both VCAM-












Figure 4.16: Correlations of gene expression of VCAM-1, ICAM-1, MCP-1, NFκBp65 






























r = 0.36,  p = 0.02























n r = 0.1, p = 0.52























n r = 0.40,  p = 0.01



























 A non-significant inverse correlation (r = -0.3, p=0.06) was present between VCAM-1 
and triglyceride levels. No significant correlations were present between triglycerides and 














Figure 4.17: Correlations of gene expression of VCAM-1, ICAM-1, MCP-1, NFκBp65 
and triglycerides. n = 40 for each graph. 
 

























n r = -0.3, p = 0.06























n r = -0.18, p = 0.25
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on r = -0.2  p = 0.22
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Omega 6:3 ratio 
 Despite the omega-6 and omega-3 fatty acids having pro- and anti-inflammatory 
properties, respectively, there was no significant association between the omega 6:3 ratio and 














Figure 4.18: Correlations of gene expression of VCAM-1, ICAM-1, MCP-1, NFκBp65 
and omega 6:3 ratio. n = 40 for each graph. 
 


























r = -0.20, p = 0.21
























r = -0.05, p = 0.77























n r = -0.04, p = 0.82


























 Despite the proinflammatory nature of saturated fatty acids(475), no significant 
association was found between the percentage of saturated fats in blood and gene expression 













Figure 4.19: Correlations of gene expression of VCAM-1, ICAM-1, MCP-1, NFκBp65 
and saturated fats. n = 40 for each graph. 
 







VCAM-1 vs saturated fats

















n r = 0.13, p = 0.42






ICAM-1 vs saturated fats

















n r = 0.08, p = 0.63






MCP-1 vs saturated fats
















n r = -0.17, p = 0.30





NFkBp65 vs saturated fats




















 The FOCUS IN study evaluated the impact of high dose omega-3 fatty acids on markers 
of acute vascular inflammation in an in vitro model. By supplementing healthy volunteers with 
4 grams of either EPA, DHA, standard fish oil or placebo daily for 30 days, the differential 
effects of EPA versus DHA were studied. To minimise confounders, participants were required 
to have a low baseline omega-3 intake, and have no significant medical illnesses or take regular 
medications such as anti-inflammatories. The addition of serum from participants to TNF-
stimulated HUVECs before and after fish oil supplementation achieved two goals: (1) the 
omega-3s were delivered to cells in a physiological manner rather than in a chemically-pure 
state, and (2) the differential effects of EPA versus DHA could be studied and compared with 
combination therapy, all at a sufficient dose. One of the major limitations of previous human 
fish oil studies has been insufficient dosing. In the recently published ASCEND study, which 
assessed the effect of fish oil on cardiovascular events in patients with diabetes mellitus, only 
one capsule of fish oil was given per day, providing less than 1 g of omega-3 fatty acids(232). 
Similarly, in the recently-published meta-analysis by Aung et al of omega-3 trials assessing 
cardiovascular outcomes(467), 6 out of the 10 trials used less than or equal to 1 g of omega-3 per 
day. Such doses are widely considered to be insufficient to produce a clinical benefit. The 
negative conclusions from these studies therefore need to be interpreted with caution. 
 Participants in the FOCUS IN study were generally well-matched at baseline, aside 
from those in the EPA group being older. The dose of 4 g of omega-3 per day was well 
tolerated, with only one participant experiencing side effects, and it achieved the desired goal 
of significantly increasing blood omega-3 levels. Those supplemented with either EPA or 
standard fish oil had a >200 % increase in EPA levels. Those supplemented with DHA had an 
almost 150 % increase in circulating DHA levels. These changes also translated into a reduced 
omega 6:3 ratio. Although a lower omega 6:3 ratio has long been considered desirable for 
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reducing the risk of chronic diseases(476), the recently-identified U-shaped association with 
mortality(472) indicates that this interpretation of the ratio may be an oversimplification. Indeed, 
there is evidence that higher levels of specific omega-6 fatty acids (namely linoleic acid)(477) 
confer more mortality benefit than others, and this likely to also be the case for omega-3s. 
Hence, the individual fatty acid contributors to the omega 6:3 ratio may be more important than 
the value. 
At follow-up, DHA significantly reduced diastolic blood pressure, and produced a 
numerical but non-significant reduction in systolic blood pressure. Previous studies have 
demonstrated a blood pressure lowering effect of omega-3 fatty acids(209-211), but this is the first 
study to compare EPA with DHA, and identified a superior effect with DHA. DHA 
significantly reduced triglyceride levels, although none of the fish oil supplements affected 
total cholesterol, LDL or HDL levels. The 27% reduction in triglyceride levels is consistent 
with the magnitude of effect previously described, of 25 to 34%(194, 478). This greater reduction 
in triglycerides with DHA compared to EPA is consistent with previous studies that have 
compared the two fatty acids directly(479-483). Lp(a) levels were reduced to the greatest extent 
in the DHA group, although not significantly, and this should be investigated in future studies. 
In the cell culture experiments, serum from healthy volunteers supplemented with one 
of three types of fish oil or with placebo was added to TNF-stimulated HUVECs in culture, 
and the effects on gene expression of inflammatory markers were measured. Fatty acids in 
blood are either incorporated into the phospholipids of red blood cell membranes(484) or 
circulate freely or bound to albumin(485). Serum is therefore an effective method of fatty acid 
delivery to cells in culture. EPA significantly reduced the gene expression of MCP-1 in TNF-
stimulated HUVECs. The oral administration of 4 g of EPA per day to healthy adults is 
sufficient to reduce markers of acute vascular inflammation and is independent of effects on 
circulating inflammatory markers and lipids. There were trends towards reductions in both 
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VCAM-1 and MCP-1 with standard fish oil, which contains a predominance of EPA, and which 
increased EPA levels to a similar extent as the EPA treatment in this study. The mechanisms 
by which EPA and DHA demonstrate differential effects on acute vascular inflammation are 
not fully understood, and require further investigation. 
 Correlations were studied between gene expression of inflammatory markers and levels 
of total cholesterol, LDL-C, HDL-C, triglycerides, omega 6:3 ratio, blood EPA, blood DHA, 
and saturated fats taken at baseline. A striking positive association was present between HDL-
C levels and both VCAM-1 and MCP-1 expression. Although the HDL molecule has anti-
inflammatory properties(486), with higher levels being associated with lower rates of 
cardiovascular events and mortality(487, 488), there is evidence that extremely high circulating 
HDL-C levels are paradoxically associated with increased mortality(489). The reasons for this 
are unclear and require further investigation, however the results from this study suggest a 
possible harmful, pro-inflammatory effect at the highest HDL-C levels. This could be 
consistent with a hypothesis that the functionality of HDLs is compromised at extremely high 
levels, with the concentration of HDL cholesterol no longer reflecting HDL function, and such 
dysfunctional HDLs being harmful(490). If this is the case, this would have implications for the 
interpretation of the results of studies of HDL-raising therapies on cardiovascular outcomes(491-
494). 
The limitations of this study include the small sample size of 10 participants per group. 
The numerical reductions seen in the gene expression of VCAM-1, ICAM-1 and MCP-1 after 
different fish oil treatments may have reached statistical significance in the setting of a larger 
cohort. However, the high threshold for a demonstrable reduction in gene expression in this 
small study highlighted the superior effect of EPA over other treatments. The requirement for 
healthy volunteers in this study allowed the effects of the fish oil preparations on inflammation 
to be demonstrated with minimal confounding factors. However, physical ambulatory 
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measures such as heart rate and blood pressure, as well as circulating factors such as lipids and 
inflammatory markers, were largely in the normal range for these healthy volunteers. 
Therefore, the effects of fish oil preparations on these variables were not expected to 
significantly reduce them even though significant beneficial effects may have been 
demonstrated in individuals at high cardiovascular risk. The changes seen in the gene 
expression of markers of AVI do not necessarily predict the changes that would occur in vivo 
or even at the protein level. Studies in the in vivo setting are required to confirm the in vitro 
findings. 
There are several clinical implications of this study. In a healthy population, high dose 
omega-3 fatty acids would not be expected to significantly reduce heart rate, body weight, or 
systolic blood pressure. DHA would likely reduce diastolic blood pressure modestly, however 
the requirement of 4 g per day of omega-3 to achieve this would not be economical or practical. 
Furthermore, the predicted 0.5 mmol/L reduction in triglycerides seen with DHA would be 
unlikely to translate into a significant benefit. High dose EPA reduced the inflammatory 
response to endothelial injury in this study, and in a healthy population the number needed to 
treat to prevent an ischaemic event would be high. For the general population, there is not a 
strong indication for daily high dose omega-3 fatty acid consumption based on this study. 
Those at high cardiovascular risk and those with established atherosclerotic disease may well 
derive benefit, and indeed these groups were the target of the recent REDUCE-IT study, which 
evaluated 4 grams of EPA daily in the form of icosapent ethyl(234). The 25% reduction in the 
incidence of first major cardiovascular event, and 30% reduction in total events occurred in 
statin-treated patients with hypertriglyceridemia and history of atherosclerosis or diabetes(495). 
Icosapent ethyl is EPA in ethyl ester form which differs from EPA in triglyceride form used in 
FOCUS IN. The benefits seen in FOCUS IN and REDUCE-IT suggest that the anti-
inflammatory and anti-atherosclerotic effects of EPA are not limited to a specific form. 
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The association seen between high plasma HDL-C levels and a greater inflammatory 
response in HUVECs to TNF-α seen in FOCUS IN is consistent with a hypothesis of disturbed 
HDL functionality at high HDL-C levels. Future studies will be required to redefine a target 
HDL-C range, however the concept of HDL-C being invariably regarded as “good cholesterol” 
in patient and population education needs to be reconsidered. 
In conclusion, the results of the FOCUS IN study provide evidence for a beneficial 
effect of EPA on markers of acute vascular inflammation by virtue of a reduction in MCP-1 by 
stimulated endothelial cells. The magnitude of the anti-inflammatory effect is modest, as the 
other inflammatory markers studied were not significantly reduced. DHA on the other hand, is 
superior for triglyceride reduction as previously described, as well as blood pressure lowering, 
which is a new finding. The results of FOCUS IN provide a mechanistic rationale for the 
reduction in major adverse cardiovascular events with high-dose EPA seen in the recently-
published REDUCE-IT study(234). This study’s findings demonstrated in vitro need to be 













CHAPTER 5: THE IMPACT OF OMEGA-3 FATTY ACIDS ON ACUTE VASCULAR 












Background: Acute vascular inflammation (AVI) is an early and critical stage of 
atherogenesis. The anti-inflammatory properties of omega-3 fatty acids have been 
demonstrated in a number of settings, however their effects on AVI, and in particular, the 
relative effects of EPA compared to DHA, have not been well defined. This is particularly 
relevant, given the recently published findings of a reduction in major adverse cardiovascular 
events with EPA treatment. Previous in vitro and in vivo studies have had methodological 
limitations, whereby omega-3s have not been administered in a physiological manner, have 
been subject to oxidation, or have not been provided in a pure form. The aim of this study was 
to determine the effects of pure EPA versus DHA on AVI in an established animal model. 
Methods: Forty, 8-week-old C57BL/6 chow-fed mice were randomised to supplementation 
with 600mg/kg/day of either EPA, DHA, olive oil as an oil control, or no treatment, for 30 days 
by oral gavage. Non-occlusive collars were surgically implanted around the right carotid artery 
to induce AVI. After 48 hours, the mice were humanely killed. The carotids underwent 
immunohistochemical staining for the inflammatory factors VCAM-1, ICAM-1, MCP-1 and 
CD18. Blood was analysed for cholesterol, triglycerides, and fatty acids. Correlations were 
made between blood omega-3 levels and the protein expression of markers of AVI. 
Results: Thirty-eight mice (95%) had successful carotid collaring. The collared carotids of 
mice had significantly more expression of all inflammatory factors compared to uncollared 
carotids which were used as internal controls (p<0.01 for all comparisons). EPA reduced the 
expression of VCAM-1 and MCP-1 by 43% and 38% respectively in collared carotids 
compared to no treatment (p<0.05 for both comparisons). There were numerical reductions in 
ICAM-1 and CD18 expression with EPA, which did not reach statistical significance. 
Furthermore, there was a numerical reduction in all four markers of AVI with DHA, which was 
less than EPA in each case, and not statistically significant. Plasma cholesterol and triglycerides 
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did not differ between treatment groups. EPA and DHA supplementation increased their 
respective blood levels by 272% and 62% (p<0.0001). There were significant inverse 
correlations observed between blood levels of both EPA and DHA and the expression of all 
four markers of AVI on immunohistochemistry. Furthermore, significant inverse correlations 
were also observed between the blood EPA:DHA ratio and all four markers of AVI. 
Conclusions: Pre-treatment with EPA, but not DHA, significantly reduced acute vascular 
inflammation in a mouse model.  This protective effect was present independent of plasma 
cholesterol and triglyceride levels, which were not significantly altered by any of the 
treatments. The greater effect of EPA compared to DHA in reducing AVI was further supported 
by significant inverse correlations observed between the EPA:DHA ratio and all four markers 
of AVI studied. The findings of this study may provide a mechanistic contribution underlying 
the significant cardiovascular benefit seen with EPA treatment in the recent REDUCE-IT 
study. Further studies of the effects of omega-3 fatty acids on vascular inflammation, including 
different ratios of EPA:DHA, are warranted. 










 In recent decades, there has been increasing interest in the role of omega-3 
polyunsaturated fatty acids in inflammation. Preclinical studies have identified a number of 
anti-inflammatory as well as pro-resolving properties of omega-3 fatty acids(195, 196). The anti-
inflammatory properties of the omega-3 fatty acids eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) have been demonstrated on multiple levels, including cellular, 
humoral, signal transduction, and gene expression(496), although there is a paucity of quality 
data on the impact on acute vascular inflammation (AVI).  
AVI is an early and critical stage of atherogenesis(4). For example, minute changes in 
LDL, glucose, blood pressure, and inflammatory markers, lead to increased endothelial cell 
permeability, which permits the migration of circulating LDL into the subendothelial space. 
Concurrent with this, endothelial cells switch to a secretory phenotype, producing a 
hyperplastic, multilayered basal lamina, which further traps LDL in the subendothelium(8). 
Trapped LDL is oxidised by macrophages, generating pro-inflammatory free radicals and 
monocyte chemoattractant protein 1 (MCP-1). The recruitment of monocytes to the 
subendothelium, and of platelets to the endothelial cell surface (after expression of von-
Willebrand factor by activated endothelial cells), triggers a plethora of changes; these include 
the release of pro-inflammatory cytokines, activation of pro-inflammatory signal transduction 
pathways, and an increase in the adhesiveness of the endothelial cell surface(9-11, 57). These 
changes of AVI promote the formation of atherosclerotic lesions, ultimately culminating in 
either plaque rupture or erosion.  
Physiological mechanisms exist to partly counteract the atherogenic effects of AVI, 
such as the efflux of LDL from the subendothelial space(497), and the release of heme 
oxygenase-1 (HO-1) which reduces monocyte transmigration and toxicity to endothelial 
cells(7). The implications of preventing or reducing AVI and hence retarding atherogenesis are 
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significant, given that cardiovascular disease is the leading cause of death worldwide(1). Since 
macroscopic evidence of atherosclerosis has been identified in humans as early as the foetal 
stage, i.e. in the form of fatty streaks(498), supplementation with a safe agent that reduces AVI 
has the potential for use in primary cardiovascular prevention in all age groups. 
 Previous studies have explored, with limitations, the effects of omega-3 fatty acids, 
found abundantly in fish and fish oil, on markers of AVI.  These include measuring the 
expression of cell adhesion molecules and endothelium-derived cytokines, and using various 
methods of exposure to omega-3s, such as direct addition to cell culture media, oral 
supplementation in the form of capsules or the addition to food, and the use of transgenic 
animals that can synthesise omega-3s due to the encoding of omega-3 fatty acid desaturase(244, 
499-503). Endothelial cell permeability, adhesion molecule expression, and chemotaxis of 
leucocytes have all been studied in the setting of omega-3 supplementation. Although omega-
3 fatty acids have not been shown to reduce lipopolysaccharide-induced endothelial cell 
permeability(504), they do reduce adhesion molecule expression by endothelial cells in 
culture(244, 505, 506) and chemotaxis of monocytes(507). However, the direct administration of 
purified omega-3 fatty acids to cells cultured in vitro is not physiological, and hence does not 
model in vivo exposure to fatty acids which have undergone modification during metabolism. 
In Chapter 4 of this thesis, omega-3 fatty acids were delivered to endothelial cells by adding 
human serum obtained before and after fish oil consumption. The omega-3 fatty acids were 
therefore presented to cells after ingestion and metabolism. Fish oil that was high in EPA (86% 
total mass) reduced gene expression of MCP-1 by TNF-stimulated human umbilical vein 
endothelial cells. EPA was superior to both DHA and standard fish oil (2:1 EPA:DHA ratio). 
The results of FOCUS-IN need to be confirmed at a protein level and in an in vivo setting. 
Previous animal studies of the effects of omega-3s on AVI have been limited by 
difficulties in eliciting a local endothelial insult without inducing atherosclerotic lesions. 
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Kockx M et al described a method of inducing AVI in the arterial wall of rabbits by surgically 
implanting a non-occlusive silicone elastic collar around the carotid arteries, and demonstrated 
intense infiltration of polymorphonuclear leucocytes from 6 hours to 3 days post-surgery(508). 
Short-term collar application did not induce atherosclerotic lesions, and this method was safely 
and effectively replicated in mice by von der Thusen et al(509). Application of a periarterial 
collar to the carotid artery increases the production of reactive oxygen species, and stimulates 
neutrophil recruitment, adhesion molecule expression, and inflammatory cytokine 
production(510). Previous studies have most commonly administered omega-3 fatty acids to 
animals by means of dietary supplementation, leading to difficulties with quantifying intake, 
and also resulting in fatty acid oxidation. Oral gavage of unoxidised and appropriately stored 
fatty acids overcomes this problem. The use of the short-term carotid collar model in animals 
supplemented with omega-3 fatty acids by oral gavage is a physiological way to study their 
effects on pure vascular inflammation. Furthermore, direct comparisons can be made between 
the effects of EPA versus DHA. 
5.1.1 Aims and rationale of study 
The aim of this study was to determine the impact of individual omega-3 fatty acids, 
administered in a physiological manner, on acute vascular inflammation in an established 
animal model. The non-occlusive periarterial collar model elicits features of pure vascular 
inflammation when used for less than 72 hours(503, 510). Chow-fed C57Bl/6 mice do not have a 
propensity to develop atherosclerosis, and hence were used for this experiment. The pre-
treatment of mice with omega-3 fatty acids and then subsequent induction of AVI mimics the 
primary prevention clinical setting. In this animal study, the collared carotids could be 
harvested so that protein expression of markers of AVI could be measured and compared 




The primary hypotheses of this study were that: 
(1) Pre-treatment with high-dose omega-3 fatty acids reduces the degree of acute 
vascular inflammation induced by periarterial collaring. 
(2) There is a differential effect among omega-3 fatty acids, with EPA reducing 
markers of acute vascular inflammation more than DHA. 
(3) Blood levels of omega-3 fatty acids, especially EPA, have an inverse 
correlation with the degree of acute vascular inflammation. 
 
5.2 Methods 
5.2.1 Study outline 
 Forty 8-week-old C57Bl/6 mice fed a standard rodent chow diet were randomised 
equally to supplementation with either EPA, DHA, olive oil, or no treatment for 30 days, by 
oral gavage. EPA and DHA were >99% pure free fatty acids purchased from Nu-Chek Prep, 
Inc (Elysian, Minnesota, USA), and all treatments were administered at a dose of 600 
mg/kg/day. Periarterial collaring of the right carotid artery was then performed under general 
anaesthesia. The collar was left in place for 48 hours, and then mice were subsequently 
humanely killed (See Figure 5.1). Blood was harvested for plasma total cholesterol and 
triglyceride levels, and fatty acid analysis. Both carotid arteries were harvested for 
immunohistochemical staining for VCAM-1, ICAM-1, MCP-1 and CD18. The left carotid 
artery was a within-animal control. 
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This study was approved by the animal ethics committees of both the South Australian 











Figure 5.1: Schematic representation of the study outline. After randomisation to one of 
four treatment groups, the mice were gavaged daily for 30 days, then had 48 hours of 
carotid collaring before being humanely killed. 
 
5.2.2 Diet and preparation of EPA, DHA, and olive oil 
 Mice were fed the Teklad Global 18% Protein Rodent Diet (Harlan Laboratories, 
Madison, WI, USA) and had free access to food and water. Free fatty acids were aliquoted into 
200 µl microcentrifuge tubes, which were sealed under nitrogen gas using paraffin film. Tubes 
were stored at -20oC, protected from light, in between uses. Each tube was resealed under 
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nitrogen gas using paraffin film after each use. Olive oil was prepared as above although was 
stored at room temperature as it solidifies when refrigerated. 
5.2.3 Periarterial collaring method 
1. Silicone tubing with internal diameter 0.64 mm and outer diameter 1.2 mm 
(BlueSky Scientific, Burnside, SA, Australia) was cut to a length of 4 mm. Two 
cuts were then made into the tubing lengthwise, 0.5 mm apart, so that a sliver of 
tubing was removed. 
2. The mouse was pre-oxygenated with 100% FiO2 for five minutes, and then 
anaesthetised with 3% isoflurane for induction and 1.5% isoflurane for 
maintenance. 
3. The anterior neck was shaved, and povidone-iodine was applied to the skin. After 
administration of subcutaneous buprenorphine (0.1 mg/kg) and intradermal 
lignocaine (50 μl) into the area to be incised, a midline incision was made into the 
skin of the neck and thorax. After blunt dissection and retraction of deep tissues, 
the right common carotid artery was exposed. 
4. The right common carotid artery was gently separated from the jugular vein and the 
vagus nerve, and then lifted by passing suture material underneath and suspending 
the vessel. The silicone tubing was slipped around the carotid artery from beneath 
while suspended, using haemostats. The tubing was placed proximal to the aorta, 
away from the carotid bifurcation, to avoid contact with local microscopic nerve 
bundles (see Figure 5.2). 
5. A small metal clip applicator (Weck Hemoclip® Plus EZ Load Applier (Teleflex 
Medical, North Carolina, USA) was used to gently apply a metal clip to the tubing 
to secure its position without compressing the vessel. 
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6. The midline incision was closed with 6-0 nylon sutures, and isoflurane was ceased. 
The mouse was given supplemental oxygen again, 100% FiO2 for 5 minutes, and 
















Figure 5.2: Schematic representation of collar placement on right carotid artery. 
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5.2.4 Fatty acid analysis 
 Whole blood was spotted onto pre-made dry blood spot (DBS) cards for fatty acid 
analysis. DBS cards were hand-made using cardboard and PUFACoat paper (developed by Dr. 
Ge Liu and Professor Robert Gibson at the FoodPlus Research Centre, University of Adelaide). 
PUFACoat paper stabilises fatty acids in biological samples for at least 9 weeks when stored 
at room temperature, and for at least 18 months when stored at -20oC. Immediately after blood 
collection, 30 µl of whole blood was pipetted directly onto the PUFACoat paper, and the DBS 
cards were then stored in sealed foil bags with desiccant at -20oC prior to processing. The 
blood-stained area of the PUFACoat paper was cut out and placed in 5 ml capped scintillation 
vials filled with 2 ml of 1% H2SO4. The vials were then heated to 70oC for 2.5 hours. After the 
first 30 mins, the caps were released briefly to expel gas and the vials were vortexed. After 
each subsequent 30-minute period the vials were vortexed only.  The vials were allowed to 
cool to room temperature, and then 250 µl of distilled water and 700 µl of heptane were added 
to the vials, which were then vortexed. Using a Pasteur pipette, the top layer was transferred to 
a gas chromatography (GC) vial. The GC vial was sealed and then stored at -20oC until GC 
analysis was performed. GC analysis was performed using a Hewlett-Packard 6890 system 
(Palo Alto, CA, USA) equipped with a BPX70 capillary column 50 m×0.32 mm, film thickness 
0.25 µm (SGC Pty Ltd., Vic, Australia), programmed temperature vaporisation injector and a 
flame ionisation detector (FID). The injector temperature was set at 250 °C and the FID 
temperature at 300 °C, a programmed temperature ramp (140–240 °C) was used. Helium gas 
was utilised as a carrier at a flow rate of 35 cm per second in the column and the inlet split ratio 
was set at 20:1. Quantification was achieved by comparing the retention times and peak area 
values of unknown samples to those of commercial lipid standards (Nu-Chek Prep Inc., 




5.2.5 Tissue harvesting 
 Blood from terminal cardiac puncture was spotted onto dry blood spot cards (40 µl in 
total), which were then stored at -20 oC for later fatty acid analysis as per Section 2.2. The 
remaining blood was collected in EDTA tubes for plasma extraction, and later analysed for 
plasma total cholesterol and triglycerides as described in Section 2.11. The left ventricle was 
flushed with normal saline, and both carotid arteries were harvested and stored in 10% neutral 
buffered formalin for later immunohistochemical analysis as described in Section 2.13.  
5.2.6 Immunohistochemistry 
 Sections (5mm) of the vessels were cut, dewaxed, and rehydrated as described(511). 
Sections were stained with rabbit anti-mouse/rat/human VCAM-1 (1:1000; Abcam ab134047), 
rat anti-mouse ICAM-1 (1:200; Abcam ab119871), rat anti-mouse MCP-1 (1:50; Abcam 
ab8101), and rat anti-mouse CD18 (1:1000; Abcam ab119830) antibodies to assess endothelial 
expression of markers of AVI. 
Quantification was performed using ImagePro Premier v9.1 (Media Cybernetics, Silver 
Spring, MD, USA). The threshold for positive staining was determined by a blinded 
pathologist. Image analysis results, which represent the average positive staining above the 
threshold for individual arterial sections, are expressed as the Integrated Optical Density in 
units of lumens x pixels2. All IgG controls were negative. 
5.2.7 Statistical and data analysis 
5.2.7.1  Sample size calculation 
 The sample size of 40 mice was calculated based on data from the paper by Borissoff 
et al(512). The neutrophil count in the vessel wall was considered the most important factor for 
calculating sample size. In Borissoff et al’s study, perivascular carotid collars were applied, 
with a resulting density of neutrophils of 151±48 per standardised area of vessel wall measured 
161 
 
by immunofluorescence staining for Ly6G+ cells. This was statistically significantly decreased 
after pharmacological intervention to 83±28 neutrophils per standardised area. To detect a 
significant difference in neutrophil count in the artery wall assuming a power of 80% and alpha 
set at 0.05, a one-way ANOVA power calculation derived a sample size of 9 per group, with 4 
groups in total. To account for a predicted 10% failure rate based on a pilot study of the 
procedure, one extra mouse per group was added. 
5.2.7.2  Statistical methods 
GraphPad Prism 7 (GraphPad Software Inc, La Jolla, CA, USA) and Microsoft Excel 
2016 (Microsoft, Albuquerque, NM, USA) were used to analyse data. The D’Agostino-Pearson 
normality test was performed to determine whether continuous data were normally-distributed. 
Normally-distributed data were analysed using the One-way Analysis of Variance (ANOVA) 
to compare means between multiple groups, and results were expressed as mean ± standard 
error of the mean (SEM). If correcting for multiple comparisons, the Dunnett test was used. If 
continuous data were not normally-distributed, analysis was performed using the Kruskal-
Wallis test, and results were expressed as median + interquartile range (IQR). If correcting for 
multiple comparisons, Dunn’s test used. Statistical correlations were analysed using a linear 
regression model. Statistical significance was set at the 0.05 level. 
 
5.3 Results 
 Thirty-eight out of forty mice (95%) completed the study. One mouse died during 
anaesthesia prior to the commencement of surgery, and another developed a reduced 






























5.3.1 Omega-3 supplementation in mice modulates fatty acid profiles 
A complete fatty acid profile of blood taken at study completion was obtained. 
Individual fatty acid levels in whole blood were expressed as a percentage of total fatty acid 
content. The relative proportions of all major fatty acids, i.e. saturated fatty acids, trans-fatty 
acids, monounsaturated fatty acids, and polyunsaturated fatty acids (including omega-3 and 
omega-6) for mice in each treatment group are presented in Figure 5.3. Saturated fatty acids 
and omega-6 polyunsaturated fatty acids comprised the majority of fatty acids in each group. 












Figure 5.3 Relative proportions of all major types of fatty acids in blood in all treatment 
groups at study completion, as measured by dry blood spot analysis. 
Fatty acid content of blood 
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5.3.1.1  Polyunsaturated omega-3 fatty acids 
Polyunsaturated fatty acids are omega-3 or omega-6 fatty acids that have more than one 
double bond in the fatty acid chain. As expected, the total omega-3 fatty acid content in blood 
was significantly higher in the EPA- (9.07±0.22%, p=0.0001) and DHA-supplemented groups 
(9.20±0.38%, p=0.0001) compared to the no treatment group (5.90±0.45%), see Figure 5.4. 
There was no significant difference in the olive oil group (6.72±0.40%, p=0.29) compared to 
the no treatment group. The same trend was also observed for EPA and DHA blood levels. 
That is, EPA levels were significantly higher in the EPA- (1.07±0.04%, p<0.0001) and DHA-
supplemented groups (0.56±0.06%, p<0.0001) compared to the no treatment group 
(0.23±0.05%). DHA levels were significantly higher in the EPA- (6.32±0.17%, p=0.0012) and 
DHA-supplemented groups (7.64±0.34%, p<0.0001) compared to the no treatment group 








Figure 5.4: Total omega-3 fatty acid content in blood from mice in each treatment group. 
Data are presented as mean ± SEM. n = 9-10 per group. NT = No treatment. OO = Olive 
oil. ****p≤0.0001 
 




































Figure 5.5: Blood levels of EPA for mice in each treatment group. Data are presented as 








Figure 5.6: Blood levels of DHA for mice in each treatment group. Data are presented as 
mean ± SEM. n = 9-10 per group. ****p<0.0001, ***p<0.001 
Levels of docosapentaenoic acid (DPA) were significantly higher in mice treated with 
EPA (1.21±0.05%) compared to those in the no treatment group (0.57±0.04%, p<0.0001), see 













































Table 5.1. This was expected, given that DPA is the intermediary product during conversion 
of EPA to DHA. 
The essential omega-3 fatty acid alpha-linolenic acid (ALA), obtained by rodents from 
their diet, comprised only 0.43±0.06% of total blood fatty acids in the no treatment group. This 
was not significantly different in the olive oil (0.39±0.06%, p=0.87), EPA (0.47±0.04%, 
p=0.91) or DHA (0.47±0.04%, p=0.94) treatment groups, see Table 5.1. 
Table 5.1: Post-treatment levels of fatty acids in blood as a percentage of total fatty acid 
content. 
Fatty acids Treatment Groups 
 NT Olive Oil EPA DHA 
Total Omega-3 (%) 5.90±0.45 6.72±0.40 9.07±0.22**** 9.20±0.38**** 
EPA (%) 0.29±0.03 0.26±0.03 1.07±0.04**** 0.56±0.06**** 
DHA (%) 4.71±0.36 5.53±0.32 6.32±0.17*** 7.64±0.34**** 
DPA (%) 0.57±0.04 0.56±0.05 1.21±0.05**** 0.53±0.02 
ALA (%) 0.43±0.06 0.39±0.06 0.47±0.04 0.47±0.04 
Total Omega-6 (%) 35.02±1.21 37.22±1.08 37.51±0.31 37.13±0.51 
Linoleic acid (%) 20.35±0.55 20.34±0.65 23.05±0.43* 23.27±0.69* 
Arachidonic acid (%) 12.22±0.71 14.28±0.59* 12.16±0.27 11.56±0.47 
Total Monounsaturated Fats (%) 11.31±0.33 11.83±0.37 11.07±0.28 10.23±0.35^^ 
Total Trans-fatty Acids (%) 0.4±0.11 0±0** 0.05±0.04** 0.13±0.09* 
Total Saturated Fats (%) 47.37±1.37 44.22±1.34* 42.29±0.31** 43.31±0.53* 
*p<0.05, **p<0.01, ***p<0.001, ****p≤0.0001 compared to NT. ^^p<0.01 compared to 
OO. 
5.3.1.2  Polyunsaturated omega-6 fatty acids 
 Omega-6 fatty acids comprised 35.02±1.21% of total blood fatty acids in the no 
treatment group. This was not significantly different in the olive oil (37.22±1.08%, p=0.19), 
EPA (37.51±0.31%, p=0.11), or DHA (37.13±0.51%, p=0.22) treatment groups, see Figure 
5.7. The most prevalent omega-6 fatty acids were linoleic acid and arachidonic acid. Linoleic 
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acid comprised 20.35±0.55% of total fatty acids in the no treatment group, and this was 
statistically significantly greater in the EPA (23.05±0.65, p=0.005) and DHA (23.27±0.69, 
p=0.003) treatment groups, although the numerical differences were modest, see Table 5.1. 
Arachidonic acid comprised 12.22±0.71% of total fatty acids in the no treatment group. This 
was significantly greater in the olive oil treatment group (14.28±0.59, p=0.03), but was not 
significantly different in either the EPA (12.16±0.27, p=0.94) or DHA (11.56±0.47, p=0.62) 









Figure 5.7: Total omega-6 levels in blood expressed as a percentage of total fatty acids. 
Data are presented as mean ± SEM. n = 9-10 per group. 
5.3.1.3  Ratio of omega 6:3 
The ratio of omega-6 to omega-3, which in humans has a positive association with 
cardiovascular mortality(220), was 6.15±0.31 : 1 in the no treatment group. This was not 
significantly different in the olive oil group (5.63±0.20 : 1, p=0.21). As expected, the omega 































6:3 ratio was significantly lower in mice supplemented with EPA (4.16±0.11 : 1, p=0.0001) 









Figure 5.8: Comparison of omega-6/omega-3 ratios in blood between treatment groups. 
Data are presented as mean ± SEM. n = 9-10 per group. p≤0.0001. 
5.3.1.4  Monounsaturated fatty acids 
 Monounsaturated fatty acids contain a single double bond in the fatty acid chain, and 
consist of omega-7 and omega-9 fatty acids. In the no treatment group, monounsaturated fatty 
acids comprised 11.31±0.33% of total fatty acid content. Given the high proportion of the oleic 
acid (omega-9) in olive oil, the olive oil treatment group had the highest proportion 
(11.83±0.37%) of monounsaturates, although the numerical differences were modest. The EPA 
(11.07±0.88%, p=0.91) and DHA (10.23±0.35%, p=0.07) treatment groups did not have 
significantly different levels of monounsaturates, see Table 5.1. 




















5.3.1.5  Trans-fatty acids 
Trans-fatty acids comprised less than 1% of total blood fatty acids in all groups. This 
value was 0.4±0.11% in the no treatment group. All supplements reduced trans-fatty acid 
levels, demonstrating the effect of fatty acid substitution. The olive oil (0.0±0.00%, p=0.001), 
EPA (0.05±0.04%, p=0.003) and DHA (0.13±0.07%, p=0.03) treatment groups had 
significantly lower levels, see Table 5.1. 
5.3.1.6  Saturated fatty acids 
 Saturated fatty acids were the major fatty acid component of blood, comprising 
47.37±1.37% of all fatty acid content in the no treatment group. All supplements reduced 
saturated fatty acid levels. The olive oil treatment group (44.22±1.34%, p=0.034), the EPA 
treatment group (42.29±0.31%, p=0.003), and the DHA treatment group (43.31±0.53%, 
p=0.015) all had significantly lower levels, see Table 5.1.  
5.3.2 Plasma cholesterol and triglycerides were not altered with omega-3 
supplementation 
Plasma total cholesterol and triglyceride levels, obtained at the time of death, were low 
in all treatment groups, consistent with the use of a non-atherogenic mouse model. Total 
cholesterol was 2.01±0.09 mmol/L in the no treatment group, and supplementation did not 
significantly alter this. Total cholesterol levels were 1.68±0.26 mmol/L in the olive oil group 
(p=0.37), 1.82±0.12 mmol/L in the EPA group (p=0.73), and 1.72±0.14 mmol/L in the DHA 













Figure 5.9: Total plasma cholesterol levels in different treatment groups at end of study. 
Data are presented as mean ± SEM. n = 9-10 per group. 
 Plasma triglyceride levels were 0.53±0.05 mmol/L in the no treatment group, and did 
not significantly differ in the olive oil (0.48±0.07 mmol/L, p=0.90), EPA (0.61±0.07 mmol/L, 







































Figure 5.10: Plasma triglyceride levels in different treatment groups at study completion. 
Data are presented as mean ± SEM. n = 9-10 per group. 
 
5.3.3 Endothelial expression of markers of acute vascular inflammation were 
significantly reduced with omega-3 supplementation 
 Immunohistochemical (IHC) staining of carotid arteries was performed for the 
following markers of acute vascular inflammation: VCAM-1, ICAM-1, MCP-1 and CD18. 
Staining of collared carotids was markedly increased compared to uncollared carotids, 
demonstrating the intense vascular inflammatory response produced by the collaring method. 
As demonstrated in Figure 5.11, the expression of all four markers was significantly increased 
in collared (right) carotids compared to uncollared (left) carotids. 
  
 

























































































































































Figure 5.11: Protein expression of VCAM-1, ICAM-1, MCP-1 and CD18 measured by 
IHC of collared compared to uncollared carotid arteries. Data are presented as mean ± 
SEM. n = 9-10 per group. ****p<0.0001, ***p<0.001 
 
VCAM-1 
 Compared with collared carotids from mice on no treatment, EPA-treated mice had a 
42.8±3.38% reduction in VCAM-1 expression (p=0.02). There was no significant change in 
VCAM-1 expression in the olive oil group (+5.78±7.40%, p=0.97). There was a notable 
reduction in the DHA (-27.5±7.82%) group, however it did not reach statistical significance 










Figure 5.12: Quantification of VCAM-1 staining by IHC in collared carotids for each 









Figure 5.13: Representative IHC staining for VCAM-1 in collared carotid arteries. 
Staining is visible in the endothelium (arrows). Carotid specimens are from mice treated 
with (A) No Treatment, (B) Olive Oil, (C) EPA, and (D) DHA. The EPA group has much 
less endothelial staining compared to the No Treatment group. 
A B 
C D 

































 ICAM-1 expression was not significantly different between treatment groups. There 
were numerical but non-significant reductions in ICAM-1 expression in the olive oil (-
13.2±2.01%, p=0.79), EPA (-28.8±0.33%, p=0.18), and DHA (-27.9±2.01%, p=0.28) 








Figure 5.14: Quantification of ICAM-1 expression by IHC in collared carotids for each 
treatment group. Data are presented as mean ± SEM. n = 6-10 per group. 
MCP-1 
 Compared with mice in the no treatment group, mice in the EPA-treated group had a 
significant reduction (-40.9±6.59%, p=0.03) in MCP-1 expression in collared carotid arteries. 
There was no significant change in MCP-1 expression in the olive oil- (+13.5±2.68%, p=0.75) 
or DHA- (-24.3±1.87%, p=0.33) treated groups compared with the no treatment group, see 
Figures 5.15 and 5.16.  
 
 









































Figure 5.15: Quantification of MCP-1 expression by IHC in collared carotids for each 









Figure 5.16: Representative IHC staining for MCP-1 in collared carotid arteries from 
mice treated with (A) No Treatment, (B) Olive Oil, (C) EPA, and (D) DHA. Endothelial 
staining is least visible in the EPA-treated group. 
A B 
C D 


































 CD18 expression was not significantly different between treatment groups. There were 
numerical but non-significant reductions in CD18 expression in the EPA (-27.1±9.27%, 
p=0.32) and DHA (-26.1±13.00%, p=0.44) treatment groups compared to the no treatment 
group. The olive oil-treated group had a numerical but non-significant increase in CD18 









Figure 5.17: CD18 expression by IHC in collared carotids by treatment group. Data are 
presented as mean ± SEM. n = 6-9 per group. 
 
5.3.4 Both EPA and DHA blood levels had an inverse correlation with inflammatory 
markers  
 The markers of AVI measured by IHC were correlated with blood levels of EPA and 
DHA, and a significant inverse relationship was demonstrated. There were significant inverse 
correlations present between blood levels of EPA, and all four inflammatory markers, see 
Figure 5.18.  













































Figure 5.18: Correlations between blood levels of EPA and the protein expression of 
VCAM-1, ICAM-1, MCP-1 and CD18 as measured by IHC. 
  
Similarly, there were significant inverse correlations between blood levels of DHA and 
the protein expression of all four markers of AVI in the vessel wall, see Figure 5.19. This was 
in the context of a numerical but non-significant reduction in VCAM-1 and MCP-1 protein 
expression in the collared carotid of DHA-treated mice. This likely reflects a genuine anti-
inflammatory effect that has not been fully demonstrated due to a modest study sample size. 
 
 

























r = -0.37, p = 0.04
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Figure 5.19: Correlations between blood levels of DHA and the protein expression of 
VCAM-1, ICAM-1, MCP-1 and CD18 as measured by IHC. 
 The superior anti-inflammatory properties of EPA compared to DHA was again 
demonstrated when correlating the protein expression of markers of AVI with the ratio of EPA 
to DHA in blood. There was a significant inverse correlation with all four markers, consistent 
































r = -0.45, p = 0.01

























r = -0.41, p = 0.02



























r = -0.41, p = 0.03







































Figure 5.20: Correlations between the EPA:DHA ratio in blood and the protein 
expression of VCAM-1, ICAM-1, MCP-1 and CD18 as measured by IHC. 
 
5.4 Discussion 
 In this study, we sought to determine the impact of omega-3 fatty acids, in particular 
the comparative effects of EPA and DHA, on AVI in an in vivo model. The omega-3 fatty acid 
EPA has been shown in this study to reduce periarterial collar-induced acute vascular 
inflammation (AVI), as evidenced by reduced endothelial protein expression of VCAM-1 and 
MCP-1. Notable reductions in markers of AVI were seen with DHA, which did not achieve 
statistical significance and may reflect the low sample size of 10 mice per treatment group. 



























r = -0.47. p = 0.01
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r = -0.68, p<0.0001
Blood EPA:DHA ratio vs MCP-1

























r = -0.48, p = 0.01
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These outcomes were in the context of EPA and DHA supplementation having no effect on 
cholesterol or triglyceride levels, which were low in all mice. 
 The effectiveness of the oral gavage method and the method of supplement preparation 
were confirmed by the significant increase in blood omega-3 levels after 30 days of omega-3 
supplementation. Omega-3 fatty acids can be administered in various biochemical forms, 
including phospholipid, free fatty acid, triglyceride, and ethyl ester forms. The free fatty acid 
form is the most bioavailable(513) and was used in this study. The dose chosen was equivalent 
to ten times the dose used in many recent human clinical trials of 4 grams per day. Four grams 
per day equates to 60mg/kg/day for a 70kg human, and hence 600mg/kg/day was used in this 
mouse study to ensure sufficient dosing. 
In eukaryotes, fatty acids may undergo enzymatic conversion to other fatty acid species, 
by such processes as elongation, desaturation, chain shortening and beta-oxidation. This allows 
multiple diverse species of fatty acids to be generated from the presence of a single fatty acid. 
These processes however, are inefficient, and hence supplementation with a specific fatty acid 
produces the highest blood and tissue concentrations of that fatty acid. EPA (20:5ω3) can be 
elongated, Δ6 desaturated, and beta-oxidised to DHA (22:6ω3) via the intermediary, DPA  
(22:5ω3)(514). Likewise DHA can be retroconverted directly back to EPA, but without an 
intermediary(515). It follows that supplementation with either EPA or DHA in this study 
significantly increased both EPA and DHA levels, with a natural predominance of the fatty 
acid being supplemented. Likewise, DPA, which is formed by the elongation of EPA, was 
significantly increased in the EPA-supplemented mice, but not in the DHA-supplemented 
mice.  
The essential omega-3 fatty acid alpha-linolenic acid (18:3ω3) was not increased by 
supplementation with either EPA or DHA, as EPA does not readily undergo carbon chain 
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shortening. Blood levels of alpha-linolenic acid hence reflect the presence of this fatty acid in 
diet. Supplementation with olive oil, rich in the omega-9 oleic acid (18:1ω9), did not alter total 
omega-3 levels or total omega-6 levels. Arachidonic acid (20:4ω6) was increased by olive oil, 
and this is likely because oleic acid is a precursor of arachidonic acid. 
A low omega-6/omega-3 ratio is associated with lower levels of oxidative stress, 
inflammation, and endothelial dysfunction(516).  Reductions of >30% were seen in the EPA- 
and DHA-supplemented mice, despite the high background blood levels of omega-6 fatty acids.  
The levels of monounsaturated fatty acids, comprised of omega-7 and omega-9 fatty acids, 
were naturally highest in the mice supplemented with olive oil. Trans-fatty acids, which are 
atherogenic and promote inflammation and oxidative stress(517) are present in very low levels 
in standard rodent diets, and this was reflected in the trans-fatty acid blood levels. 
Supplementation with large quantities of alternative fatty acids, in the form of EPA, DHA and 
olive oil in this study, reduced trans-fatty acid levels to nearly undetectable in each case. 
Saturated fats were present in high concentrations in all mice in the study, which is consistent 
with previous fatty acid profiling in mice(518, 519). Supplementation with high doses of 
unsaturated fatty acids in this study led to reductions in the proportions of saturated fatty acids 
in all groups. Thus, it is emphasised that the omega-6/omega-3 ratio, and levels of trans-fatty 
and saturated fatty acids, are lowered by substitution by more favourable fatty acids, namely 
monounsaturated fatty acids and omega-3 polyunsaturated fatty acids. 
 Periarterial, non-occlusive collaring for 48 hours produced an intense inflammatory 
response throughout the vessel wall. VCAM-1 and ICAM-1, which are adhesion molecules 
that are upregulated during early vascular inflammation(520), were present in significant 
concentrations in the endothelium of collared carotids. MCP-1, another marker of early 
vascular inflammation, which regulates migration of monocytes into the vessel wall(521), was 
similarly induced in the endothelium by collaring. Leucocyte recruitment to the vessel wall is 
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a key, early event in acute vascular inflammation(522), and this was studied using the pan-
leucocyte marker CD18. CD18 was also induced in the endothelium by collaring. The 
numerical reductions in endothelial protein expression of all factors by both EPA and DHA is 
consistent with the known anti-inflammatory effects of omega-3 fatty acids(195). The significant 
reductions seen in VCAM-1 and MCP-1 in the mice supplemented with EPA provides evidence 
for a differential anti-inflammatory effect on acute vascular inflammation between EPA and 
DHA. Significant inverse correlations were present between blood levels of both EPA and 
DHA and the expression of VCAM-1, ICAM-1, MCP-1, and CD18. However, a higher 
EPA:DHA ratio in blood correlated with lower levels of all four inflammatory markers. This 
further demonstrates the superior anti-inflammatory effect of EPA compared to DHA, while 
also providing evidence of the anti-inflammatory properties of DHA. The superior anti-
inflammatory effect of EPA may simply reflect a more potent anti-inflammatory effect, or 
different mechanisms of action. 
Omega-3 fatty acids are known to modulate inflammation through several mechanisms. 
These include incorporation into the phospholipids of inflammatory cells(292, 293), reduced 
eicosanoid production(294),  synthesis of resolvins(295), inhibition of the pro-inflammatory NF-
κB transcription pathway(296-298), induction of the anti-inflammatory PPAR-γ transcription 
pathway(299), disruption of lipid rafts(300, 301), and binding to the G-protein coupled receptor 
GPR120(302), which initiates an anti-inflammatory signalling cascade. The expression of 
VCAM-1, ICAM-1 and MCP-1 are regulated via the NF-κB transcription pathway(523). 
Additionally, ICAM-1 is regulated by the MRTF-A/B pathway(524) and is inhibited by mIR-
22(525), both of which are not known to be a target of omega-3 fatty acids. This may explain the 
lack of a significant reduction in ICAM-1 expression observed. Moreover, the recruitment of 
leucocytes to the vessel wall, measured by CD18, is regulated by several factors(526), some of 
which are not a target of omega-3 fatty acids. There is a paucity of quality data on the 
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differential effects of EPA versus DHA on inflammation. Some studies that have examined 
this in vitro have noted comparable downregulation of gene expression of inflammatory 
markers with both EPA and DHA(527-529), or seen differential effects between the two fatty acids 
that have been discordant between studies(530, 531). Other in vitro studies have demonstrated 
differential effects of EPA compared to DHA on the expression of regulatory genes by 
concanavalin A-treated T-lymphocytes (DHA superior)(532), and in lipopolysaccharide-
stimulated THP-1 macrophages (EPA superior)(527). The specific pathways studied were 
cytokines and related receptors, signal transduction pathways, transcription factors, immune 
response, cell cycle, defence and repair, apoptosis, DNA synthesis, cell adhesion, cytoskeleton, 
and hormone receptors(527, 532). These studies have provided some mechanistic clues to explain 
differential effects on inflammation but much further study is required. 
Whether there is a differential effect of EPA compared to DHA on chronic vascular 
inflammation and atherosclerosis is yet to be determined. This is relevant since there is now 
clear evidence that certain anti-inflammatory therapies reduce cardiovascular events. The 
CANTOS study evaluated the effects of canakinumab, a monoclonal antibody that targets 
interleukin 1-β, which plays an important role in the pathogenic mechanisms leading to 
vascular inflammation(236). Canakinumab reduced cardiovascular death, nonfatal MI and 
nonfatal stroke compared to placebo in patients with a previous history of MI and an elevated 
C-reactive protein, independent of lipid levels. Thrombosis is a major pathophysiological event 
leading to these cardiovascular endpoints, with plaque rupture being the most common 
cause(533). The intense inflammatory milieu present in ruptured plaques is a potential target for 
therapies such as omega-3 fatty acids that reduce acute inflammation. Although EPA has not 
been compared directly with DHA in cardiovascular outcome trials, high-dose EPA has been 
shown to significantly reduce major adverse cardiovascular events. The recently-published 
REDUCE-IT study evaluated high-dose EPA (4 grams daily of icosapent ethyl) in 
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hypertrigyceridemic patients who had established cardiovascular disease or were diabetics with 
other cardiovascular risk factors. Icosapent ethyl reduced the primary endpoint of a composite 
of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularisation and unstable 
angina by 25% (first event) and 30% (all events) compared to placebo(234). The reductions in 
triglyceride levels that occurred with icosapent ethyl did not influence its efficacy in reducing 
the primary endpoint. This further highlights the importance of inflammation reduction as a 
mediator of atheroprotection in this study, and the likelihood that targeting acute inflammation 
impacts all stages of atherogenesis from endothelial dysfunction to thrombosis. Future well-
designed studies of omega-3 fatty acids on acute vascular inflammation are warranted, and will 
have implications for a number of acute and chronic vascular diseases. 
 The limitations of this study include a small sample size of 10 mice per group. There 
were numerical reductions in the protein expression of all four markers of acute vascular 
inflammation with both EPA and DHA supplementation. EPA had a greater anti-inflammatory 
effect than DHA, however only reached statistical significance for VCAM-1 and MCP-1. It is 
likely that with a greater sample size, significant reductions would have been demonstrated for 
both EPA and DHA. This study was designed to directly compare pure EPA with pure DHA, 
and no mice were supplemented with formulations with different ratios of EPA and DHA. 
Therefore this study was unable to identify an optimal EPA:DHA ratio to reduce acute vascular 
inflammation. The design of this study best modelled a primary prevention setting, as wildtype 
mice fed a standard rodent diet were pre-treated with omega-3s and then given an acute 
inflammatory insult. An additional treatment arm in which mice were first collared and then 
treated with omega-3s would have permitted a comparison of primary prevention versus acute 
therapy. However, attempting to orally gavage mice after neck surgery would have 




This is the first animal study of the differential effects of EPA versus DHA 
supplementation on pure acute vascular inflammation. Pre-treatment with high dose EPA 
significantly reduced protein expression of VCAM-1 and MCP-1 in an established perivascular 
collar model of AVI. This occurred independent of lipid levels, and was supported by strong 
inverse correlations seen between blood EPA levels as well as the EPA:DHA ratio with protein 
expression of all four markers of AVI studied. This was consistent with the findings of Chapter 
4, where gene expression of MCP-1 was reduced by EPA in an in vitro model of AVI. The 
recently published REDUCE-IT study demonstrated a significant reduction in major adverse 
cardiovascular events with high dose EPA supplementation, and the effects of EPA on AVI 
may contribute to this. Moreover, the effects of EPA and DHA on chronic vascular 
inflammation and atherogenesis require further study, to further elucidate a mechanistic 
rationale for the results of REDUCE-IT. 
 
5.5 Appendix A – Periarterial collaring materials 
1. Normal saline 
2. Betadine 
3. Isoflurane for anaesthesia 
4. Anaesthetic machine with nose cone and oxygenation chamber 
5. Dissecting microscope 
6. Small metal clip applicator [Weck Hemoclip® Plus EZ Load Applier (Teleflex 
Medical, North Carolina, USA)], with small metal clips 
7. Silicone tubing with 0.64 mm internal diameter, 1.2 mm outer diameter (Catalogue 
number: JHS06412, Blue Sky Scientific, Burnside, SA, Australia).  
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8. Clippers for fur removal 
9. Lignocaine for injection, diluted to 0.5% in normal saline 
10. Buprenorphine 
11. 6/0 nylon sutures (Dyloc D602D sutures, Dynek, SA, Australia). 
12. Heatpad 
13. Cotton tips 
14. 25 gauge or smaller needles for injection 
15. 1 ml syringes 
16. Metal retractors 
17. Scalpel 
18. Small, blunt forceps x 2 
19. Suture holder 
20. Ligation aid (hook-shaped) 
21. Ruler 
22. Blunt haemostats for blunt dissection 
23. Small, fine scissors 
24. Lubricating eye drops 













CHAPTER 6: THE IMPACT OF OMEGA-3 FATTY ACIDS ON 













Background: Despite the significant advances that have occurred in the prevention and 
management of cardiovascular disease, there remains a significant residual risk in the general 
population. Inflammation has received considerable attention as a target for new therapies. 
Omega-3 fatty acids have anti-inflammatory properties, and clinical evidence is emerging that 
supports an atheroprotective role, especially when provided at a high dose. Previous animal 
studies have attempted to evaluate the effects of omega-3 fatty acids on atherogenesis, which 
have frequently had methodological limitations, and have not explored the relative effects of 
EPA versus DHA. This study aimed to determine the effects of omega-3 fatty acids on chronic 
vascular inflammation and atherogenesis, specifically the burden and characteristics of 
atherosclerotic plaque, in an animal model. The relative effects of EPA were to be compared 
with DHA. 
Methods: Forty 8-week-old ApoE-deficient mice, 20 of each sex, were fed an atherogenic diet 
for 16 weeks to induce chronic vascular inflammation and advanced atherosclerotic plaques. 
After the first 8 weeks, a blood sample was taken for fatty acid and lipid analysis. The mice 
were then randomised equally to supplementation with 600mg/kg/day of either (1) EPA, (2) 
DHA, (3) olive oil as an oil control, or (4) no treatment, by oral gavage, to be given for the 
final 8 weeks. The mice were subsequently humanely killed and a terminal blood sample was 
taken for fatty acid and lipid analysis. Organs were harvested, and plaque burden, intimal and 
medial layer expansion, plaque collagen content, smooth muscle cell content and inflammatory 
cell content were measured in the aortic sinuses and brachiocephalic arteries. The aortas were 
stained for lipid using Oil Red O. Aortas were snap-frozen, and gene expression of markers of 
chronic inflammation and regulatory transcription factors were measured by RT-PCR 
(including IL-1β, TNF-α, MCP-1, NFκB-p65, and PPAR-γ). Correlations were made between 
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the blood concentrations of EPA, DHA, and the EPA:DHA ratio at study completion and the 
plaque, lipid, and inflammatory measures. 
Results: 38 out of 40 mice completed the study. Blood EPA and DHA levels increased 
significantly in the respective treatment groups. Plasma cholesterol levels were high in all mice 
after 8 weeks (17.96±5.4 mmol/L), continued to increase in the no treatment and placebo 
groups, but stabilised in the EPA and DHA treatment groups. Triglyceride levels were elevated 
in all mice after 8 weeks (2.27±0.70 mmol/L), and were significantly reduced by EPA and 
DHA treatment. All mice developed advanced atherosclerotic plaques, however the burden of 
plaque in the aortic sinuses and brachiocephalic arteries did not differ among treatment groups. 
Although the combined thickness of the intima and media was similar between treatment 
groups, there was an inverse correlation between blood EPA levels and intimal plus medial 
thickness (r=-0.49, p=0.04). Collagen content, a marker of plaque stability, did not significantly 
differ among treatment groups in the aortic sinus or brachiocephalic artery plaques. In these 
sites, the density of smooth muscle actin staining and macrophage (CD107b) staining on 
immunohistochemistry was similar among treatment groups. Lipid was present throughout the 
aorta in all mice, with 6.3 (IQR 5.0 – 10.6) % of the aortic surface staining positively for Oil 
Red-O in the no treatment group; this did not differ significantly among treatment groups. In 
aortic tissue, the gene expression of markers of chronic inflammation, IL-1β and TNF-α, were 
significantly lower in the mice treated with EPA (-44.3% [p=0.04] and -48.8% [p=0.04], 
respectively). There were significant inverse correlations present between IL-1β and TNF-α 
expression and both blood EPA levels and the EPA:DHA ratio. 
Conclusions: In an atherogenic mouse model, supplementation with both EPA and DHA 
stabilised cholesterol levels and reduced triglyceride levels. Despite this, neither EPA nor DHA 
had a significant effect on plaque burden, lipid burden, markers of plaque stability, or the 
inflammatory cell content of plaque. EPA significantly reduced gene expression of the markers 
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of chronic vascular inflammation IL-1β and TNF-α in the arterial wall, with a strong inverse 
correlation present between these markers and blood EPA levels and the EPA:DHA ratio. The 
findings of this study, in particular the reduction in chronic vascular inflammation by EPA 
supplementation, may provide a mechanistic contribution to the reduction in major adverse 
cardiac events seen with EPA in the recently-published REDUCE-IT trial. The 
pharmacodynamics of individual omega-3 fatty acids and their effects on all stages of 
atherogenesis require continued investigation. 
 
















 Cardiovascular disease is the leading cause of death worldwide, with the largest 
contribution being from atherosclerotic diseases(1). Significant advances in the prevention and 
treatment of atherosclerotic diseases have led to major reductions in morbidity and mortality(2). 
Despite these advances, there remains a substantial residual cardiovascular risk in the general 
population(3). There have been continued efforts to identify and target new atherogenic 
pathways, and much attention has been focused on the role of inflammation, which is present 
in all stages of atherogenesis(534). Given the essential contribution of acute and chronic vascular 
inflammation to atherogenesis, agents that attenuate these processes are likely to have anti-
atherosclerotic properties and reduce cardiovascular risk. This has recently been demonstrated 
using canakunimb, a monoclonal antibody to interleukin-1β, which contributes significantly to 
the inflammatory state of plaques, especially in the vessel wall(79-81). Canakinumab reduced 
cardiovascular events in patients with a previous myocardial infarction and a raised C-reactive 
protein levels(120). The same may be applicable to omega-3 fatty acids, which have beneficial 
effects on inflammation(535, 536), as well as on endothelial function(537, 538), oxidative stress(197, 
539), and lipids(540, 541). As demonstrated in Chapter 4 and 5 of this thesis, omega-3 fatty acids, 
in particular eicosapentaenoic acid (EPA), reduce acute vascular inflammation (AVI). Since 
AVI is an early and critical stage of atherogenesis, it is predictable that omega-3 fatty acid 
supplementation would reduce the volume and inflammatory nature of atherosclerotic plaques. 
Moreover, inflammation in plaque promotes vulnerability(542, 543), and hence omega-3s may 
also have a favourable effect on plaque stability. The effects of omega-3 fatty acids on the 
pathology of chronic vascular inflammation and atherosclerosis have been studied 
predominantly in animal models of atherosclerosis. In a study by Matsumoto et al, EPA 
improved plaque and lipid burden in ApoE-deficient mice, and improved plaque stability and 
inflammatory cell content in LDLR-deficient mice(255). However a similar study by Xu et al, 
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which assessed the effects of combined EPA and DHA in the form of fish oil on plaque and 
lipid burden in ApoE-deficient mice demonstrated no benefit(254). Favourable effects of 
combined EPA and DHA on the inflammatory state were seen in a study by Li et al, where 
efferocytosis by macrophages was increased in the atherosclerotic plaques of ob/ob mice(256). 
The prevalence of inflammatory cells, namely macrophages, dendritic cells and CD4+ T cells 
in atherosclerotic plaques, was reduced by EPA supplementation in LDLR-deficient mice in a 
study by Nakajima et al(259). In that study, EPA was also shown to significantly regress 
atherosclerotic plaque. DHA on the other hand, has been less studied in the setting of chronic 
vascular inflammation and atherosclerosis, yet was shown in one study to reduce 
atherosclerotic lesion size in ApoE-deficient mice when added to their diet(260). These studies 
have provided evidence for beneficial effects of omega-3 fatty acids on chronic vascular 
inflammation and atherosclerosis, which require further investigation. These studies have not 
directly compared EPA with DHA. The method of supplementation used in these animal 
studies, i.e. the addition of omega-3 fatty acids to food has limitations such as a propensity for 
both fatty acid oxidation and variability in dosing. 
 Cardiovascular outcome trials (CVOTs) of omega-3 supplementation in the primary 
and secondary prevention settings have produced variable results(226-230, 232, 233), despite overall 
positive results from dietary studies(222-224). Some of the limitations of those CVOTs were 
overcome by the well-designed REDUCE-IT trial, which demonstrated a 25% reduction in 
major adverse cardiovascular events with EPA supplementation(234). Although there was no 
comparison with DHA in REDUCE-IT, data from a recent cohort study by Veno et al provided 
evidence for a superior atheroprotective effect of EPA compared to DHA(544). Middle-aged 
adult subjects had adipose tissue analysed for fatty acid content at baseline, and were followed 
for a median period of 13.5 years for the development of ischaemic strokes. There was a 
significant inverse correlation between EPA content and ischaemic stroke risk (HR 0.74, 95% 
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CI, 0.62–0.88), which was not present for DHA or for total omega-3 fatty acid content(544). The 
evidence for a cardioprotective effect of omega-3 fatty acids mandates further evaluation of 
mechanisms of benefit. This may include beneficial effects on chronic vascular inflammation 
and on the characteristics and burden of plaque. Given the results of REDUCE-IT, the 
comparative effects of EPA compared to DHA in a model of secondary prevention would be 
of significant interest. 
6.1.1 Aims and rationale of study 
The aims of this study were to: 
(1) Determine in an animal model of atherosclerosis the impact of omega-3 fatty acids on (i) 
plaque burden, characteristics, inflammatory content and stability, (ii) arterial lipid burden and 
circulating lipids, and (iii) markers of chronic inflammation in the vessel wall.  
(2) Compare the relative effects of EPA versus DHA supplementation on the above measures. 
 
An ideal animal model for this study is the ApoE-deficient mouse fed an atherogenic 
diet, which rapidly develops advanced atherosclerotic lesions that resemble those of 
humans(545). The very high cholesterol levels induce endothelial dysfunction as early as four 
weeks of age, followed by fatty streak formation by 6 weeks, and early inflammatory 
atherosclerotic plaques by 10 weeks of age(546).  By 10-15 weeks of age, foam cell formation 
and smooth muscle cell proliferation are evident, and after 20 weeks of age advanced plaques 
are seen, progressing from the proximal aorta distally throughout the arterial tree, characterised 
by a necrotic core and fibrous cap(547). Precise quantities of omega-3 fatty acids can be 
administered to mice by oral gavage, and mice do not have a natural aversion to the taste or 





The hypotheses of this study were that: 
(1) Omega-3 fatty acids alter the development of atherosclerotic plaques by 
reducing total plaque content, reducing intimal and medial proliferation, reducing 
inflammatory cell content, and increasing collagen and smooth muscle cell content. 
(2) Omega-3 fatty acids reduce the lipid content of aortic lesions independent of 
effects on plasma cholesterol and triglyceride levels. 
(3) Omega-3 fatty acids reduce markers of chronic vascular inflammation in the 
arterial wall. 
(4) For all of the above measures, EPA will have a greater effect compared to DHA. 
(5) A significant inverse correlation will be present between blood omega-3 levels, 
especially EPA, and the above measures of plaque, lipid and vascular inflammation. 
 
6.2 Methods 
6.2.1 Study outline 
Forty 8-week-old chow-fed ApoE-deficient mice, 20 of each sex, previously fed a 
standard rodent chow diet, were commenced on an atherogenic diet (22% fat, 0.15% 
cholesterol, SF00-219, Specialty Feeds, Glen Forrest, WA, Australia) for 16 weeks. Mice were 
weighed at baseline and then weekly thereafter. After 8 weeks, a blood sample was taken by 
superficial facial vein bleeding. Whole blood was spotted onto dry blood spot cards for fatty 
acid analysis. Blood was also collected for plasma total cholesterol and triglycerides. The mice 
were then randomised equally to daily supplementation with either EPA, DHA, olive oil (OO), 
or no treatment for the last 8 weeks of the 16-week period, by oral gavage. EPA and DHA were 
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in the form of ethyl esters (>97% purity), and were provided by Bizen Chemical Company 
(Okayama, Japan). The olive oil was Bertolli brand (Florence, Italy). The dose administered 
was 600 mg/kg/day. At the end of the treatment period, the mice were humanely killed as per 
Section 2.10, and the blood that was obtained from terminal cardiac puncture was analysed for 
fatty acids, plasma total cholesterol and plasma triglycerides. The study outline is presented 
schematically in Figure 6.1. Organ harvesting was then performed. Organs were stored in 10% 








Figure 6.1: Schematic representation of study outline. Forty ApoE-deficient mice were 
randomised equally to one of four treatment groups. After 8 weeks on an atherogenic 
diet, a cheek bleed was performed and treatment by oral gavage was commenced. After 




 The harvested hearts were sectioned parallel to the aortic valve, through its entire depth, 
in 5 µm increments. Sections were stained for haematoxylin and eosin, as well as the Masson’s 
trichrome stain, to allow quantification of plaque burden, intimal and medial expansion, and 
plaque collagen content. In addition, sections were assessed for the presence of smooth muscle 
cells by immunohistochemical staining for smooth muscle actin. Quantification of all 
immunohistochemical staining was performed using ImageJ software as per Section 2.15. The 
inflammatory content of plaque was assessed by immunohistochemical staining for 
macrophages using the CD107b (Mac3) stain. The brachiocephalic artery was sectioned 
through its entire length, and staining and quantification were as per the aortic valves. The 
aortas were stained for lipid using the Oil Red O and quantified using ImageJ software as per 
Section 2.16. The snap-frozen aortas were homogenised, and gene expression of markers of 
chronic inflammation and regulatory transcription factors were measured by PCR. These 
comprised IL-1β, TNF-α, MCP-1, NFκB-p65, and PPAR-γ. Correlations were made between 
the blood concentrations of EPA, DHA, and the EPA:DHA ratio at study completion and the 
plaque, lipid, and inflammatory measures. 
6.2.2 Statistical methods 
6.2.2.1  Sample size calculation  
The sample size calculation for this study was based on a paper by Liu M et al(549). The 
macrophage content of plaques was deemed to be the most important factor in demonstrating 
differences between treatment groups. In Liu M et al’s study, 17% of the atherosclerotic plaque 
area of ApoE-deficient mice fed an atherogenic diet stained positively for macrophages. 
Treatment with the active drug (simvastatin) reduced this to 10%, and was significantly greater 
than an inactive vehicle. Using a one-way ANOVA power calculation for 4 groups with a 
significance level of 0.05, with 80% power, and a standard deviation of 10, a sample size of 40 
was chosen, i.e. 10 mice per group. 
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6.2.2.2  Statistical analysis 
GraphPad Prism 7 (GraphPad Software Inc, La Jolla, California, USA), SPSS 19 (IBM 
Corporation, Armonk, New York, USA), and Microsoft Excel 2016 (Microsoft, Albuquerque, 
New Mexico, USA) were used to analyse data. The D’Agostino-Pearson normality test was 
performed to determine whether continuous data were normally-distributed. Normally-
distributed data were analysed using either the T-test if comparing means between two groups, 
or the One-way Analysis of Variance (ANOVA) if comparing means between multiple groups. 
If correcting for multiple comparisons, the Dunnett test was used. If comparing means between 
multiple groups adjusted for a covariate, an Analysis of Covariance (ANCOVA) was 
performed. Results were expressed as mean ± standard error of the mean (SEM). If continuous 
data were not normally-distributed, analysis was performed using the Kruskal-Wallis test, with 
Dunn’s test used to correct for multiple comparisons. Results were expressed as median + 
interquartile range (IQR). Statistical correlations were analysed using a linear regression 
model. Statistical significance was set at the 0.05 level. 
 
6.3 Results 
Thirty-eight out of 40 mice completed the study. Two mice were culled on humane 
grounds; one after pulmonary aspiration occurred following oral gavage in the 9th week of 
supplementation (DHA group), and another due to the development of significant dermatitis 
(olive oil group). 
6.3.1 Mouse body weight increased appropriately in the omega-3 treatment groups 
At baseline, the 8-week-old ApoE-deficient mice fed a standard chow diet had a mean 
weight of 22.63±0.51 g. On the atherogenic diet, this increased by approximately 1.2 g per 
week to 32.40±0.13 g by 8 weeks. There were no significant differences between mice 
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allocated to different treatment groups at baseline (p=0.65) or after 8 weeks (p=0.52). In the no 
treatment group, the mice gained 5.90±0.50 g from weeks 9 to 16.  This did not significantly 
differ in the EPA or DHA treatment groups (p=0.50 and p=0.10 respectively, adjusted for 
differences in weight after 8 weeks). Olive oil reduced further weight gain, with only a 
2.22±0.47 g increase over the last 8 weeks of the study, which was notably less than that of the 










Figure 6.2: Weight of mice in each treatment group over the 16-week atherogenic feeding 
period. Note that treatment began after 8 weeks on this diet. n = 9-10 per group. Results 
expressed as mean ± SEM. NT = No treatment, OO = Olive oil. 
 




Mouse body weight over time

















6.3.2 Fatty acid analysis of whole blood 
6.3.2.1  Summary of fatty acid content of blood by treatment group 
A complete fatty acid profile of blood was taken after 8 weeks and then again after 16 
weeks of atherogenic feeding. This was to record the fatty acid content of blood before and 
after supplementation, and to confirm the effectiveness of the oral gavage delivery method. 
Fatty acid levels in whole blood were expressed as a percentage of total fatty acid content. The 
highest proportion of fatty acids in blood were monounsaturated and saturated fatty acids. 
Omega-6 fatty acids were more prevalent than omega-3s, and trans-fatty acids were the least 
prevalent overall. The relative proportions of all major fatty acids at study completion are 











Figure 6.3: Relative proportions of all major fatty acid groups in blood at study 
































6.3.2.2  Polyunsaturated omega-3 fatty acids 
Total omega-3 fatty acid content 
The SF00-219 rodent atherogenic diet has very low levels of omega-3 fatty acids 
(0.35% of total), and amongst those, it is predominantly composed of alpha-linolenic acid. 
After 8 weeks on this diet, the mean omega-3 content of blood for all mice was 2.60±0.11%. 
In the no treatment group, with continued feeding of the atherogenic diet, the total omega-3 
content of blood increased by study completion to 3.79± 0.28%. A similar outcome was seen 
in the olive oil group, with an increase to 4.06±0.21%. As predicted, EPA and DHA 
supplementation markedly increased total omega-3 levels, with significantly higher values 
compared to that of the no treatment group (13.34±0.96%; p=0.001, and 9.98±0.67%; 









Figure 6.4: Proportion of total blood fatty acids comprised of omega-3s at study 
completion. n = 9–10 per group. Results expressed as mean ± SEM. ****p<0.0001. 
***p<0.001. 































Eicosapentaenoic acid levels in blood 
  The omega-3 fatty acids with established anti-inflammatory properties are EPA, DPA 
and DHA. In rodents, the plant-derived omega-3 fatty acid ALA (18:3ω3), is not efficiently 
converted to longer chain omega-3 fatty acids. Hence, blood levels of EPA (20:5ω3), DPA 
(22:5ω3) and DHA (22:6ω3) reflect their respective supplementation in a dose-dependent 
manner. Favourable properties of EPA include its superior hypolipidemic effect, and its effect 
on endothelial function. After 8 weeks, which was before randomisation, blood EPA levels 
were 0.60±0.02% of total fatty acid content in the 40 mice. Over the subsequent 8 weeks, blood 
EPA content increased mildly in the no treatment and olive oil groups to 0.97±0.07% and 
0.98±0.06%, respectively. Blood EPA levels were markedly increased in the EPA 
(9.27±0.81%) and DHA (3.68±0.29%) groups (p<0.0001 for both comparisons with the no 
treatment group). EPA supplementation naturally produced significantly higher levels of EPA 








Figure 6.5: The percentage of EPA in whole blood at study completion. n = 9-10 per 
group. Results expressed as mean ± SEM. ****p<0.0001. 
 
























Docosahexaenoic acid levels in blood 
DHA is the most unsaturated omega-3 fatty acid, and the one present in highest 
concentrations in blood and tissue. After 8 weeks of atherogenic feeding, DHA comprised 
1.41±0.07% of total fatty acids in the 40 mice. By study completion, those in the no treatment 
and olive oil groups had a mild increase in DHA levels, to 2.13±0.18% and 2.3±0.15%, 
respectively. EPA supplementation only mildly increased DHA levels (to 2.70±0.16%; p=0.23 
for comparison with the no treatment group). DHA supplementation was highly effective at 
increasing blood DHA levels, which were significantly greater than those in all other groups 









Figure 6.6: The percentage of DHA in whole blood at study completion. n = 9-10 per 






























Docosapentaenoic acid (DPA) levels in blood 
 DPA is an intermediary between the conversion of EPA to DHA, although the 
retroconversion of DHA to EPA does not have the DPA intermediary in rodents. It is present 
in lower concentrations in blood and tissue, and has received considerably less attention than 
EPA and DHA. Consequently, its effects on inflammation and atherosclerosis are largely 
unknown. After 8 weeks of atherogenic feeding, DPA comprised 0.32±0.01% of total fatty 
acids in the 40 mice. This remained low in the no treatment and olive oil groups for the duration 
of the study, with levels of 0.38±0.03% and 0.40±0.02%, at study completion, respectively. 
There was a predictable increase in DPA levels (231%) in the EPA-treated mice to 1.06±0.05%, 









Figure 6.7: The percentage of DPA in whole blood at study completion. n = 9-10 per 
group. Results expressed as mean ± SEM. ****p<0.0001. 
 
 























Alpha-linolenic acid (ALA) 
 ALA (18:3ω3) is present in low quantities in the bloodstream of rodents, and much of 
the ALA that is present is used as a substrate for the synthesis of EPA (20:5ω3) and DHA 
(22:6ω3). Longer chain omega-3s are not readily converted back to ALA, but despite this, small 
increases in ALA levels are expected after supplementation with longer chain omega-3s. After 
8 weeks, ALA comprised 0.27±0.01% of total fatty acids in the 40 mice. Small increases 
occurred in the no treatment and olive oil groups by the end of the study, to 0.32±0.02% and 
0.34±0.02%, respectively. Despite the prolonged, high-dose omega-3 supplementation, there 
were no significant increases in ALA levels in the EPA (0.27%±0.03%; p=0.43) or DHA 
(0.37±0.03%; p=0.51) treatment groups, see Table 6.1. ALA levels were higher in those treated 
with DHA compared to EPA (p=0.03), despite the higher total omega-3 levels in the EPA 
group.  
Table 6.1: Summary of blood fatty acids levels in each treatment group at study 
completion. 
Fatty acids in blood Treatment Groups 
 NT Olive Oil EPA DHA 
Total omega-3 (%) 3.79±0.28 4.06±0.21 13.34±0.96**** 9.98±0.67**** 
EPA (%) 0.97±0.07 0.98±0.06 9.27±0.81**** 3.68±0.29**** 
DHA (%) 2.13±0.18 2.34±0.15 2.70±0.16**** 5.52±0.38**** 
DPA (%) 0.38±0.03 0.40±0.02 1.06±0.05**** 0.43±0.03 
ALA (%) 0.32±0.02 0.34±0.02 0.27±0.03 0.37±0.03 
Total omega-6 (%) 10.9±0.53 11.57±0.51 6.92±0.24**** 8.14±0.29**** 
Linoleic acid (%) 5.23±0.19 5.48±0.14 4.16±0.14**** 5.04±0.10 
Arachidonic acid (%) 4.67±0.33 4.96±0.32 2.13±0.11**** 2.34±0.16**** 
Total Monounsaturated Fats (%) 45.58±0.69 45.64±0.76 37.53±0.82**** 38.32±0.59**** 
Total Trans-fatty Acids (%) 1.52±0.09 1.34±0.11 1.54±0.12 1.61±0.11 
Total Saturated Fats (%) 38.15±0.63 37.38±0.73 40.70±0.97 41.82±0.94* 
*p<0.05, ****p<0.0001 compared to NT. Results expressed as mean ± SEM. 
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6.3.2.3  Polyunsaturated omega-6 fatty acids 
Total omega-6 fatty acid content 
Omega-6 fatty acids have pro-inflammatory properties, and are highly prevalent in 
“Western-type” diets. After 8 weeks, omega-6 comprised 9.59±0.24% of total fatty acids in the 
40 mice. With the continued atherogenic feeding, this increased to 10.90±0.53% and 
11.57±0.51% in the no treatment and olive oil groups, respectively. Omega-3 supplementation 
had a favourable effect by significantly reducing omega-6 levels, likely by simple fatty acid 
substitution. In the EPA and DHA groups, the relative proportions of omega-6 significantly 
decreased, to 6.92±0.24% and 8.14±0.29%, respectively (p<0.0001 for both comparisons with 









Figure 6.8: The proportion of total fatty acids in blood comprised of omega-6 fatty acids 
at study completion. n = 9-10 per group. Results expressed as mean ± SEM. ****p<0.0001. 
 
 






























 The two main omega-6 fatty acids are linoleic acid (LA) and arachidonic acid (AA). 
The enzymes that convert LA (18:2ω6) to AA (20:4ω6) are the same as those that convert ALA 
to EPA and DHA. Therefore, higher LA levels result in less conversion of ALA to EPA and 
DHA. After 8 weeks, linoleic acid comprised 5.03±0.10% of total fatty acids in the 40 mice. 
This did not increase with ongoing atherogenic feeding, and was 5.23±0.19% in the no 
treatment group and 5.48±0.14% in the olive oil group. DHA supplementation did not alter LA 
levels (5.08±0.14%; p=0.999), however EPA supplementation significantly reduced LA levels 
to 4.16±0.12% (p<0.0001), see Table 6.1. 
Arachidonic acid 
 Arachidonic acid (AA) is a biologically important fatty acid as it is a substrate for the 
production of eicosanoids, hormone-like mediators of tissue inflammation. After 8 weeks, 
arachidonic acid comprised 3.65±0.14% of total fatty acids in the 40 mice. With the ongoing 
atherogenic diet, this increased in the no treatment (4.67±0.33%) and olive oil (4.96±0.32%) 
groups. EPA and DHA supplementation reduced the proportion of arachidonic acid in blood to 
2.13±0.11% and 2.34±0.16% respectively, and these were significantly lower than in the no 
treatment group (p<0.0001 for both comparisons), see Table 6.1. 
Omega-6/Omega-3 ratio 
The omega-6/omega-3 ratio is a summary of the ratio of pro-inflammatory omega-6 to 
anti-inflammatory omega-3 fatty acids. Higher levels favour a pro-inflammatory state and 
confer a higher mortality risk(472). After 8 weeks on the atherogenic diet, the 40 mice had a 
mean omega-6/omega-3 ratio of 3.81±0.07. In the no treatment and olive oil groups, the omega-
6/omega-3 ratios reduced by the end of the study to 2.95±0.14 and 2.86±0.08, respectively. In 
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the EPA and DHA groups, there were major reductions, to 0.54±0.03 and 0.84±0.04 









Figure 6.9: The blood omega-6:omega-3 ratio for all treatment groups at study 
completion.  n = 9-10 per group. Results expressed as mean ± SEM. ****p<0.0001.  
 
6.3.2.4  Monounsaturated fatty acids 
Total monounsaturated fatty acid content 
 The monounsaturated fatty acids (omega-7 and omega-9) are the most biologically 
neutral of the fatty acids from an inflammatory perspective. However, mere substitution of 
unfavourable fatty acids with monounsaturates, leads to a reduction in inflammation. After 8 
weeks, monounsaturated fatty acids comprised 43.76±0.33% of all blood fatty acids in the 40 
mice. This was unchanged in both the no treatment (45.6±0.69%) and olive oil (45.6±0.76%) 
groups, despite the high concentration of omega-9s in olive oil. By comparison, there were 




















significant reductions, in the EPA (37.5±0.82%; p<0.0001) and DHA (38.3±0.59%; p<0.0001) 
treatment groups, see Table 6.1. 
6.3.2.5  Trans-fatty acids 
Total trans-fatty acids 
Trans-fatty acids, which promote inflammation and increase cardiovascular risk, are 
present in low levels in rodent diets. After 8 weeks, trans-fatty acids comprised only 
1.46±0.04% of total blood fatty acids in the 40 mice. There was no significant change by the 
end of the study regardless of treatment group (no treatment: 1.52±0.09%, olive oil: 
1.34±0.11%, EPA: 1.54±0.12%, and DHA: 1.61±0.11%; p=0.88 for comparison between 
treatment groups, see Table 6.1). 
6.3.2.6  Saturated fats 
Total saturated fatty acids 
Saturated fats lack double bonds and do not readily undergo conformational changes to 
other fatty acid species. Saturated fats are pro-inflammatory although have not been 
conclusively shown to increase cardiovascular risk(137). After 8 weeks, saturated fatty acids 
comprised 42.6±0.36% of total blood fatty acids of the 40 mice. In the no treatment and olive 
oil groups, this decreased to 38.2±0.63% and 37.4±0.73%, respectively. This value was 
40.7±0.97% in the EPA group (p=0.10), and 41.8±0.94% in the DHA group, which was 
significantly higher than the no treatment group (p=0.02), see Table 6.1. 
6.3.3 Plasma cholesterol and triglycerides 
Total cholesterol 
 All mice developed hypercholesterolaemia after 8 weeks on the atherogenic diet with a 
mean total cholesterol level of 17.96±0.9 mmol/L. Before treatments commenced, there were 
no significant differences in total cholesterol levels between mice allocated to each treatment 
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group (p=0.53). In the no treatment and olive oil groups, total cholesterol levels continued to 
increase for the last 8 weeks of the study, to 20.13±1.1 mmol/L and 27.21±2.9 mmol/L, 
respectively, with significant increases from their 8-week levels (p=0.005 and p=0.02, 
respectively). Both EPA and DHA stabilised total cholesterol levels, with an increase by 
0.0±2.8 mmol/L to 20.8±1.6 mmol/L in the EPA group (p=0.999 for change from the levels at 
8 weeks), and an increase by 2.75±1.9 mmol/L to 19.96±1.3 mmol/L in the DHA group (p=0.16 









Figure 6.10: Changes in plasma total cholesterol levels for mice in each treatment group 
from 8 weeks until study completion. n = 9-10 per group. Results are expressed as mean 



























 Triglyceride levels were mildly elevated after 8 weeks, with a mean level of 2.27±0.70 
mmol/L. There were no significant differences between allocated treatment groups (p=0.25). 
In the no treatment group, the mean triglyceride level after 16 weeks was not significantly 
different to that after 8 weeks, with a -0.11±0.30 mmol/L change (p=0.71). In the olive oil 
group, there was mild, non-significant reduction of 0.56±0.30 mmol/L (p=0.08). This reduction 
is consistent with the known triglyceride-lowering effects of diets high in monounsaturated 
fatty acids. In the EPA and DHA groups, triglyceride levels reduced by 0.73±0.27 mmol/L 









Figure 6.11: Changes in plasma triglyceride levels for mice in each treatment group from 
8 weeks until study completion. n = 9-10 per group. Results expressed as mean ± SEM. 
***p<0.001. *p<0.05. NT = no treatment, OO = olive oil. 
 























6.3.4 Atherosclerotic plaque quantification 
Brachiocephalic artery 
 The brachiocephalic artery is a site of predilection for plaque formation in ApoE-
deficient mice fed an atherogenic diet. In this study, brachiocephalic arteries were harvested 
from male mice, resulting in a maximum of 5 mice per treatment group. When plaque was 
present it was quantified and expressed as a percentage of total cross-sectional artery area. In 
the no treatment group, plaque comprised 32.0 (IQR 24 - 40) % of total cross-sectional artery 
area. There were no significant differences in plaque burden in the olive oil [30.3 (13-38) %, 
p=0.46] and EPA [27.1 (16.3 – 51.5) %, p=0.54] groups. Mice in the DHA group had notably 
less plaque compared to the no treatment group [18.1 (16.3 – 20.7) %], although it did not reach 
statistical significance in the context of a small sample size (p=0.09), see Figure 6.12. 









Figure 6.12: Comparison of brachiocephalic artery plaque burden as a percentage of total 
cross-sectional area. n= 3-4 per group. Results expressed as median + interquartile range. 






































Figure 6.13: Representative haematoxylin and eosin-stained sections of brachiocephalic 
arteries from mice in each treatment group. Advanced plaques are seen, including 
cholesterol crystals and intimal and medial expansion. No significant differences are 
present between treatment groups. 
 
 





 Plaque burden in the aortic sinuses was expressed as the percentage area of each sinus 
comprised of plaque. The plaque burden in each sinus was averaged for each mouse. In the no 
treatment group, plaque comprised 34.2 (IQR 19 – 35) % of total sinus area. This was similar 
to the plaque burden seen in the brachiocephalic arteries. There were no significant differences 
among treatment groups (p=0.95 for the overall comparison), see Figure 6.14. In the olive oil 
group, plaque comprised 33.5 (26.1 – 39.6) % of total sinus area, and in the EPA and DHA 
groups plaque comprised 32.8 (20.1 – 37.3) % and 30.5 (26.1 – 35.6) % of total sinus area, 
respectively. Representative images from haematoxylin and eosin-stained slides are presented 










Figure 6.14: Comparison of plaque burden in the aortic sinuses between treatment 
groups. n = 4 per group. Results expressed as median + interquartile range. 
 






































Figure 6.15: Representative haematoxylin and eosin-stained sections of the aortic sinuses 
from mice in each treatment group. Advanced plaques with inflammatory infiltrates and 
cholesterol crystals can be seen. No significant differences were present between 
treatment groups.  
6.3.5 Expansion of the intima and media in the artery wall 
 Following endothelial injury, an early event in atherogenesis, smooth muscle cells 
(SMCs) are recruited to the intima and proliferate. Over time, this expands the extracellular 




matrix and results in thickening of the intimal and medial layers of the arterial wall. This 
thickening narrows the lumen. The impact of omega-3 supplementation on this process was 
quantified histologically in the brachiocephalic artery specimens. The area comprised by the 
intimal and medial layers was measured and expressed as a proportion of the total area of the 
artery wall. In the no treatment group, the median value was 30.7 (IQR 26.1 – 37.2) %. In the 
olive oil group, this was significantly greater at 48.2 (38.6 – 52.0) % (p=0.02). However, there 
were no significant differences noted in the EPA [36.2 (28.5 – 42.6) % (p=0.42)] or DHA [39.9 
(34.5 – 49.2) % (p=0.10)] treatment groups, see Figure 6.16). The representative H & E sections 









Figure 6.16: The percentage of total artery wall area comprised of the intima and media, 
compared between treatment groups. n = 4-6 per group. Results expressed as median + 
interquartile range. *p<0.05. 
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6.3.6 Collagen content of plaque as a measure of stability 
 Atherosclerotic plaques that are stable are less prone to rupture. The amount and 
organisation of matrix collagen is positively associated with the mechanical stability of the 
fibrous cap(550). In advanced plaques, inflammatory cells release metalloproteinases (MMPs), 
which degrade collagen and cause apoptosis of collagen-producing SMCs. The collagen 
content of plaques in the brachiocephalic arteries and aortic sinuses were quantified using the 
Masson’s trichrome stain. Collagen comprised 60.6 (IQR 55.1 – 68.6) % of brachiocephalic 
artery plaque in the no treatment group. There were no significant differences in collagen 
content amongst different treatment groups, with mean values for the olive oil, EPA, and DHA 
treatment groups of 60.1 (38.1 – 70.3) %, 65.6 (46.2 – 71.8) %, and 48.8 (36.9 – 62.5) %, 
respectively (p=0.65 for differences between the groups), see Figure 6.17. Representative 
images of slides stained with Masson’s trichrome stain from each treatment group are presented 








Figure 6.17: Comparison of the collagen content of plaque in the brachiocephalic arteries 
between treatment groups. n = 3-5 per group. Results expressed as median + interquartile 
range.  















































Figure 6.18: Representative sections of brachiocephalic arteries from mice in each 
treatment group stained with the Masson’s Trichrome stain. The collagen content of 
plaques was high, and not significantly different between treatment groups. 
 




Plaque in the aortic sinuses had a higher collagen content than that in the 
brachiocephalic arteries. In the no treatment group this was 83.4±1.1%, and not significantly 
different in the EPA (72.9±5.4%, p=0.11) or DHA (73.5±2.5%, p=0.11) treatment groups. It 
was significantly reduced in the olive oil treatment group (70.9±4.0%, p=0.04), see Figure 6.19. 
Representative images of aortic sinus plaques stained with the Masson’s trichrome stain are 










Figure 6.19: Comparison of the collagen content of aortic sinus plaques between 
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Figure 6.20: Representative sections of aortic sinuses from mice in each treatment group 
stained with the Masson’s Trichrome stain. The content of collagen, stained blue, was 
higher than that of the brachiocephalic artery plaque, and was not significantly different 
between treatment groups. 
 




6.3.7 Smooth muscle cell content of plaque 
 In atherosclerotic plaques SMCs contribute to the formation of the fibrous cap. With 
degradation of SMCs and collagen by MMPs in inflammatory plaques, SMC content and 
plaque stability are reduced. Brachiocephalic artery and aortic sinus sections underwent 
immunohistochemical staining for SMCs in plaque using the smooth muscle actin (SMA) 
antibody. The density of SMA staining in the brachiocephalic arteries in the no treatment group 
was 43.2 (IQR 38.8 – 56.3) % of the maximum possible. No significant differences were seen 
between treatment groups (p=0.45), with 25.5 (25.2 – 54.1) % in the olive oil group, 32.2 (24.4 
– 54.1) % in the EPA group, and 51.7 (33.2 – 59.0) % in the DHA group, see Figure 6.21. 









Figure 6.21: Smooth muscle cell content of brachiocephalic artery plaques, measured by 
IHC staining for smooth muscle actin (SMA). n = 3-5 per group. Results expressed as 
median + interquartile range. 
 








































Figure 6.22: Representative images of brachiocephalic arteries in each treatment group 
stained for smooth muscle actin. Staining was positive throughout plaques and did not 
significantly differ between treatment groups. 
 The density of SMA staining in aortic sinus plaques was less than that of the 
brachiocephalic artery plaques. In the no treatment group, the staining density of SMA was 
19.1 (IQR 18.2 – 21.4) % of the maximum possible. No significant differences were present 




between treatment groups (p = 0.94). In the olive oil, EPA, and DHA treatment groups, the 
staining density was 17.3 (16.0 – 25.1) %, 20.4 (18.4 – 21.9) %, and 19.1 (13.7 – 21.6) %, 
respectively, see Figure 6.23. The pattern of staining was diffuse in the brachiocephalic artery 
plaques. The aortic sinus plaques had a striking intensity of staining localised to the plaque 









Figure 6.23: Density of IHC staining for smooth muscle actin (SMA) in aortic sinus 
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Figure 6.24: Representative images of aortic sinus plaques stained for smooth muscle 
actin. Intense staining is present on the surface of plaques. No differences in staining 
density were present between treatment groups. 
 




6.3.8 Chronic inflammation in plaque and in the vessel wall 
6.3.8.1  Macrophage content of plaques 
Atherosclerotic plaques with a high inflammatory cell content are more biologically 
active and vulnerable(551). Macrophages are highly prevalent at sites of chronic inflammation, 
and play a critical role in all stages of atherosclerosis. The macrophage content of plaques was 
measured by performing immunohistochemical staining of brachiocephalic arteries and aortic 
sinuses for CD107b (Mac3), which is expressed on the surface of macrophages. In the no 
treatment group, the staining density of CD107b in brachiocephalic artery plaques was 22.1 
(IQR 21.5 – 27.8) % of the maximum possible. This was not significantly different amongst 
treatment groups (p=0.14), with 26.2 (16.9 – 46.7) % in the olive oil group, 20.1 (16.4 – 25.5) 









Figure 6.25: Density of IHC staining for CD107b (Mac3) in brachiocephalic artery 
plaques. n = 3-4 per group. Results expressed as median + interquartile range. 




























Figure 6.26: Representative images of brachiocephalic artery plaques stained for the 
macrophage marker CD107b (Mac3). Staining is present diffusely throughout plaque, 
and the density of staining is no different between treatment groups. 
  
Aortic sinus plaques had less CD107b staining than the brachiocephalic plaques, with 
a median plaque staining density of 6.1 (IQR 5.4 – 7.5) % of the maximum possible in the no 




treatment group. This was consistent with other measures of plaque stability, indicating that 
brachiocephalic artery plaques were more vulnerable than aortic sinus plaques. There were no 
significant differences in the olive oil and EPA groups, with staining densities of 7.1 (6.8 – 8.1) 
% and 7.0 (6.3 – 10.5) %, respectively. Staining was unexpectedly higher in the DHA group 










Figure 6.27: Density of IHC staining for CD107b (Mac3) in aortic sinus plaques. Results 














































Figure 6.28: Representative images of aortic sinus plaques stained for CD107b (Mac3). 
Staining is diffuse throughout plaque but weaker than that seen in brachiocephalic artery 
plaques. There was a greater density of staining in the DHA group which reached 
borderline significance. 
 




6.3.8.2  Chronic inflammation in the vessel wall 
Prolonged atherogenic feeding in ApoE-deficient mice induces a chronic inflammatory 
state. The following markers and transcriptional regulators of chronic inflammation were 
measured at the gene level by RT-PCR in snap-frozen aortas: IL-1β, TNF-α, MCP-1, NFκB-
p65, and PPAR-γ. IL-1β is a potent pro-inflammatory cytokine that is produced after NFκB-
dependent activation of the inflammasome, and is prevalent in states of chronic inflammation. 
It is produced by endothelial cells and macrophages in the setting of atherosclerosis. TNF-α is 
a cytokine secreted by numerous immune cells including those in the vessel wall at sites of 
acute and chronic injury. Its presence stimulates other inflammatory mediators that contribute 
to a chronic inflammatory milieu. MCP-1 is a chemotactic cytokine which is highly expressed 
in atherosclerotic lesions. It recruits leukocytes to sites of endothelial injury and induces 
chronic vascular inflammation. The transcription factor NFκB regulates the transcription of 
pro-inflammatory genes. NFκB is detectable in atherosclerotic plaques, with higher levels seen 
in plaques that are unstable, and p65 is its most important subunit. PPAR-γ regulates the 
transcription of anti-inflammatory genes, and is also detectable in plaques. 
 Compared to the no treatment group, the relative gene expression of IL-1β in the EPA 
group was 44.3 (IQR 33.4 – 51.8) % lower (p=0.04). In the DHA group it was 48.8 % (25.2 – 
51.8) lower, but it did not reach statistical significance (p=0.06). Gene expression was 33.5 
(16.4 – 80.8) % greater in IL-1β expression in the olive oil group, but was not statistically 















Figure 6.29: Relative gene expression of IL-1β in mouse aortas, measured by RT-PCR. 
Notable reductions were seen in the EPA and DHA treatment groups. n = 4-6 per group. 
Results expressed as median + interquartile range. *p<0.05. 
 
Similarly, the EPA and DHA groups had significantly lower TNF-α expression 
compared to the no treatment group. Gene expression was 47.9 (IQR 31.0 – 63.2) % lower in 
the EPA group (p=0.04), and 49.8 (27.4 – 70.1) % lower in the DHA group (p = 0.05). Gene 
expression was 20.3 (-22.2 – 46.6) % lower in the olive oil group, which was not statistically 










































Figure 6.30: Relative gene expression of TNF-α in mouse aortas, measured by RT-PCR. 
TNF-α was significantly reduced by EPA and DHA. n = 4-6 per group. Results expressed 
as median + interquartile range.  *p<0.05. 
 
Despite the reductions in IL-1β and TNF-α seen with EPA and DHA, there were no 
significant differences between treatment groups seen for MCP-1 expression. Compared to the 
no treatment group, MCP-1 gene expression was 6.2 (-25.8 – 37.5) % lower in the EPA group 
(p=0.79), and 36.3 (24.0 – 51.0) % lower in the DHA group (p=0.15). Gene expression was 4.0 








































Figure 6.31: Relative gene expression of MCP-1 in mouse aortas, measured by RT-PCR. 
n = 4-6 per group. Results expressed as median + interquartile range. 
 
Gene expression of the transcription factors NFκBp65 (pro-inflammatory) and PPAR-
γ (anti-inflammatory) were similar in all treatment groups, see Figures 6.32 and 6.33. 
Compared to the no treatment group, the gene expression of NFκBp65 was 5.6 (-16.7 – 44.7) 
% greater in the EPA group (p=0.65), 21.4 (-16.1 – 50.9) % greater in the DHA group (p=0.43), 
and 11.3 (-31.1 – 19.8) % greater in the olive oil group (p=0.96). Compared to the no treatment 
group, the gene expression of PPAR- γ was 15.7 (-30.1 – 67.2) % greater in the EPA group 
(p=0.98), 41.8 (-20.1 – 92.3) % greater in the DHA group (p=0.69), and 55.3 (27.3 – 107.0) % 
greater in the olive oil group (p=0.29). Functional changes in transcription factors are likely to 
be more important than the magnitude of gene expression. 
 
 



































Figure 6.32: Relative gene expression of NFκBp65 in mouse aortas, measured by RT-









Figure 6.33: Relative gene expression of PPAR-γ in mouse aortas, measured by RT-PCR. 
n = 4-6 per group. Data are presented as median + interquartile range. 



















































6.3.9 Lipid content of the aorta 
 After 16 weeks of atherogenic feeding, the aortas of all ApoE-deficient mice stained 
positively for Oil Red-O. Lipid was present diffusely throughout the aorta in all mice. In the 
no treatment group, 6.3 (IQR 5.0 – 10.6) % of the aortic surface area stained positively for Oil 
Red-O. Treatment with neither olive oil, EPA or DHA significantly modified aortic lipid 
content, with 7.1 (5.2 – 13.0) %, 6.9 (6.6 – 8.1) %, and 4.4 (4.1 – 8.1) % of aortic surface area 
staining positively, respectively (p>0.99 for all comparisons with no treatment), see Figures 
6.34 and 6.35. The lack of effect of EPA or DHA on aortic lipid burden was in spite of their 









Figure 6.34: Burden of lipid in the aorta, as a proportion of total aortic surface area. n = 




































Figure 6.35: Representative images from analysis of Oil Red-O staining in aortas pinned 
en-face. Lipid deposition spans the entire length of the aorta, with a similar lipid burden 
amongst the different treatment groups. 
 
6.3.10 Correlations between blood omega-3 levels and measures of plaque burden, 
plaque characteristics, lipid burden and vascular inflammation 
 The blood concentrations of EPA, DHA and the EPA:DHA ratio at study completion 
were correlated with (1) all measures of plaque burden, stability, inflammatory cell content, (2) 
gene expression of markers of inflammation in the vessel wall, and (3) the burden of lipid in 
the aorta. A summary of the correlation (Spearman) coefficient and level of statistical 
significance for each correlation is presented in Table 6.2. No significant correlation was seen 
between blood omega-3 concentrations and the burden of plaque in the aortic sinuses or 
brachiocephalic arteries, however there was a significant inverse correlation between EPA 
levels and the thickness of the intima and media in the arterial wall (see Figure 6.36). 
No Treatment Olive Oil EPA DHA 
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Table 6.2: Summary of correlations between blood concentrations of EPA, DHA, and the 
ratio of EPA to DHA with measures of plaque burden and characteristics, lipid burden 
and vascular inflammation. 
Parameter Correlation coefficient and significance level 
 EPA DHA EPA:DHA 
Aortic sinus plaque burden r = -0.07, p = 0.82 r = 0.11, p = 0.70 r = 0.05, p = 0.86 
BCA plaque burden r = 0.10, p = 0.74 r = -0.36, p = 0.22 r = 0.08, p = 0.79 
Arterial intimal + medial thickness r = -0.49, p = 0.04 r = -0.11, p = 0.67 r = -0.39, p = 0.11 
Aortic sinus plaque collagen r = -0.22, p = 0.25 r = -0.34, p = 0.06 r = -0.12, p = 0.53 
BCA plaque collagen r = -0.06, p = 0.85 r = -0.47, p = 0.09 r = -0.13, p = 0.65 
SMA staining in aortic sinus plaque r = 0.06, p = 0.76 r = 0.09, p = 0.65 r = 0.04, p = 0.83 
SMA staining in BCA plaque r = 0.13, p = 0.66 r = 0.56, p = 0.54 r = 0.12, p = 0.68 
CD107b staining in aortic sinus plaque r = 0.32, p = 0.09 r = 0.58, p = 0.0008 r = 0.05, p = 0.79 
CD107b staining in BCA plaque r = -0.04, p = 0.89 r = 0.66, p = 0.01 r = -0.29, p = 0.32 
IL-1β expression in arterial wall r = -0.63, p = 0.009 r = -0.47, p = 0.06 r = -0.67, p = 0.004 
TNF-α expression in arterial wall r = -0.50, p = 0.04 r = -0.45, p = 0.06 r = -0.47, p = 0.049 
MCP-1 expression in arterial wall r = -0.13, p = 0.61 r = -0.43, p = 0.07 r = 0.02, p = 0.93 
NFκBp65 expression in arterial wall r = -0.11, p = 0.66 r = -0.13, p = 0.62 r = -0.02, p = 0.95 
PPAR-γ expression in arterial wall r = -0.31, p = 0.21 r = -0.13, p = 0.60 r = -0.35, p = 0.16 
Lipid burden in aorta (Oil Red-O) r = -0.21, p = 0.39 r = -0.40, p = 0.09 r = 0.18, p = 0.46 
 





















Figure 6.36: Correlation between blood EPA concentration at study completion and 
intimal plus medial thickness in the artery wall. n = 18 mice.  
No significant correlation was present between omega-3 levels and two important 
measures of plaque stability, i.e. collagen content and smooth muscle actin staining (See Table 
6.2). The macrophage content of both aortic sinus and brachiocephalic artery plaques correlated 
positively and significantly with blood DHA levels, indicating that DHA may have a pro-
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Figure 6.37: Correlation between blood DHA concentration at study completion and 









Figure 6.38: Correlation between blood DHA concentration at study completion and 
staining for CD107b (Mac3) in brachiocephalic artery plaques. n = 14 mice. 
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 Consistent with the reductions in gene expression of IL-1β and TNF-α in the arterial 
wall occurring with EPA supplementation, there was a significant inverse correlation present 
between (1) blood EPA levels and (2) the EPA:DHA ratio with the expression of those genes 
(see Figures 6.39 to 6.42). No significant correlations were demonstrated between blood 
omega-3 levels and the gene expression of MCP-1, NFκBp65, or PPAR-γ in the arterial wall 
(see Table 6.2). Furthermore, no significant correlations were demonstrated between blood 









Figure 6.39: Correlation between blood EPA concentration at study completion and the 
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Figure 6.40: Correlation between blood EPA:DHA ratio at study completion and the gene 









Figure 6.41: Correlation between blood EPA concentration at study completion and the 
gene expression of TNF-α in the arterial wall. n = 18 mice. 
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r = -0.67, p = 0.004
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Figure 6.42: Correlation between blood EPA:DHA ratio at study completion and the gene 
expression of TNF-α in the arterial wall. n = 18 mice. 
 
6.4 Discussion 
 This is the first study comparing direct supplementation of purified EPA with DHA on 
atherogenesis and chronic vascular inflammation in a mouse model. Previous studies have 
administered combinations of EPA and DHA, or individual fatty acids alone, typically by their 
addition to diet. Chapters 4 and 5 of this thesis demonstrated that EPA reduces acute vascular 
inflammation and has a superior effect over DHA. This chapter extends the study of omega-3 
fatty acids to their effects on the development of advanced atherosclerotic lesions and on 
chronic vascular inflammation. ApoE-deficient mice fed an atherogenic diet were 
supplemented with high dose EPA, DHA, olive oil, or had no treatment, for the last 8 weeks of 
a 16-week atherogenic feeding period prior to being humanely killed. The dose chosen was 
equivalent to ten times the dose used in many recent human clinical trials of 4 grams per day. 





EPA:DHA vs gene expression






















r = -0.47, p = 0.049
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Four grams per day equates to 60 mg/kg/day for a 70kg human, and hence 600 mg/kg/day was 
used in this mouse study to ensure sufficient dosing. The effects of treatments on the rate of 
weight gain, lipid levels, the burden of plaque and lipid, the inflammatory characteristics and 
stability of atherosclerotic plaque, and on chronic inflammation of the vessel wall were 
quantified. 
 The neutral effects of EPA and DHA on the rate of weight gain in this study are 
consistent with previous studies showing no effect of omega-3 fatty acid supplementation on 
body weight(552-554). Olive oil reduced the rate of weight gain, and this may be because oleic 
acid, its dominant fatty acid, is a substrate for the lipid messenger oleoylethanolamide, which 
induces satiety after fat consumption(555). 
 The effect of fish oil on total cholesterol levels has been studied extensively, but this is 
one of few studies using pure EPA and DHA. The stabilising effect of EPA and DHA on 
cholesterol levels demonstrated in this study is consistent with a study by Guo et al, where 
EPA, DPA, and DHA were administered to C57Bl/6 mice fed an atherogenic diet, and all three 
fatty acids reduced total cholesterol and LDL levels(556). These cholesterol-lowering effects of 
omega-3 fatty acids are in contrast to the small increase typically seen in humans(541), and even 
differ between rodent species(557). Mechanisms for this effect in mice may be the activation of 
AMP-activated protein kinase(558), activation of fatty acid oxidation genes(559), and suppression 
of liver fatty acid synthesis(560). 
Triglyceride levels were naturally elevated in all mice after 8 weeks, as ApoE-deficient 
mice have reduced triglyceride clearance(561). Both EPA and DHA significantly reduced these 
levels by the end of the study. This is consistent with findings from Guo et al’s study, with 
EPA, DPA, and DHA all reducing triglyceride levels. Previous animal studies have also shown 
reductions in plasma triglycerides with combination omega-3 (EPA plus DHA) 
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supplementation(558, 562), and a triglyceride-lowering effect with DHA administered alone(563). 
Human studies have likewise consistently demonstrated triglyceride lowering with omega-
3s(207, 564). This has been attributed to reduced triglyceride production and increased 
clearance(565). Specifically, the stimulation of PPAR-α causes beta-oxidation of fatty acids, 
which reduces their availability for VLDL production(559). The superior effect of DHA in 
reducing triglyceride levels compared to EPA in the current study is also consistent with human 
studies(288, 479, 480, 482, 483, 566). 
Neither EPA nor DHA altered the burden of atherosclerotic plaque. Atherosclerotic 
plaques were quantified at sites of predilection for advanced plaque formation, namely the 
aortic sinuses and brachiocephalic arteries. Omega-3 fatty acids have numerous pleiotropic 
effects beyond lipid lowering, which lower cardiovascular risk(567), but which were clearly 
insufficient to lead to a measurable anti-atherosclerotic effect. In the current study, plaque in 
the aortic sinuses and brachiocephalic arteries was extensive and morphologically advanced. 
The burden of plaque was similar in both locations (32-34% of total area), however the stability 
of plaque was higher in the aortic sinuses as evidenced by a higher collagen content, a high 
concentration of smooth muscle cells on the plaque surface, and a lower inflammatory cell 
(macrophage) content. Blood flow at arterial branch points (such as the brachiocephalic artery) 
is subject to abnormal haemodynamic shear stress, which induces endothelial dysfunction and 
promotes atherosclerosis(568) compared to sites of more laminar flow, such as the aortic root. 
This explains the discrepant findings at the two sites. It is plausible that omega-3s would have 
a favourable effect on arterial shear stress given the reductions in arterial stiffness(569) and 
increases in local nitric oxide production(570) previously demonstrated. However, this has not 
been studied directly using omega-3 fatty acids and warrants further investigation. 
Furthermore, neither EPA nor DHA reduced the degree of expansion of the arterial intima and 
media. There was, however, a significant inverse correlation between the content of EPA in 
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blood and the thickness of the intima and media. This is consistent with evidence for an 
association between higher blood omega-3 levels and lower carotid intima-media thickness in 
certain population groups, however a greater association of EPA compared to DHA has not 
been previously reported(571, 572). The collagen content, smooth muscle cell content, and 
inflammatory cell (macrophage) content were not altered by any of the treatments. However, 
there was a significant positive correlation between DHA levels and the macrophage content 
of plaques. This would naturally be considered to represent a pro-inflammatory relationship of 
DHA with plaque. This is in contrast to evidence of a macrophage-lowering effect of omega-3 
fatty acids, which has been demonstrated in carotid endarterectomy specimens after fish oil 
supplementation(253). It has been suggested that omega-3 fatty acids lower macrophage content 
in plaque by inducing their death by apoptosis(253). Macrophages in plaque contribute to plaque 
instability, both pathologically(573) and clinically(574), and hence their apoptosis would generally 
be considered beneficial. However, apoptotic macrophages in plaques are incompletely 
scavenged, and their death results in the release of extracellular lipid into plaque. The cellular 
debris and extracellular lipid may propagate the chronic inflammatory response in plaque(575). 
Therefore, the positive correlation of DHA with plaque macrophage content demonstrated in 
this study suggests, but does not necessarily imply, a pro-atherosclerotic relationship, with EPA 
being more protective than DHA. 
Lipid was detected using Oil Red-O staining throughout the aorta. EPA and DHA did 
not reduce lipid burden despite lowering serum cholesterol and triglyceride levels. Although 
the positive and continuous association between serum cholesterol and atherosclerosis has been 
well-established(275, 576), only recently has the lipid content of plaque become quantifiable in 
vivo, using near-infrared spectroscopy (NIRS)(577-579). Unlike total plaque burden, the lipid 
content of plaque does not correlate directly with serum cholesterol levels. Rather, changes in 
the lipid content of plaque has been associated with changes in HDL-C but not other lipid 
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parameters(580). This may explain the discordance between serum cholesterol levels and aortic 
lipid burden. Given that only 4-5 mice per treatment group had aortic Oil Red-O staining 
performed, an effect on plaque lipid by omega-3 fatty acids cannot be excluded. Larger studies 
will be required to further elucidate the differential effects of EPA and DHA on plaque lipid, 
and the clinical implications of this. 
EPA significantly reduced the gene expression of two important markers of chronic 
vascular inflammation in plaque, IL-1β and TNF-α. There was also a significant inverse 
correlation between the gene expression of both IL-1β and TNF-α and blood levels of EPA as 
well as the EPA:DHA ratio. This provides evidence for a differential and superior effect of 
EPA compared to DHA on chronic vascular inflammation. The suppressive effect of EPA on 
IL-1β gene expression may be due to its effects on the inflammasome. There are numerous 
stimulators of the inflammasome in atherosclerotic plaques, including cholesterol crystals and 
inflammatory cytokines. Indeed, there are significant amounts of NLRP3, caspase-I and IL-1β 
in plaques(74). Hence, the requirement for a two-step activation process for the inflammasome 
and subsequent IL-1β generation is not a hindrance for continued inflammatory activity in 
atherosclerotic plaques. Dietary fatty acid composition is sensed by the NLRP3 inflammasome 
in human macrophages, and omega-3 fatty acids (studied in the forms of fish oil and DHA) 
have been shown to have an inhibitory effect(353, 354, 581). Williams-Bey et al demonstrated that 
inhibition of the G-Protein-coupled Receptor, GPR120, also known as Free Fatty Acid 
Receptor 4, was necessary for this to occur, which suppressed the nuclear translocation of NF-
κB(581). It is likely that EPA inhibits the inflammasome by the same mechanisms demonstrated 
for fish oil and DHA. Based on the success of IL-1β inhibition on reducing cardiovascular 
events in high risk patients(120), it is likely that the cardioprotective effects of high-dose EPA 
seen in the REDUCE-IT trial are partly due to this mechanism(234). 
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The suppressive effect of omega-3 fatty acids on TNF-α has been demonstrated for both 
circulating and tissue forms. Circulating TNF-α has been reduced with fish oil supplementation 
in both mice(582) and humans(583). In vitro studies have corroborated this with reductions seen 
in endotoxin-induced TNF production by monocytes(296, 584) after the addition of omega-3 fatty 
acids. This was shown to be due to inhibition of NFκB activation(297, 298). TNF-α has been 
measured in the vessel wall by Western Blot after EPA supplementation in a rabbit model of 
acute vascular inflammation. In this study, pre-treatment of Japanese white rabbits for 1 week 
with high dose EPA resulting in a reduction in TNF-α levels in the vessel wall both before and 
3 days after carotid cuff placement(585). In the setting of chronic vascular inflammation and 
atherosclerosis, a study of LDL-R-deficient mice fed an atherogenic diet demonstrated a 
reduction in gene expression of TNF-α in established atherosclerotic plaques after EPA 
supplementation(259). A proposed mechanism elucidated by Vassiliou et al is that the omega-3 
metabolite Resolvin D1 inhibits T cell proliferation (a source of TNF-α) through increasing 
indoleamine 2,3-dioxygenase expression in dendritic cells(586). This is the first study to compare 
the effects of EPA with DHA on the gene expression of TNF-α in vessel wall in the setting of 
chronic vascular inflammation, and hence the finding of a superior effect of EPA is a novel 
finding. 
An important limitation of this study is the small sample size. Although a power 
calculation guided the overall allocation of 10 mice per treatment group, several analyses of 
plaque, inflammation and lipid were performed with only 5 mice per treatment group because 
they included only mice of a single sex. Hence, these analyses per underpowered, and the 
negative results should be interpreted with caution. 
Supplementation of omega-3 fatty acids for the final 8 weeks of a 16-week atherogenic 
feeding period in ApoE-deficient mice models a clinical scenario of the commencement of fish 
oil supplementation in an adult with atherosclerotic cardiovascular disease. Nakashima et al 
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demonstrated that by 15 weeks of age, approximately the same age that the mice in the current 
study were randomised to treatments, ApoE-deficient mice fed an atherogenic diet have 
developed foam cell lesions, smooth muscle cell proliferation and early fibrous plaques(546). 
Neither EPA nor DHA significantly altered the burden of plaque or several measures of its 
stability. Nor did EPA or DHA alter lipid burden in the aorta. Consistent with the reduction in 
acute vascular inflammation in collared carotid arteries by EPA seen in Chapter 5, the current 
study demonstrates a reduction in markers of chronic vascular inflammation in aortas with EPA 
treatment. Furthermore, these reductions were significantly inversely correlated with blood 
EPA levels. These findings may contribute to the mechanisms underlying the reduction in 
major adverse cardiac events seen with EPA in the recently-published REDUCE-IT trial(234). 
The results of the current study predict a superior atheroprotective effect of EPA compared to 
DHA, however this will need to be confirmed in clinical trials. Although atherosclerosis is 
fundamentally an inflammatory disease(4), the neutral effect of omega-3s on atherogenesis 
despite a clear anti-inflammatory effect highlights the complex mechanisms underlying this 
disease process. The pharmacodynamics of individual omega-3 fatty acids and their effects on 
























7.1 Rationale for body of work 
 The effects of omega-3 fatty acids on atherosclerosis have been studied extensively, 
including mechanistic studies, observational studies, clinical trials, and epidemiological 
research. Throughout the period of investigation, which has continued for approximately half 
a century, there have been discrepancies in the findings of these studies, with numerous 
examples. Mechanistic studies typically demonstrated beneficial effects of omega-3 fatty acids 
on inflammation and atherogenesis. Observational studies, both prospective and retrospective, 
have most commonly demonstrated inverse associations between fish and fish oil consumption 
as well as blood omega-3 levels on cardiovascular events and mortality. Notably, these inverse 
associations were more consistent with fish compared to fish oil consumption. Clinical trials 
of fish oil have produced varied results, however, from an overall neutral effect to significant 
reductions in cardiovascular events and mortality. Neutral effects were seen more commonly, 
and identified a paradox of basic research studies identifying cardioprotective properties of 
omega-3 fatty acids that did not reliably translate into clinical benefit. Moreover, omega-3 fatty 
acids have consistently been shown to reduce inflammation and triglyceride levels, with both 
associated with increased cardiovascular risk. 
 The omega-3 formulations used in basic and clinical studies have been highly 
heterogeneous, including a variety of doses and EPA:DHA ratios. There is a possibility that an 
optimal ratio of EPA:DHA exists, and that a dose threshold may be required to achieve an 
atheroprotective effect. Furthermore, the form in which omega-3 fatty acids are consumed may 
also play an important role. In most oily fish, omega-3 fatty acids are primarily in triglyceride 
form, and to a lesser extent phospholipid and free fatty acid forms. However, fish oil 
supplements are predominantly in either ethyl ester or triglyceride forms. The doses of omega-
3 fatty acids used in prospective clinical studies have often been ≤ 1 gram per day, with issues 
of intolerance, compliance, bleeding risk, and cost all being considered in study design. 
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However, in pre-clinical studies, omega-3 fatty acids have commonly been supplemented at 
comparatively high doses, such as 5% of total food intake for animal studies. The latter is an 
example of a commonly-implemented method of omega-3 supplementation, which has 
limitations both due to the imprecision of measuring total omega-3 intake and also due to 
oxidation of fatty acids that occurs upon exposure to air. 
 The question of whether fish oil consumption is atheroprotective has been confounded 
broadly by the limitations and heterogeneity of previous study designs, the temporal changes 
in background anti-atherosclerotic therapies, and the lack of specific omega-3 target levels. 
The current body of work aimed to answer several important questions about the role of omega-
3 fatty acids for atheroprotection by focusing on vascular inflammation. There has been 
increasing recognition of the role of inflammation in all stages of atherogenesis, and given the 
established anti-inflammatory properties of omega-3 fatty acids, it was important to investigate 
their impact on the inflammatory processes in the vessel wall that promote atherosclerosis. 
7.2 Findings of individual studies 
7.2.1 The impact of omega-3 fatty acids on circulating mediators of atherosclerosis 
– a systematic review 
 This systematic review, which included only high-quality (NHMRC Evidence Level I 
or II) randomised, placebo-controlled omega-3 fatty acid studies indexed in the Cochrane 
Library, demonstrated that supplementation with omega-3 fatty acids reduced levels of all four 
classes of atherogenic mediators. These four classes were: atherogenic lipoproteins, 
atherogenic cytokines and adipokines, atherogenic amino acids and derivatives, and advanced 
glycation endproducts. Atherogenic mediators were required to be measured in blood either 
directly in vivo, or ex vivo in cell culture after human omega-3 supplementation. The Cochrane 
Library search yielded 1012 results, of which 109 studies were eligible for inclusion in the final 
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analysis. These comprised 1 Cochrane systematic review, 6 non-Cochrane systematic reviews 
and meta-analyses, and 102 randomised controlled trials. Each mediator was assessed 
individually, and the overall effect of omega-3 fatty acids was evaluated qualitatively due to 
the heterogeneity of study types included. The fatty acid contents of the supplements studied 
were highly variable, although mostly included mixtures of EPA and DHA, such as what occurs 
in standard fish oil. Significant reductions were noted for oxLDL, VLDL-C, non-HDL-C, 
leptin, homocysteine, and advanced glycation endproducts. Mild reductions were noted for IL-
6, and TNF-α. No significant changes were noted for the other mediators evaluated. 
 Amongst included studies, there was significant heterogeneity in sample size, duration 
of supplementation, the choice of placebo, and omega-3 formulation. Although this systematic 
review did not attempt to segregate studies based on omega-3 dose or measured blood omega-
3 levels, it is predictable that the degree of suppression of atherogenic mediators would 
correlate with blood omega-3 concentrations. This, as well as the relative effects of EPA versus 
DHA, and the effects on vascular inflammation measured at the tissue level, requires further 
evaluation. 
7.2.2 Fish Oil Cell Uptake Study of INflammation (FOCUS IN). A randomised 
controlled trial of fish oil supplementation in healthy volunteers. 
 The FOCUS IN study enrolled 40 healthy adult volunteers with a low baseline omega-
3 intake, and randomised them in a double-blind fashion to four grams per day of either (1) fish 
oil high in EPA, (2) fish oil high in DHA, (3) fish oil with a standard 2:1 EPA: DHA ratio, or 
(4) a placebo oil as an oil control, for 30 days. Participants in the EPA group were older, 
however the groups were otherwise evenly matched at baseline in terms of age, gender, body 




 There were no significant differences in resting heart rate or systolic blood pressure 
between the 4 treatment groups, although DHA significantly reduced diastolic blood pressure 
compared to placebo. Total cholesterol, LDL-C and HDL-C did not significantly differ 
between treatment groups, although DHA significantly reduced triglyceride levels. High-
sensitivity CRP and lipoprotein (a) levels did not significantly differ between treatment groups.
 Serum collected before and after treatment was added to human umbilical vein 
endothelial cells (HUVECs) in culture at a concentration of 10%, before and after TNF-α 
stimulation (10ng/ml). Changes in the gene expression of the following markers of vascular 
inflammation were measured by RT-PCR: VCAM-1, ICAM-1, MCP-1 and NFκBp65. Serum 
from participants taking EPA reduced the gene expression of MCP-1 by TNF-stimulated 
HUVECs by 25% compared to placebo (p=0.03). No significant differences were seen between 
treatment groups for the other markers. 
 The expression of VCAM-1, ICAM-1, MCP-1 and NFκBp65 by stimulated HUVECs 
was correlated with the following patient characteristics to determine whether any significant 
associations exist: total cholesterol, LDL-C, HDL-C, triglycerides, omega 6:3 ratio, blood EPA 
levels, blood DHA levels, and blood saturated fats. HDL-C levels correlated positively and 
significantly with both VCAM-1 (r=0.36, p=0.02) and MCP-1 (r=0.40, p=0.01) expression. 
This is consistent with HDL dysfunctionality at very high HDL-C levels, and this warrants 
further investigation. 
7.2.3 The impact of omega-3 fatty acids on acute vascular inflammation in a mouse 
model 
 In this study, eight-week-old C57Bl/6 mice fed a chow diet were randomised to 
supplementation with 600mg/kg/day of either EPA, DHA, olive oil as an oil control, or no 
treatment, for 30 days by oral gavage. Subsequently, pure acute vascular inflammation was 
induced using the surgical application of non-occlusive silicon elastic collars to the right carotid 
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artery, which remained in place for 48 hours. Subsequently, the mice were humanely killed and 
both carotid arteries were harvested for immunohistochemical analysis for markers of acute 
vascular inflammation, namely VCAM-1, ICAM-1, MCP-1 and CD18. A blood sample was 
obtained by terminal cardiac puncture. 
 Carotid collaring significantly upregulated the protein expression of all markers 
measured. EPA reduced the protein expression of VCAM-1 and MCP-1 by 43% and 38% 
respectively in collared carotids compared to no treatment (p<0.05 for both comparisons). 
There were numerical reductions in ICAM-1 and CD18 expression with EPA, which did not 
reach statistical significance. Furthermore, there was a numerical reduction in all four markers 
of AVI with DHA, which was less than EPA in each case, and not statistically significant.
 Plasma total cholesterol and triglycerides were low, and did not differ significantly 
between treatment groups. EPA and DHA supplementation increased their respective blood 
levels by 272% and 62% (p<0.0001). There were significant inverse correlations observed 
between blood levels of both EPA and DHA and the expression of all four markers of AVI on 
immunohistochemistry. Furthermore, significant inverse correlations were also observed 
between the blood EPA:DHA ratio and all four markers of AVI, consistent with the superior 
effect of EPA compared to DHA. 
 The reduction in protein expression of markers of AVI by EPA supplementation 
measured in the arterial wall, is consistent with the in vitro gene expression findings of FOCUS 
IN. 
7.2.4 The impact of omega-3 fatty acids on atherosclerosis and chronic vascular 
inflammation 
 In this study, forty 8-week-old ApoE-deficient mice were fed an atherogenic diet for 16 
weeks to induce chronic vascular inflammation and advanced atherosclerotic plaques. After 8 
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weeks, a blood sample was taken and the mice were randomised to supplementation with 
600mg/kg/day of either: (1) EPA, (2) DHA, (3) olive oil as an oil control, or (4) no treatment. 
Supplementation was performed by oral gavage, and continued for the last 8 weeks of the 16-
week treatment period, after which time the mice were humanely killed and blood and organ 
harvesting were performed. 
 The body weight of mice in all four treatment groups increased over the atherogenic 
feeding period, with no effect of EPA or DHA. Plasma total cholesterol levels were high in all 
mice after 8 weeks, and were stabilised by both EPA and DHA. Plasma triglyceride levels were 
elevated in all mice after 8 weeks, and EPA and DHA significantly reduced these levels by 
study completion. 
 Atherosclerotic plaque was measured in the aortic sinuses and brachiocephalic arteries. 
Although advanced plaques had developed by study completion, no differences in plaque 
burden were demonstrated between treatment groups. Similarly, the thickness of the intimal 
and medial layers, and the collagen content of plaques did not differ among treatment groups. 
The smooth muscle cell content and macrophage content of plaques, measured by 
immunohistochemical staining for smooth muscle actin and CD107b, did not differ between 
treatment groups. Hence, omega-3 supplementation did not impact on measures of plaque 
stability. The lipid content of aortas was assessed by Oil Red-O staining, and in all mice lipid 
was distributed diffusely throughout the aorta. Omega-3 supplementation did not significantly 
impact the burden of lipid. 
 In aortic tissue, the gene expression of markers of chronic inflammation, IL-1β and 
TNF-α, were significantly lower in the mice treated with EPA (-44.3% [p=0.04] and -48.8% 
[p=0.04], respectively). Consistent with this beneficial effect on EPA on chronic vascular 
inflammation, there were significant inverse correlations present between IL-1β and TNF-α 
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expression and both blood EPA levels and the EPA:DHA ratio. Blood EPA levels also 
correlated inversely with intimal and medial thickness in the artery wall. This finding suggests 
a signal for a favourable effect of EPA on plaque, that may not have been demonstrated due to 
the low sample size in this study (n < 5 mice for some measures).  
7.3 Overarching conclusions 
 Omega-3 fatty acids reduce vascular inflammation from the earliest stages of 
endothelial injury to the advanced stages of atherosclerosis. In the in vitro study FOCUS IN, 
and in the acute and chronic mouse studies, EPA was consistently shown to be superior than 
DHA. Omega-3 fatty acids reduce triglyceride levels and stabilise cholesterol levels. 
Nonetheless, the beneficial effects of omega-3 fatty acids on vascular inflammation in the 
experimental studies have largely occurred independent of effects on both cholesterol and 
triglyceride levels.  Despite the critical role of vascular inflammation in atherogenesis, and the 
reduction in circulating atherogenic mediators by omega-3 fatty acids established in the 
systematic review, omega-3 fatty acids did not improve plaque burden or characteristics, nor 
lipid burden. In view of the small sample size of the chronic mouse study, which was less than 
5 mice for some analyses, an atheroprotective effect has not been excluded. Moreover, the 
findings of the recent REDUCE-IT study demonstrated a significant reduction in major adverse 
cardiovascular events with high-dose EPA supplementation(234). 
 In the experimental studies presented in this thesis, omega-3 fatty acids were 
supplemented at high doses. In FOCUS IN, this was 4 grams of omega-3 per day. In both 
mouse studies, a daily omega-3 dose of 600mg/kg was given (equivalent to 40 grams per day 
for a weight of 70kg). Consistent with the results of previous dietary omega-3 studies(222, 223), 
which demonstrated dose-dependent effects, and the high dose of EPA ethyl esters (4 grams 
per day) utilised in the positive REDUCE-IT trial, it is likely that high doses of omega-3 fatty 
acids are required to demonstrate beneficial effects. 
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7.4 Clinical implications of research findings 
7.4.1 Omega-3 fatty acids for primary prevention  
In this body of work, the beneficial effects of omega-3 fatty acids on vascular 
inflammation have been demonstrated in experimental studies that model primary and 
secondary prevention settings. In FOCUS IN, serum from healthy volunteers supplemented 
with fish oil was added to HUVECs in culture for a duration of 24 hours, prior to the addition 
of an inflammatory stimulus (TNF-α). Similarly, in the mouse study of AVI, omega-3 fatty 
acids were supplemented for 30 days prior to the induction of AVI by carotid collaring. 
However, in the chronic mouse study, the ApoE-deficient mice were 16 weeks of age and had 
had 8 weeks of atherogenic feeding prior to the commencement of omega-3 supplementation. 
By this stage, foam cell lesions, smooth muscle cell proliferation and early fibrous plaques 
would likely have developed(546). 
 Regular high-dose consumption of omega-3 fatty acids, whether in dietary or 
supplement form, is likely to have a role in the primary prevention of cardiovascular disease. 
Since macroscopic evidence of atherosclerosis has been identified in humans as early as the 
foetal stage, i.e. in the form of fatty streaks(498), omega-3 supplementation has the potential for 
use in primary cardiovascular prevention in all age groups. High-dose omega-3 consumption 
on a population level for primary prevention is not feasible, however, for several reasons. 
Firstly, the number needed to treat in order to prevent one cardiovascular event has not been 
established and is likely to be high. Secondly, to achieve 4 grams of omega-3 fatty acids per 
day would be prohibitively expensive and potentially cumbersome for the consumer. For 
example, in the FOCUS IN study, 6-8 capsules per day were required for each of the 
supplements. Thirdly, as the main source of omega-3 fatty acids is marine-derived, 
consideration must be given to sustainability of the aquaculture industry and the risk of 
extinction to fish populations(587). In recent years, Australian scientists have been among those 
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pioneering the development of genetically-modified crops that produce omega-3 oils, as a 
sustainable source(588-590). Finally, although generally well-tolerated, fish oil consumption is 
associated with a number of mild adverse effects that may lead to discontinuation, in 
particularly gastrointestinal complaints(591). 
 A more feasible approach for the use of omega-3 fatty acids for primary prevention 
would be to target specific population subgroups. Conceivably, these could include individuals 
with risk factors that have been shown to be ameliorated by omega-3 fatty acids. Based on the 
results of the systematic review, individuals with elevated VLDL-C and non-HDL-C levels, 
hyperhomocysteinemia, the overweight or obese (likely to have elevated leptin levels), and 
those with hyperglycaemia or vascular diabetic complications (expected to have circulating 
advanced glycation endproducts) could have a slowed progression of atherogenesis. The two 
experimental studies that modelled primary prevention (FOCUS IN and the mouse collar study) 
were conducted using subjects with minimal cardiovascular risk factors (healthy volunteers 
and wild-type mice), however some additional target groups could be surmised. For example, 
individuals with very high levels of HDL-C, which correlated positively with VCAM-1 and 
MCP-1, may be a target for therapies that reduce these inflammatory markers, namely EPA. In 
addition, among these subgroups, individuals with low blood omega-3 levels, especially EPA, 
are likely to have a greater inflammatory response to a future vascular insult, which could be 
reduced by omega-3 supplementation. Triglyceride levels, although not a focus of this body of 
work, were lowered by omega-3 fatty acids in the experimental studies - their atherogenic 
effects being exerted by virtue of their incorporation into atherogenic triglyceride-rich 
lipoproteins. Prospective studies will be required to demonstrate the effectiveness of targeting 
these population subgroups for primary prevention, however REDUCE-IT produced 
encouraging findings. Almost 30% of patients in REDUCE-IT were in the primary prevention 
setting, i.e. were diabetics with elevated triglyceride levels and other risk factors but no 
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established history of cardiovascular disease. Although not statistically-significant, the hazard 
ratio for the primary endpoint for these patients was 12% lower in the icosapent ethyl group 
compared to placebo(234). 
7.4.2 Omega-3 fatty acids for secondary prevention  
The results of the chronic mouse study suggest promising roles for the use of omega-3 
fatty acids in the secondary prevention setting. In the context of established atherosclerosis, 
omega-3 fatty acids did not significantly reduce plaque burden or favourably modify plaque 
characteristics seen histologically. Furthermore, atheromatous lesions were no less lipidic. 
These findings would naturally suggest that in patients with atherosclerotic cardiovascular 
disease, omega-3 fatty acids would not modify the risk of future acute plaque events or 
progressive myocardial ischaemia. However, markers of chronic inflammation in the vessel 
wall were significantly reduced by EPA. Given the intensely inflammatory nature of ruptured 
plaques, it is possible that the significant reduction in acute plaque events with icosapent ethyl 
reported in REDUCE-IT was partially driven by a reduction in vascular inflammation. If indeed 
modifications in the cytokine profile of the vessel wall in the setting of atherosclerosis are 
sufficient to contribute to a reduction in major adverse cardiovascular events, then this may 
require a paradigm shift in cardiovascular risk assessment, in particular the role of plaque 
imaging. The traditional focus on the assessment of the characteristics of intracoronary plaque 
using intravascular ultrasound and optical coherence tomography, could be complemented in 
future by the increased use of functional molecular imaging. Indeed, several radionuclide 
tracers are available such as 18F fluorodeoxyglucose (FDG) and 18F sodium fluoride that can 
detect and measure aspects of plaque inflammation when combined with imaging modalities 
such as positron emission tomography and computed tomography(592, 593). 
 In the days immediately following an acute coronary syndrome (ACS), culprit plaques 
are highly inflamed and may be most responsive to anti-inflammatory therapies(594, 595). 
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Features of both acute and chronic vascular inflammation are present in these plaques, and 
hence high-dose EPA supplementation may be beneficial in the early post-ACS period. A 
reduction in vascular inflammation could contribute to reduced coronary spasm and infarct size 
in the acute period, and a reduction in recurrent events in the long term. 
7.5 Suggestions for future research 
7.5.1 Elucidating the differential mechanistic effects of EPA compared to DHA  
The experimental studies demonstrated a superior effect of EPA compared to DHA for 
the reduction of vascular inflammation. The mechanisms underlying these differences need to 
be further elucidated. Although structurally very similar, there is emerging evidence for 
different pharmacodynamic effects of these two molecules. Differences in effects on adhesion 
molecule expression with EPA compared to DHA, for example, may relate to differences in  
(1) the inhibition of the translocation of TLR4 into lipid raft domains, (2) the suppression of 
TAK1 phosphorylation, (3) the attenuation of NFκB activity by suppressing p38 and IκBα 
activation, and (4) the induction of the expression of the anti-inflammatory and NFκB-
suppressor gene A20(246). The differences in the magnitude of effects may partly relate to their 
concentration and assembly in cell membrane phospholipids; for example DHA is incorporated 
into (sphingomyelin and cholesterol-rich) membrane rafts with more than twice the affinity of 
EPA(249). Hence, although much of the focus of the effects of fatty acids has been on their 
pharmacodynamics, differences in pharmacokinetics may also be relevant. 
Future mechanistic omega-3 studies should use purified forms of EPA and DHA 
provided for sufficient duration to allow for incorporation into the cell membranes of interest, 
and with care taken to minimise oxidation. 
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7.5.2 Targeting blood omega-3 concentrations 
The inverse correlations between blood omega-3 levels and markers of vascular 
inflammation demonstrated in the experimental studies provide further evidence for a dose-
dependent effect. As with blood pressure and lipid targets, there is a rationale for establishing 
a therapeutic target for blood omega-3 levels. The Omega-3 Index, which is the percentage of 
EPA and DHA in red blood cell fatty acids, identified a cut-off value (< 4%) that associates 
with coronary heart disease mortality(213), but this index does not profile individual fatty acids. 
This is critically important, given the consistent demonstration of stronger correlations with 
EPA levels in the experimental studies. A sub-study of the JELIS trial examined the 
relationships between various plasma fatty acid concentrations and the risk of coronary events 
using a Cox proportional hazard model. High plasma EPA concentrations, but not DHA 
concentrations, were significantly inversely associated with major coronary events, with a 
hazard ratio of 0.71 for those with the highest tier of EPA concentrations(596). Ohnishi et al 
examined this association further, and found that a ratio of EPA to arachidonic acid of > 0.75 
also significantly inversely associated with major coronary events(597). This provided further 
evidence for the prognostic value of blood omega-6:omega-3 ratios, with a focus on individual 
fatty acids. 
To establish therapeutic blood omega-3 concentrations, future cardiovascular outcome 
trials will need to achieve both high omega-3 levels and a range of levels, and hence consider 
both the dose and bioavailability of omega-3 sources. For the currently ongoing STRENGTH 
trial, the treatment group has received a high dose of omega-3 (4 grams per day) provided as 
free fatty acids (omega-3 carboxylic acids), which do not require hydrolysis by pancreatic 
lipase and therefore have optimal intestinal absorption(235). This large (>13000 participants 
recruited) randomised, placebo-controlled trial, is investigating the effects of omega-3 
carboxylic acids on the risk of cardiovascular events in statin-treated patients with high 
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triglyceride and low HDL-C levels. Fatty acid levels in both plasma and red blood cells have 
been taken at baseline, during treatment, and at the end of treatment, and will be correlated 
with clinical events(235). 
Future clinical studies should evaluate the therapeutic effects of achieving specific 
blood omega-3 concentrations in the context of the complete fatty acid profile in a range of 
clinical settings. 
7.5.3 The concept of dysfunctionality 
 Fatty acids undergo metabolism, oxidation, shortening, elongation and conversion to 
other fatty acids after oral ingestion. Oxidation changes the structure and function of fatty acids, 
and longer chain polyunsaturated fatty acids are more susceptible to oxidation due to the higher 
number of double bonds present. It has been proposed that oxidised products in fish oils may 
attenuate their beneficial effects(598). However, Mishra et al provided evidence that the anti-
inflammatory effects of fish oil on the endothelium after cytokine stimulation result from the 
inhibitory effects of oxidised omega-3 fatty acids on NF-κB activation(252). It is not clear at 
present to what extent conformational changes in omega-3 fatty acids after oral ingestion may 
lead to dysfunction, and further research is needed in this area. 
 The incorporation of fatty acids into cellular membranes is critical to their effects on 
downstream signalling. Fatty acids incorporate into the membrane rafts of the most abundant 
phospholipids, initially phosphatidylcholine and phosphatidylethanolamine(599). Fatty acid 
uptake is an active process regulated by fatty acid transporters(600). Hence, there may be 
pathophysiological conditions which reduce fatty acid uptake by fatty acid transporters, leading 
to a state of “fatty acid resistance” akin to insulin resistance. The conditions which may 
contribute to a fatty acid-resistant state and limit the functional effects of omega-3 
supplementation would be worthy of exploration. 
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 FOCUS IN demonstrated a strongly-positive correlation between blood levels of HDL-
C and the gene expression of VCAM-1 and MCP-1 by stimulated HUVECs. The correlations 
were not a primary focus of the study, but occurred on a background of a recent report from 
two prospective cohort studies of extremely high levels of HDL-C being associated with 
increased all-cause mortality(489). This paradoxical association raises the possibility of HDL 
dysfunctionality at very high levels. If this is the case, HDL may develop pro-inflammatory 
properties. The effects of HDL particles on the vessel wall in the setting of extreme HDL-C 
levels warrant further investigation.  
 Despite the advances that have occurred in our understanding of the impact of omega-
3 fatty acids on atherogenesis over the last half-century, there remain significant knowledge 
deficits that will lead to fertile and exciting areas for continued investigation. The findings of 
this body of work provide mechanistic insights into the atheroprotective effects of omega-3 
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